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INVESTIGATING THE ROLE OF PRESCRIPTION DRUG MONITORING PROGRAMS IN 
REDUCING RATES OF OPIOID-RELATED POISONINGS 
 
The United States is in the midst of an opioid epidemic. In addition to other system level 
interventions, almost all states have responded to the crisis by implementing 
prescription drug monitoring programs (PDMPs). PDMPs are state-level interventions 
that track the dispensing of Controlled Substances. Data generated at the time of 
medication dispensing is uploaded to a central data server that may be used to assist in 
identifying drug diversion, medication misuse, or potentially aberrant prescribing 
practices.  
 
Prior studies assessing the impact of PDMPs on trends in opioid-related morbidity have 
often failed to take into account the wide heterogeneity of program features and how 
the effectiveness of these features may be mitigated by insurance status. Previous 
research has also failed to differentiate the effects of these programs on prescription vs. 
illicit opioid-related morbidity. The studies in this dissertation attempt to address these 
gaps using epidemiological techniques to examine the associations between specific 
PDMP features and trends in prescription and illicit opioid-related poisonings in 
populations of different insurance beneficiaries.  
 
Results of these studies demonstrate that implementation of specific PDMP features is 
significantly associated with differential trends in prescription and illicit-opioid related 
poisonings and that the effectiveness of these features vary depending on the insurance 
status of the population studied. These results suggest that PDMPs offer a valuable tool 
in addressing the United States’ opioid epidemic, and may be used as empirical evidence 
to support PDMP best practices in the future. 
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Introduction 
In February 2011, the US Centers for Disease Control and Prevention (CDC) 
labelled recent increases in opioid-related morbidity and mortality as ‘a US epidemic’.1 
Opioid-related poisonings recently surpassed automobile accidents as the leading cause 
of accidental injury death in the US.2 In 2016, over 42,000 individuals died from an 
opioid-related poisoning—about 115 deaths per day—and in October 2017, President 
Trump declared the crisis a national public health emergency.3,4 This burgeoning 
epidemic has afflicted Americans from all walks of life including the young, poor, rich, 
and old, and has united activists, politicians, and scientists in an attempt to stymie the 
overwhelming increase in preventable mortality.  
The opioid epidemic has roots as an iatrogenic crisis. In the late 1990’s a host of 
factors converged to result in rapid increases in the prescribing of opioid analgesics. The 
patient-centered health movement combined with a growing recognition of pain as a 
legitimate clinical condition led to a push to treat pain throughout the healthcare sector. 
At the same time, the potent opioid analgesic OxyContin® was aggressively marketed to 
physicians as an efficacious and non-addictive method of pharmacological pain 
management.5-8 From 1999 to 2010, opioid analgesic prescriptions in the US increased 
approximately 4-fold along with a concurrent increase in opioid-related morbidity and 
mortality.9-11  
In recent years, a variety of state and federal-level interventions have been 
deployed in an effort to encourage more responsible opioid prescribing practices. 
Interventions include crackdowns on ‘pill mills’ in certain states, the development of 
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abuse deterrent formulations, and the revision of prescribing guidelines.12-19 Policy 
makers have also responded to the ongoing crisis by establishing prescription drug 
monitoring (PDMPs). PDMPs are state-based programs that the track the prescribing 
and dispensing of controlled substances to consumers with a goal of mitigating misuse 
and diversion.20 PDMP data may assist prescribers and pharmacists in their decision-
making at the point of care and may also assist law enforcement and licensure boards in 
the identification of potentially aberrant prescribing and dispensing practices. Ideally, 
PDMPs offer the opportunity for providers to adequately manage pain with opioid 
analgesics while also preventing opioid misuse and opioid-related morbidity and 
mortality.  
At present, 49 states and the District of Columbia have operational PDMPs.21 
Given the widespread implementation of these programs, numerous studies have 
sought to examine associations between PDMPs and trends in opioid-related morbidity 
and mortality. This previous research has found generally inconsistent evidence of 
PDMP efficacy.22 There are a number of prominent shortcomings in the current body of 
PDMP research. Many studies have to adequately account for program heterogeneity 
between states. Also, no studies to date have explored the differential effects of these 
programs on trends in prescription and illicit opioid-related morbidity and mortality, or 
whether insurance status effects program efficacy. The research presented in this 
dissertation makes use of robust epidemiological methods and multiple data sources to 
address these gaps in the PDMP literature. 
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Chapter 1 contains a literature review that explores the history of PDMPs as a 
response to the opioid epidemic, and summarizes previous work examining associations 
between PDMPs and trends in opioid related-morbidity and mortality. Chapter 2 
consists of two separate, but related, analyses that asses associations between specific 
PDMP features and trends in prescription and illicit opioid-related poisonings in a 
nationally representative sample of privately insured adults. Chapter 3 presents an 
examination of differential associations between PDMP features and trends in 
prescription opioid-related poisonings in populations with different types of insurance 
coverage. Finally, Chapter 4 compares the results of the previous two chapters and 
explores policy recommendations and future research on this topic. Taken together, 
these studies make a novel contribution to the existing PDMP literature that will 
ultimately be useful to both researchers and policy makers seeking to quell the opioid 
epidemic.  
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Chapter 1: A Brief History of Prescription Drug Monitoring Programs and Their 
Associations with Opioid-Related Morbidity and Mortality 
1.1 Introduction: Prescription Drug Monitoring Programs as a Response to the Opioid 
Epidemic 
In 1998, the Veterans Health Administration (VHA) began developing a clinical 
strategy to improve pain management for its beneficiaries.23 The next year, the VHA 
rolled out an initiative called “Pain as the 5th Vital Sign” that mandated the assessment 
and documentation of self-reported pain at every clinical encounter.24 This initiative 
placed pain on par with blood pressure, respiratory rate, heart rate, and temperature, 
and encouraged VHA physicians to treat pain as a condition in and of itself. In 2001, the 
Joint Commission on Accreditation of Healthcare Organizations (JCAHO) released new 
Pain Management Standards which continued to suggest that chronic pain is an 
undertreated problem in American healthcare.25,26 Though the JCAHO did not explicitly 
endorse the “Pain as the 5th Vital Sign” initiative, this report may have helped popularize 
the concept.27 
Interest in pain as a potentially undertreated condition has persisted throughout 
the 21st century. The National Center for Health Statistics (NCHS) releases an annual 
report regarding the current state of health in the US, and their 2006 report included a 
special feature on pain.28 Also in 2006, the Centers for Medicare and Medicaid Services 
implemented the Hospital Consumer Assessment of Healthcare Providers and Systems 
survey, which requires hospitals to ask discharged patients subjective questions 
regarding pain management, amongst other things.29 More recently, the 2010 Patient 
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Protection and Affordable Care Act mandated that the Department of Health and 
Human Services enlist the Institute of Medicine (IOM), “to increase the recognition of 
pain as a significant public health problem in the United States.”30 In keeping with this 
requirement, the IOM conducted a study in 2011 to assess the current state of science 
regarding pain research, care, and education. Results of the IOM study revealed that 
more than 116 million adults living in the US experience chronic pain conditions.30 Pain 
also exerts a significant financial burden on US society, costing at least $560-$625 billion 
annually, and in 2008, the estimated direct cost to federal and state governments for 
medical expenditures related to pain was approximately $99 billion.30  
Prescription opioid analgesics have demonstrated short-term effectiveness in 
relieving many types of moderate to severe pain.30-34 Use of opioid analgesics has 
increased markedly since the late 90’s, owing, in part, to increasing awareness and 
efforts to address untreated pain.9,30,35-38 From 1999 to 2010, opioid prescriptions in the 
US increased approximately 4-fold.9 In 2012, 259 million prescriptions were written for 
opioid analgesics—more than one for every US adult.39 Furthermore, it has been 
estimated that Americans presently consume approximately 80% of the global supply of 
prescription opioids and 99% of the global supply of hydrocodone, despite comprising 
less than 5% of the world’s population.38 The explosion in opioid analgesic use in the US 
has surely benefitted some patients suffering from chronic pain; however, it has also 
been associated with a number of serious negative ramifications. 
The increasing use of opioid analgesics has been paralleled by increasing rates of 
nonmedical use, use disorders, and diversion of these medications.38,40-43 In 2014, more 
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than 10 million Americans reported using opioids non-medically, and 1.9 million 
Americans met the criteria for an opioid use disorder based on their past-year use of 
prescription opioids.44 A 2015 study by Dart et al.  assessed changes in the rate of opioid 
misuse using three different datasets managed by the Researched Abuse, Diversion, and 
Addiction-Related Surveillance (RADARS) System.40 Results were consistent across all 
three datasets and revealed that rates of opioid misuse and opioid-related poisonings all 
nearly doubled from 2002 to 2013.40 Persons with nonmedical prescription opioid 
analgesic use and/or opioid use disorders often obtain medications from multiple 
providers, a behavior known as “doctor shopping”, or from friends, relatives, or 
strangers who are prescribed the medication for legitimate medical reasons, a practice 
known as “diversion”. Importantly, most illicit drugs in the US are from foreign 
countries, while most misused prescription opioids originate from US prescribers.45  Dart 
et al. also used the RADARS data to examine changes in opioid diversion and found that 
the rate of opioid diversion increased by nearly 67% from 2002 to 2013.40  
In addition to increasing rates of nonmedical use, opioid use disorders, and 
diversion, increasing use of opioid analgesics since the late 1990’s has also been 
associated with a corresponding increase in opioid analgesic related mortality. One of 
the first studies to identify this trend found that the number of opioid analgesic 
poisonings listed on death certificates increased 91.2% from 1999 – 2002, and by 2002, 
opioid analgesics resulted in more poisoning deaths than heroin and cocaine 
combined.10 A 2009 study found that the number of fatal poisonings involving opioid 
analgesics more than tripled from 1999 to 2006 and also found that the percentage of 
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poisonings involving opioid analgesics increased steadily over the same time period.46 
The number of fatal poisonings involving opioids increased nearly 8% from 2006 to 2008 
and in 2008, it was observed that opioid analgesics were involved in 73.8% of all 
prescription drug overdose deaths.46,47 More recently, a 2014 study found that the rate 
of opioid related poisonings (prescription opioids and heroin) increased 200% from 2000 
to 2014 and in 2014 the number of fatal opioid related poisonings was nearly equal to 
the number of deaths from motor vehicle accidents.11 Rates continued to increase 
across the United States from 2014 to 2015 in all demographic subgroups assessed.2 
The American healthcare system thus finds itself at the nexus of two 
interconnected and seemingly paradoxical public health epidemics. One being the 
chronic under-treatment of pain, or the ineffective treatment of underlying causes of 
pain, and the other being morbidity and mortality stemming from opioid analgesic 
medications used to treat that pain. Recognizing this conundrum, the Executive Office of 
the President released a plan in 2011 to address these intertwined problems and set 
forth a call to, “take urgent action to ensure the appropriate balance between the 
benefits these medications [opioid analgesics] offer… and the risks they pose.”48 The 
President’s call may represent a delayed recognition of the problem. In the years leading 
up to the release of this plan, many states had already attempted to strike such a 
balance through the adoption of Prescription Drug Monitoring Programs (PDMPs).  
PDMPs are state-based programs that track the prescribing and dispensing of 
Controlled Substances (CS) to consumers. Information on a consumers’ CS use history 
may be made available to prescribers, dispensers, or law enforcement agents 
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authorized to query the PDMP data. These data may assist providers in making 
prescribing decisions and may also assist in the identification of individuals engaged in 
doctor shopping or medication diversion. Ideally, the hope was that PDMPs would offer 
the opportunity to adequately treat pain with opioid analgesics while also stymieing 
doctor shopping and diversion—two of the primary drivers of prescription opioid 
related morbidity and mortality. At present, 49 states and the District of Columbia have 
operational PDMPs.49 Over the last 15 years, many studies have sought to examine the 
impact of PDMPs on prescription opioid-related morbidity and mortality, yet the 
findings of these studies are at times inconsistent. This review seeks to summarize 
academic literature pertaining to the history, evolution, and impact of PDMPs on opioid 
related morbidity and mortality in the United States. The specific aims of this review are 
to:  
1. Describe the history and evolution of PDMPs  
2. Examine associations between PDMPs and opioid-related morbidity (e.g. 
nonfatal poisonings, treatment admissions, etc.) 
3. Assess associations between PDMPs and opioid-related mortality 
4. Describe gaps in the existing PDMP literature 
1.2 Methods 
The search engines PubMed and Google Scholar were used to search for 
combinations of the following keywords and phrases: prescription drug monitoring 
program, PDMP, PMP, opioid, heroin, poisoning, treatment, mortality, and morbidity. 
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Literature was excluded if the topic lay outside the specific aims listed above, was 
published in a language other than English, or was published as a ‘letter to the editor’ or 
opinion piece. In terms of evaluating aims 2 and 3 above, only studies where the 
outcome of interest was specifically related to prescription or illicit opioid-related 
morbidity or mortality were included the review.  
1.3 Results 
1.3.1 History and Evolution of PDMPs 
Interest in tracking the prescribing of addictive goods has existed in the United 
States since the early 1900s.50 In 1914, New York State passed The Boylan Act, which 
required physicians to use state-issued, serial-numbered, prescription order blanks 
when prescribing certain narcotics.51 The Act mandated that patients be given a copy of 
their prescription order while physicians were required to keep a duplicate copy on file 
for five years to be available for inspection by state authorities at any time.51 This was 
the first Multiple Copy Prescription Program (MCPP) in the United States and 
symbolized the regulatory/public policy desire to be able to track prescriptions over 
time – essentially foreshadowing the advent of future PDMPs. California and Hawaii 
soon followed New York’s suite and instituted their own MCPPs in 1939 and 1943, 
respectively.50  Although all three of the early MCPPs operated similarly, the drugs they 
chose to monitor varied greatly and formal requirements dictating use of the programs 
differed in each state.50 
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The Controlled Substances Act of 1970 established federal policy that regulates 
the manufacture, possession, and use of certain substances.52 This legislation created 
five federally designated ‘Schedules’ that classify substances based on their abuse 
potential and medical utility. The Food and Drug Administration (FDA) and the Drug 
Enforcement Agency (DEA) jointly determine which substances are added to or removed 
from the five various schedules. Notably, individual states can reschedule a medication 
to a more restrictive schedule or make a federally unscheduled drug a scheduled drug in 
that particular state. While only illicit substances with no recognized medical utility are 
included in Schedule I, prescription medications may be found in Schedule II—drugs 
with an accepted medical use but with a high potential for abuse or physical 
dependence—to Schedule V—drugs with accepted medical use but with very low 
potential for abuse or physical dependence.   
Thus, the Controlled Substances Act offered guidance to states seeking to 
monitor the prescribing of potentially dangerous medications and implicitly encouraged 
other states to join in the effort. Sure enough, the early adopters of MCPPs amended 
their programs in the wake of the Controlled Substances Act to specifically monitor 
Schedule II prescription medications.50 Several other states soon began efforts to 
implement their own monitoring programs, and by 1998, ten states had functioning 
PDMPs.53 Only seven years later, the number of states with functioning PDMPs had 
more than doubled to 25.54 Over this same time period, states began moving away from 
traditional MCPPs and instead began implementing more advanced, computer based 
Electronic Data Transmission (EDT) systems.50,55 EDTs were quickly seen to be more 
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user-friendly and efficacious than MCPPs, and by 2006, the last MCPP had been phased 
out and all states with active PDMPs utilized EDT systems.50,56 Now, 49 states and the 
District of Columbia have operational electronic PDMPs.49  
Modern PDMPs serve a variety of both individual and system level purposes. 
Perhaps most importantly, by tracking CS prescribing, PDMPs may assist physicians and 
pharmacists in identifying patients who may be doctor or pharmacy shopping for the 
purposes of diverting or misusing prescription opioids.50,57-60 A recent review of laws 
that articulate the purpose of PDMPs found that most PDMP legislation cites the goals 
of reducing abuse, misuse, and diversion as the primary goals of the PDMP.20 This 
review found that only five PDMPs specifically list improving public health as a goal, and 
none specifically listed preventing opioid-related poisonings as goals.20 Misuse, 
diversion, and doctor shopping for prescription opioids are all risk factors for opioid-
related poisonings.61-64 If PDMPs are successful in reducing misuse, diversion, and 
doctor shopping then they may also help mitigate population-level risk of opioid-related 
poisonings. PDMPs may also be useful to law enforcement entities and boards of 
licensure who can use the programs to identify providers that are prescribing 
abnormally large quantities of CS.  
In general, all PDMPs operate similarly. Prescription data is captured at the time 
of CS dispensing and these data are periodically uploaded to a central database, which is 
accessible upon query to a variety of authorized users. PDMPs may, or may not, allow 
data access to prescribers, dispensers, regulatory agencies, and law enforcement 
officials conducting active investigations into potentially illicit or aberrant prescribing. 
12 
 
States also choose specifically which Schedules are required to be reported to the 
PDMP. Currently all states monitor Schedule II medications, but there is some variability 
in terms of monitoring Schedules III-V.65 Variability also exists in terms of which state 
agency oversees operation of the PDMP.49 There is also wide heterogeneity in terms of 
state laws requiring practitioners to register with the PDMP or mandating that they 
query the central database in certain situations, with more states implementing these 
requirements in recent years.53 An increasingly popular feature of PDMPs is to send 
unsolicited reports to prescribers, law enforcement agencies, or regulatory bodies.53 
Prescribers may receive unsolicited reports if their patients are visiting multiple 
prescribers, and licensure bodies may receive unsolicited reports if providers are 
observed prescribing abnormal quantities of CS. Most PDMPs have experienced major 
changes to key program features throughout their lifetimes.54,65 The Prescription Drug 
Abuse Policy System (PDAPS) publishes data on historical changes to PDMPs over time, 
as well as interactive maps to visualize the status of current PDMPs.66 Figures 1.1, and 
1.2 are two of these maps that visualize PDMPs with requirements for unsolicited 
reporting and mandatory querying, respectively. 
Specific features of PDMPs may have important impacts on the programs’ 
efficacy in terms of reducing non-medical prescription opioid use and/or mortality. For 
example, PDMPs that operate proactively by sending unsolicited reports to prescribers 
or law enforcement may have a greater impact on opioid prescribing relative to states 
with strictly reactive PDMPs.67 Additionally, states with PDMPs that monitor more CS 
and require pharmacies to report data to the PDMP more frequently, may have a more 
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significant impact on prescription drug misuse and mortality than states with less 
comprehensive programs.54 Finally, requiring prescribers or dispensers to register with 
and query the PDMP data in certain circumstances can have major impacts on program 
efficacy.42,68 One 2015 study of Kentucky’s PDMP found that requiring prescribers to 
register and utilize the program in certain situations reduced doctor shopping by over 
50% compared to the year prior to the requirement going into effect.68   
Considering the past and present heterogeneity in terms of PDMP operation, 
there have been several efforts to identify and promote PDMP best practices. Partially 
in response to increasing opioid related morbidity and mortality and the subsequent 
popularization of PDMPs, the Bureau of Justice Assistance (BJA) created the Harold 
Rogers Prescription Drug Monitoring Program (HRPDMP) in 2002.53,55 This program 
made  grant funding available to certain states to assist in the planning, implementation, 
and enhancement of PDMPs, and charged the National Association for Model State Drug 
Laws (NAMSDL) to assist in the process.53,55 In 2004, NAMSDL released a list of 7 key 
characteristics of strong PDMPs and highlighted the importance of monitoring all 
Schedules of CS, sending proactive reports to various entities, providing training to 
providers, and allowing data access to dispensers, prescribers, law enforcement 
agencies and licensing officials.69 The next year, Congress authorized additional federal 
funding for PDMPs with the passage of the National All Schedules Prescription Electronic 
Reporting Act (NASPER). In 2009 and 2010, nearly $10 million was appropriated by 
Congress for the HRPDMP and NASPER.53 With assistance from the Alliance of States 
with PDMPs, the BJA funded the PDMP Technical Training and Assistance Center (PDMP 
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TTAC) at Brandeis University in 2008, and charged this group with conducting research 
to enhance the effectiveness of PDMPs.55 In 2012, PDMP TTAC released a 
comprehensive assessment of the evidence for PDMP best practices and determined 
that more systematic research and evaluation is required to establish the value of 
certain PDMP features.55  
1.3.2 Associations between PDMPs and opioid-related morbidity 
Since PDMPs became widely implemented in the early 2000’s, a number of 
researchers have attempted to quantify the impact of the programs on measures of 
prescription opioid misuse and mortality. Before delving into this literature, it is 
important to clarify the language used to describe prescription opioid misuse. The 
International Classification of Disease, Ninth Revision, Clinical Modification (ICD-9-CM) 
has specific codes for both prescription opioid abuse and prescription opioid 
dependence.70 These codes are defined based on criteria found in the Diagnostic and 
Statistical Manual, 4th edition, text revision (DSM-IV), which also differentiates between 
substance abuse disorders and dependence.71 In the more recent Diagnostic and 
Statistical Manual, 5th edition (DSM-V), though, these categories have been collapsed 
into a single umbrella diagnosis of substance use disorder, which is further categorized 
by severity.72 These changes reflect a trend in the medical community moving away 
from describing substance use as an abusive behavior to more accurately reflect the 
underlying neurobiological condition contributing to substance misuse or dependence.73 
Referring to individuals with substance use disorders as ‘drug abusers’ stigmatizes these 
individuals and fails to properly convey the subtleties of their disorder.73 In October 
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2016, the Office of National Drug Control Policy released draft guidelines for federal 
agencies to use appropriate language when referring to addiction, dependence, and 
substance use disorders.74 Some of the literature discussed in this section uses the 
misappropriated language of ‘opioid abuse’ to refer to various measures of opioid 
misuse. In reality, opioid abuse is only accurate terminology when referring to the 
specific DSM-IV diagnosis. Thus, for the purposes of this paper, authors’ definitions of 
opioid abuse will be explained, but the term opioid misuse will be used to refer to the 
results of their studies.  
Commonly Used Data Sources 
One of the most popular datasets for studying trends in prescription opioid 
misuse is the Treatment Episode Data Set (TEDS). The TEDS system is maintained by the 
Substance Abuse and Mental Health Services Administration (SAMHSA) and includes 
data on 1.5 million substance abuse treatment admissions annually. TEDS includes data 
collected at the state level on admissions to state or federally funded substance abuse 
treatment facilities.75 Importantly, TEDS captures information on primary substance of 
misuse (defined as the substance bringing the patient into treatment) as well as other 
patient characteristics at the time of treatment admission.75 A notable limitation of the 
TEDS data is that it only captures admissions to publicly funded treatment facilities, and 
in doing so only offers a snapshot of the overall burden of opioid misuse in the US. An 
additional limitation is that patients presenting for treatment and included in the TEDS 
data may or may not actually have a DSM-4 diagnosis of ‘opioid abuse’. Thus, while 
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many researchers use TEDS data to study trends in ‘opioid abuse’, they are in fact 
assessing a measure of prescription opioid misuse.  
TEDS is not the only publicly available data source that may be used to track 
national trends in opioid-related morbidity. The National Survey on Drug Use and Health 
(NSDUH) from SAMHSA is a nationally representative survey collecting information on 
drug use and mental health in non-institutionalized adults.76 These data permit 
evaluation of state-level policies related to both non-medical use of prescription drugs 
as well as illicit drugs. The Researched, Abuse, Diversion and Addiction-Related 
Surveillance (RADARS) System consists of eight separate datasets that may also be used 
to study a variety of opioid-related morbidity outcomes.77 RADARS is an independent 
nonprofit organization that collects data on trends in drug misuse treatment, diversion, 
and opioid related poisonings amongst other things.77 Finally, the Drug Abuse Warning 
Network (DAWN) which is also administered by SAMHSA captures data on ED visits in 
which illicit or prescription drugs are a cause or contributing factor.78 DAWN offers 
nationally representative estimates of ED visits related to drugs as well as regional 
estimates for certain metropolitan statistical areas. 
TEDS  
In 2006, Simeone and Holland were the first to use TEDS data to assess the 
impact of PDMPs on rates of prescription opioid misuse.79 State-level measures of 
opioid misuse were defined as the number of TEDS admissions for prescription opioids 
divided by the corresponding population in each state in each year. The authors did not 
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investigate the impact of PDMPs on TEDS admissions directly, but rather constructed an 
aggregate model in which they assessed the impact of PDMPs on supply of Schedule II 
opioids and then estimated how changes in opioid supply effect changes in rates of 
TEDS treatment admissions related to prescription opioid misuse from 1997-2003. 
Results showed that PDMPs significantly reduced per capita supply of Schedule II 
opioids and in so doing, significantly reduced the probability of prescription opioid 
treatment admissions in PDMP states.79 The authors also found that this effect was 
particularly pronounced in states with PDMPs that proactively monitored prescribing 
and generated unsolicited reports.79 Interestingly, Simeone and Holland observed that 
the annual prescription opioid admission rate was higher, on average, in PDMP states 
than non-PDMP states, but argued that in the absence of these programs, the 
probability of misuse would be even higher in PDMP states.79 This suggests that the 
states with the worst relative magnitude of opioid misuse may be the first to implement 
PDMPs. 
Reisman et al. also used TEDS data to model the impact of PDMPs on 
prescription opioid misuse, but did so with a vastly different methodology than Simeone 
and Holland. While Simeone and Holland used the rate of opioid admissions per capita 
as the outcome of interest, Reisman et al. defined the rate of ‘prescription opioid abuse’ 
as the number of TEDS prescription opioid admissions per 100 total treatment 
admissions observed in TEDS.41 Reisman et al. conducted two distinct analyses: one in 
which they used a time series linear regression to model the annual percent change in 
opioid treatment admissions per year, and a separate cross-sectional analyses in which 
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they used a logistic regression to assess the odds of reporting prescription opioids as the 
primary drug of misuse by TEDS patients in PDMP states relative to non-PDMP states. 
Results of the study showed that from 1997 – 2003, PDMP states had lower increases in 
the rate of opioid admissions relative to non-PDMP states but this association was not 
statistically significant.41 The authors also observed that the odds that a patient entering 
treatment reported prescription opioids as the primary drug of misuse, was nearly 30% 
higher in non-PDMP states relative to states with PDMPs.41 
More recently, in 2017, Branham used TEDS data to examine associations 
between the number of treatment admissions where patients reported heroin as their 
primary drug used, and the number where patients reported prescription opioids as 
their primary drug used, following implementation of PDMPs. The author hypothesized 
that post-PDMP implementation, reduced admissions for prescription opioids would be 
associated with increased admissions for heroin treatment. Branham utilized an 
autoregressive integrated moving average model with a sample of 22 states from 1992 – 
2012 to test this hypothesis. Results of the study showed a statistically significant, and 
positive, association between increasing prescription opioid and heroin admissions 
following implementation of PDMPs.80 The author concedes, however, that these results 
do not answer the question of whether PDMPs are associated with increasing use of 
heroin, only that they are positively associated with individuals entering treatment.  
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NSDUH 
Ali et al. used the NSDUH data in a 2017 analysis to examine associations 
between PDMP implementation and trends in both prescription opioid misuse and 
heroin use from 2004 – 2014. The authors modeled both outcomes as binary variables 
indicating any nonmedical opioid use or heroin use, as well as continuous variables 
indicating the number of days of nonmedical opioid use or heroin use in the past year.81 
Binary outcomes were estimated using logit regression and continuous outcomes were 
estimated using gamma generalized linear models with a log-link function. The primary 
independent variable of interest was whether states had operational PDMPs, and the 
authors further categorized PDMPs by whether they had requirements for prescribers to 
register with, or query, the PDMP in certain situations. Results indicated that PDMP 
implementation was not associated with nonmedical prescription opioid use or heroin 
use in the binary models. However, in the continuous models, the authors did find 
associations between PDMP implementation and decreases in the number of days of 
nonmedical opioid use and increases in the number of days of heroin use reported in 
the past year.81 These associations were stronger in states that had operational PDMPs 
that required prescribers to register with, or query, the PDMP data.  
RADARS 
In 2012, Reifler et al. used RADARS data to assess the impact of PDMPs on both 
rates of prescription opioid misuse and intentional opioid poisonings. The Opioid 
Treatment dataset in RADARS consists of data from seventy-four treatment centers in 
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33 states and captures information regarding participants’ demographics and opioid 
misuse history.77 The RADARS Poison Center data consists of data from 48 of the 60 
total poison control centers in the US and tracks information on calls reporting 
intentional opioid poisonings—note that ‘intentional’ here refers to the actual 
medication use and not necessarily to the poisoning itself being intentional.77 Two 
separate models were constructed, with one modeling changes in opioid misuse defined 
as the rate of opioid-related treatment admissions from the Opioid Treatment data, and 
the other modeling changes in opioid-related poisoning defined from the Poison Center 
data. Both models used negative binomial regressions with the rates of opioid misuse or 
poisoning from 2003-2009 as the outcomes of interest. Results showed that states with 
PDMPs had significantly lower increases in the rate of opioid related poisonings 
(average annual increase in non-PDMP states 8% vs. 0.8% in PDMP states) and also had 
non-significantly lower increases in the rate of opioid misuse relative to states without 
PDMPs.82 The authors also conducted a sensitivity analysis that differentiated states 
with standard PDMPs vs. five states deemed to have ‘superior’ PDMPs. Results of the 
sensitivity analysis were consistent with the main analyses but effects did not maintain 
their statistical significance.82 This sensitivity analysis suggests that states with 
particularly comprehensive PDMPs do not fare better than other states with PDMPs. 
However, this finding may be due to the relatively small sample included in the ‘superior 
PDMP’ group or because the authors fail to take into account temporal changes to the 
PDMPs—i.e. the states with superior PDMPs did not necessarily have these ‘superior’ 
characteristics for the entire study period.  
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DAWN 
More recently, in 2015, Maughan et al. sought to examine associations between 
PDMP implementation and prescription opioid-related ED visits using DAWN data.83 The 
authors estimated rates of opioid-related ED visits for 11 geographically diverse 
metropolitan areas on a quarterly basis from 2004 – 2011. A generalized estimating 
equation Poisson regression model with a first-order autoregressive working covariance 
matrix was used to model the outcome of interest. The authors defined a PDMP as 
being operational when it allowed prescribers access to the PDMP data. Other 
covariates of interest included the unemployment rate in each metropolitan statistical 
area, as well as indicators for each metro area and calendar quarter, and an interaction 
term between the metro area and calendar quarter. Results of the study indicated that 
PDMP implementation was not significantly associated with the rate of prescription 
opioid-related ED visits.84 However this study suffered from several prominent 
limitations. First, the study was limited in sample size, and only included 11 
metropolitan areas. Second, the authors failed to take into account the heterogeneity of 
individual PDMP characteristics in these areas. And third, the authors did not investigate 
the effect of an interaction between the PDMP indicator variable and calendar time.  
Administrative Health Claims Data 
Interest in the impact of PDMPs on prescription opioid-related poisonings 
persisted in the wake of Refiler et al.’s and Maughan et al.’s studies, and was again 
assessed in 2016 by Meara et al.85 Meara and colleagues used Medicare claims data to 
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study the impact of PDMPs on nonfatal prescription opioid-related poisonings in a 
population of disabled fee-for-service Medicare beneficiaries from 2006-2012. Nonfatal 
prescription opioid-related poisonings were identified from emergency department and 
inpatient claims where the primary or secondary diagnosis code corresponds to an 
opioid-related poisoning, excluding heroin related poisonings. The authors used logistic 
regression to model the odds of having an opioid-related poisoning while controlling for 
residence in a PDMP state and other clinical and demographic characteristics. Results of 
the study showed that individuals living in PDMP states did not have significantly 
different odds of experiencing an opioid-related poisoning relative to individuals in non-
PDMP states.85 The primary limitation of this study was that it only included a 
population of disabled Medicare beneficiaries, so the generalizability of these results to 
the overall US population is questionable.  
1.3.3 Associations between PDMPs and opioid-related mortality 
Several of the studies discussed in the previous section chose to focus on 
associations between PDMP implementation and trends in nonfatal opioid-related 
poisonings. Since 2010 however, additional studies have examined the impact of PDMPs 
on opioid-related mortality. While one of the initial studies on this topic was conducted 
using DAWN data and one with state specific mortality data, most have relied on the 
National Vital Statistics System’s underlying cause of death data. Organized by the CDC, 
the Wide-ranging Online Data for Epidemiologic Research (WONDER) is a web 
application consisting of 20 collections of public-use data files related to US births, 
deaths, and disease specific trends.86 The mortality data presents state-year specific 
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estimates of the underlying cause of death listed on death certificates, as coded by 
medical examiners. WONDER also includes demographic data from the Census Bureau, 
so it is commonly used to analyze trends in disease specific death rates across the US.86 
Paulozzi and Stier’s 2010 descriptive manuscript was the first to directly examine 
associations between PDMP status and rates of opioid-related mortality.87 The authors 
used DAWN data to compare rates of opioid-related mortality in New York and 
Pennsylvania—two states with similar populations but radically different PDMPs. 
Paulozzi and Stier report that in 2007, the prescription opioid mortality rate was nearly 
three times higher in Philadelphia than in New York City.87 The authors argue that this 
difference may be due, in part, to the fact that New York had a much more 
comprehensive PDMP at the time than Pennsylvania. Notably, this was only a 
descriptive study that did not include any statistical testing and only included a cross-
sectional assessment of two metropolitan areas over a period of one year.87  
Building off the hypothesis proposed in his 2010 study, Paulozzi and colleagues 
conducted a robust methodological study in 2011 assessing the impact of PDMPs on 
rates of fatal opioid-related poisonings using national mortality data from 1999 – 2005 
from the CDC WONDER data.67 The authors calculated state-year rates for both overall 
drug poisoning deaths as well as prescription opioid-related deaths. Panel regression 
techniques were used to model the impact of PDMPs on year-to-year changes in the 
rates of prescription opioid and overall drug poisoning deaths. Importantly, the authors 
differentiated between states with PDMPs that sent proactive reports to prescribers, 
dispensers, or law enforcement, and those that did not require proactive reporting. 
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Results of the study showed that presence of a PDMP was not a significant predictor of 
changes in either overall drug mortality or prescription opioid-related mortality.67 The 
authors also found that proactive PDMP states did not have significantly lower rates of 
either outcome than other states with PDMPs.67 Finally, it was observed that New York, 
California, and Texas—the three states with historical serialized prescription forms—had 
substantially lower rates of both overdose outcome relative to all other states.67  
A more recent study by Delcher et al., used a slightly different methodology to 
assess the impact of PDMP implementation on the rate of oxycodone-caused mortality 
in the state of Florida.88 Delcher and colleagues received data from the Florida Medical 
Examiners Commission on all drug-related deaths in the state from 2003-2012. The main 
outcome of interest consisted of monthly counts of deaths caused by oxycodone, not 
including deaths where oxycodone was observed to be present in nonlethal quantities. 
Notably, Florida is home to some of the top opioid prescribers in the country by volume, 
and has also been noted to be the source of diverted oxycodone to several states.88,89 
Delcher et al. took two distinct approaches in modeling the PDMP variable. First, the 
PDMP variable was modeled as a binary variable representing program implementation. 
Next, it was modeled as the ‘health care provider query rate’, calculated as the total 
number of queries per registered health care provider per month after implementation 
of the PDMP.  The authors used an autoregressive integrated moving average (ARIMA) 
time series model to assess the impact of the PDMP on oxycodone-caused mortality 
while controlling for external trends (i.e. national trends in opioid misuse) and internal 
state-policy changes (i.e. operation pill nation). There was a statistically significant 
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decline in oxycodone-caused mortality in the month after implementation of Florida’s 
PDMP, and this effect persisted when controlling for the effects of other state-wide 
policies and national trends.88 The authors also found that increases in the health care 
provider query rate were associated with significant reductions in oxycodone-caused 
mortality.88 This study was the first to find that PDMPs are significantly associated with 
lower rates of fatal prescription opioid-related poisonings, however, the generalizability 
of these results are limited because this study only describes a single state and also only 
considered opioid-related poisonings caused by oxycodone.  
In 2016, Patrick et al. used CDC WONDER data from 1999 – 2013 to examine 
state-year rates of prescription opioid-related poisoning deaths per 100,000 residents.42 
Patrick et al. made significant improvements over previous studies on this subject by 
modeling the effects of specific PDMP characteristics. The authors used panel regression 
models with state fixed effects, similar to the one used by Paulozzi et al. in 2011, to 
assess the impact of PDMP implementation alone and also to examine the marginal 
effects of different PDMP characteristics on the rate of prescription opioid-related 
mortality. Patrick and colleagues were specifically interested in whether PDMPs that 
monitored more CS schedules, required more frequent data reporting, and required 
providers to register or query the data were associated with significant reductions in the 
rate of fatal opioid-related poisonings. Results of the study show that PDMP 
implementation was associated with a statistically significant reduction in the rate of 
prescription opioid-related deaths.42 Furthermore, the authors also found that PDMPs 
that monitored four or more CS schedules, or updated data at least weekly were 
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associated with significantly greater reductions in the rate of opioid-related deaths 
relative to programs without these characteristics.42  
More recently, Pardo used CDC WONDER data from 1999 – 2014 to examine the 
association between ‘strength’ of PDMPs and trends in prescription opioid-related 
mortality.90 As in the Patrick et al. study, Pardo identified rates of fatal prescription 
opioid-related poisonings at the state-year level. The author then classified PDMPs using 
a numeric system that he created to describe the programs overall strength. This system 
applies different points to features of the PDMP—e.g. 1 point if PDMPs allow access to 
prescribers and 4 points if the PDMP requires prescribers to query the PDMP data in 
certain situations. Two-way fixed-effects models were used to control for state-level and 
time-dependent factors associated with trends in prescription opioid-related mortality. 
The independent variable of interest—‘strength’ of the PDMP—was separately modeled 
as both a continuous score as well as a categorical variable roughly defined by quartile 
(e.g. having score 1-7, vs. 8-13 etc.).  Results indicated that every 1-point increase in 
PDMP ‘strength’ was associated with a 1% reduction in the rate of prescription opioid-
related mortality.90 Further, states in the third quartile of PDMP ‘strength’ were 
associated with an 18% reduction in opioid-related death relative to states without 
PDMPs.90 The primary limitation of this study however, is that the scoring system 
created by the author is based solely on his personal judgement. Weights are applied to 
several factors, such as having a data retention policy or oversight board, that have no 
empirical evidence to suggest that they are associated with opioid-related mortality. 
Further, the magnitudes of certain weights seem misappropriated. For example, having 
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an appropriated funding mechanism was given three times the weight as allowing 
prescribers or pharmacists to access the data.  
Nam et al. also used CDC WONDER data in 2017 to examine associations 
between PDMP implementation and trends in opioid-related mortality.91 The authors 
identified all fatal prescription opioid-related poisonings in the WONDER data from 1999 
– 2010 and created a time-varying binary indicator variable to define whether each 
state’s PDMP was operational in a given year. Multivariate regression models were 
constructed with state and year fixed effects as well as state-specific linear time trends. 
This methodology differed from that used by Patrick et al. who constructed models with 
state fixed effects and a single national linear time trend rather than state-specific 
trends. Results of the study indicated that implementation of PDMPs was not associated 
with rates of prescription opioid-related mortality relative to expected rates in the 
absence of PDMPs.91 The primary limitations of this study are that the authors fail to 
define what they considered as an operational PDMP, and they also failed to take into 
account the heterogeneity of PDMP features—potentially explaining why their results 
differed from those observed in the Patrick et al. study.42,91  
1.3.4 Gaps in existing literature 
PDMPs today are vastly different than the MCPPs that preceded them in the in 
the early 20th century. As the United States finds itself amidst a surging prescription 
opioid epidemic, modern PDMPs offer an unprecedented tool for public health and law 
enforcement entities to monitor the prescribing of these medications while also 
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allowing for the adequate treatment of chronic pain. The impact of PDMPs on opioid 
related morbidity and mortality has been thoroughly researched, yet many of these 
studies have found inconclusive evidence of their efficacy. Early studies found that 
implementation of PDMPs was associated with reductions in publically funded TEDS 
opioid treatment admissions, but not all results were statistically significant.41,79,82 A 
recent study using NSDUH data found that PDMPs were associated with nonsignificant 
decreases in the number of days of reported prescription opioid misuse and increases in 
the number of days of reported heroin use.81 Only one of the three studies investigating 
associations between PDMPs and trends in nonfatal prescription opioid-related 
poisonings found that PDMPs were significantly associated with decreased rates of 
poisonings.82,83,85 Finally, three of the five studies examining associations between 
PDMP implementation and rates of prescription opioid-mortality found that the 
programs were associated with lower rates of opioid-related deaths.42,67,88,90,91  
This review has identified four common shortcomings of the existing PDMP 
literature: 1. Many studies fail to clearly define when PDMPs are considered ‘active’ or 
operational. 2. Most studies do not take into account the heterogeneity of individual 
PDMP characteristics between states or changes to these characteristics over time. 3. 
No studies to date have investigated the differential impact of PDMPs on prescription 
vs. illicit opioid-related poisonings. 4. None of the previous research investigates 
differential associations between PDMP implementation and trends in opioid-related 
outcomes in populations with different types of insurance coverage.  
29 
 
Generally, all PDMPs will experience three major transitions over the course of 
their lives. First, state legislation is passed authorizing the creation of the PDMP. 
Second, at some point after that legislation is passed, the PDMP will begin collecting 
data on CS prescribing. This data collection may not begin for weeks or even years after 
the initial legislation is enacted. Third, at some point users will be provided access to the 
PDMP data. The time of user access may be simultaneous with the beginning of data 
collection or again, it may not occur for months or years after the data collection has 
begun. A PMDP may theoretically be considered ‘operational’ after any of these three 
time periods, but unfortunately much of the existing PDMP literature is generally vague 
about when they classify PDMPs as active. At least one study has explicitly controlled for 
the time period during which PDMP legislation has been enacted but programs are not 
yet operational—only to fail to define whether they consider operational to mean that 
the PDMP is collecting data or that it has made that data available to prescribers.42 
Presumably, a PDMP will only really be able to achieve its intended purpose if it both 
collects data and makes that data available to authorized users. Given that previous 
research has failed to use a uniform date for defining when PDMPs are ‘operational’, it 
is unsurprising that this research has found conflicting results 
Failing to account for specific features of operational PDMPs also confounds the 
results of previous research examining associations between PDMPs and trends in 
opioid-related morbidity and mortality. This point was astutely made by Green et al. in a 
prominent rebuke of Paulozzi et al.’s 2011 study of associations between PDMPs and 
trends in opioid-related mortality.92 Green et al. argued that it was inappropriate for 
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Paulozzi and colleagues to treat all PDMPs as homogenous programs that were either 
‘on’ or ‘off’ given the fact that many of the programs included in their study had vastly 
different programmatic features in terms of data availability and reporting 
requirements.92 Although this criticism was published after one of the very first studies 
examining PDMPs, authors have continued to neglect this heterogeneity in many more 
recent studies. Also, some studies that do take into consideration specific features of 
PMPDs, fail to account for temporal changes to these characteristics—i.e. a state 
requiring proactive reporting now may not have required it when the PDMP was first 
implemented.67,79,82 Neglecting to control for PDMP heterogeneity is also problematic 
because it prevents researchers and policy makers from understanding which features 
of PDMPs have the greatest impact on opioid-related morbidity and mortality. Several 
groups have released PDMP best practice guidelines that offer advice on efficacious 
operation of PDMPs, however there is a general dearth of empirical evidence to support 
the guidelines that they recommend.55,69 As PDMPs grow and change over time, it is of 
the utmost importance that empirical evidence exist to guide their evolution in the 
future. 
Almost all of the research to date investigating associations between PDMPs and 
trends in opioid-related morbidity and mortality has focused exclusively on prescription 
opioid-related morbidity and mortality. As trends in prescription opioid-related deaths 
have levelled off in recent years, there has been an extraordinary increase in the rate of 
heroin and illicit fentanyl-related mortality. As illicit opioid mortality has increased, 
anecdotal suggestions that this increase is, in part, driven by PDMPs and other policies 
31 
 
intended to decrease the supply of prescription opioids have surfaced. One previous 
study found that PDMP implementation was associated with a statistically insignificant 
increase in reported number of days of heroin use in the NSDUH data.81 Another study 
found a significant increase in the ratio of heroin deaths to prescription opioid deaths in 
North Carolina from 2007 to 2013, however, this study did not investigate the role of 
the state’s PDMP.93 As heroin deaths increase across the country, it is critical that 
researchers and policy makers understand whether PDMPs play a role in this 
burgeoning trend. Furthermore, if PDMPs are contributing to the heroin epidemic, it is 
important to determine which features of PDMPs are most strongly associated with 
trends in illicit opioid-related mortality.  
In addition to elucidating associations between PDMP features and trends in 
prescription and illicit opioid-related morbidity and mortality, it is also critical to 
understand how features of these programs impact different populations. Much of the 
previous research described above relies on de-identified mortality data or data from a 
single payer source. As such, none of this research explores how PDMPs may 
differentially impact populations with various types of insurance. As healthcare based 
programs that operate at the point-of-care, it is plausible that operational PDMPs and 
PDMPs with certain features will exert differential impacts on trends in opioid-related 
morbidity and mortality in different insurance beneficiary populations. Privately insured 
individuals and Medicare beneficiaries have frequent engagement with the healthcare 
system and thus present many opportunities for PDMPs to intervene and stymie opioid-
related morbidity in these populations. On the other hand, previous research shows that 
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uninsured individuals and Medicaid beneficiaries have the greatest odds of suffering 
from opioid use disorder (OUD) relative to other insurance beneficiaries, so it is also 
plausible that PDMPs could exert a more tangible impact on these populations.94 
1.4 Conclusion 
Despite the plethora of research examining associations between PDMPs and 
trends in opioid-related morbidity, this review has identified four common shortcomings 
in this previous work that may explain the inconclusive evidence of PDMP efficacy. 1. 
Many studies fail to clearly define when PDMPs are considered ‘active’ or operational. 2. 
Most studies do not take into account the heterogeneity of individual PDMP 
characteristics between states or changes to these characteristics over time. 3. No 
studies to date have investigated the differential impact of PDMPs on prescription vs. 
illicit opioid-related poisonings. 4. None of the previous research investigates 
differential associations between PDMP implementation and trends in opioid-related 
outcomes in populations with different types of insurance coverage. 
Together, these shortcomings represent potential confounding factors in 
previous studies as well as significant gaps in the existing body of literature. This 
dissertation will address each of these issues in turn, using robust epidemiological 
methods with multiple data sources. Chapter 2 uses administrative health claims data 
from a nationally representative sample of privately insured adults to address the first, 
second, and third shortcomings listed above. Chapter 3 uses hospital discharge data 
from all payer types to address the first, second and fourth shortcomings identified in 
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this review. The final chapter of this dissertation will summarize how the key findings 
from these studies address gaps in previous research, and will explore the policy 
implications of these findings and make recommendations for future research. 
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A brief note on language used to describe prescription and illicit opioid-related 
poisonings 
This dissertation is primarily interested in associations between PDMPs and 
trends in prescription and illicit opioid-related poisonings. Prior to delving into the 
research, however, it is important to pause and briefly discuss what exactly these terms 
are referring to. Use of the terms ‘prescription opioid-related poisoning’ (PORP) and 
‘Illicit opioid-related poisoning’ (IORP) is inspired by the official CDC guide to ICD-9-CM 
codes related to poisonings.95 This guide uses these exact terms to differentiate 
between poisonings related to prescription opioids and those related to ‘illicit’ opioids, 
which it defines as ‘opium and heroin’. However, it is important to note that these terms 
fail to capture the reality that PORPs may include illicit use of prescription opioids, and 
IORPs may misclassify use of adulterated prescription opioids. This is particularly 
relevant due to recent increases in rates of fentanyl-related poisonings. Fentanyl is a 
prescription opioid that may be illicitly manufactured and sold as heroin.96 In these 
cases, fentanyl-related poisonings that are technically PORPs may be miscoded as IORPs 
in administrative claims data. Alternatively, certain types of fentanyl that are 
manufactured in China and sold in the US are not used in legitimate medical practice 
here, and in this sense should rightfully be considered ‘illicit opioids’.96 Unfortunately, 
the ICD-9-CM codes used to identify PORPs and IORPs in these studies are not specific 
enough to identify the underlying drugs causing the poisoning—this limitation is 
discussed in more detail in section 2.5. Please be aware moving forward that my use of 
the terms IORP and PORP is strictly referring to these codes as described in the CDC 
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guide to ICD-9-CM codes related to poisonings. Further, my use of these terms is not 
intended to make any comment on the actual legality of the substances resulting in 
PORP or IORP codes, nor the legality of use of the substances resulting in these codes. 
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Chapter 2: Associations Between PDMP Features and Trends in Prescription and Illicit 
Opioid-Related Poisonings In a Population of Privately Insured Adults 
2.1 Introduction 
From 1999 to 2010, opioid analgesic prescriptions in the US increased 
approximately 4-fold.9 Increasing use of opioid analgesics has been associated with a 
corresponding increase in rates of prescription opioid-related poisoning (PORPs).10 
Deaths involving PORPs quadrupled from 1999 to 2015, killing more than 183,000 
people over this time period.2 Opioid-related inpatient hospital admissions and 
emergency department (ED) visits also increased substantially from 2005-2015.97 In 
February 2011, the US Centers for Disease Control and Prevention (CDC) labelled recent 
increases in PORPs as “a US epidemic”.1 Figure 2.1 from the CDC displays the rate of 
opioid poisoning-related mortality by type of opioid from 2000 – 2016.  
In recent years, increases in PORP rates have been dwarfed by even larger 
increases in rates of heroin-related poisonings (henceforth referred to as illicit opioid-
related poisonings or IORPs).2 Previous research has found increases in rates of heroin 
use across the US, and particularly dramatic increases among white, middle aged 
individuals living in rural areas.98,99 Many individuals who currently use heroin began by 
first engaging in nonmedical use of prescription opioids.98,100 Surveys with heroin users 
reveal that many have chosen to substitute heroin for prescription opioids due to the 
increasing cost and reduced availability of prescription opioids.98  
PDMPs are state-based programs that track the prescribing and dispensing of 
controlled substances (CS) to consumers with a goal of mitigating misuse and 
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diversion.101 Chapter 1 contains an in-depth review of the history and evolution of 
PDMPs. Ideally, PDMPs offer the opportunity for providers to adequately manage pain 
with opioid analgesics while also providing a barrier to prescription opioid misuse. 
PDMPs are programs that fundamentally act to restrict the aggregate availability, or 
supply, of prescription opioids, and thus may be considered ‘supply side’ interventions. 
Recently, Some pundits and journalists have anecdotally reported that by reducing the 
availability of prescription opioids, PDMPs—and specifically PDMPs with particular 
robust features—may be driving individuals to use heroin rather than prescription 
opioids and thus may in part be responsible for increasing rates of IORPs.102-106 
 In general, all PDMPs operate similarly. Data generated at the time of medication 
dispensing is uploaded to a central data server that is accessible to authorized users. 
Though all programs have this same basic functionality, it is well known that there is 
tremendous heterogeneity between states in terms of individual PDMP features.20,54,107 
PDMPs may vary in terms of CS Schedules monitored, reporting requirements, and 
whether prescribers are required to use the PDMP data, among other characteristics. 
These specific PDMP features may have important impacts on the efficacy of individual 
programs. For example, a PDMP that monitors all CS Schedules, requires dispensers to 
report CS dispensing on a daily basis, generates unsolicited reports for prescribers, and 
requires prescribers to query the data before issuing CS prescriptions, may allow for 
easier detection of potential medication misuse or diversion relative to less 
comprehensive programs.69,108-110 
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 Though there have been many previous efforts to examine associations between 
PDMP implementation and trends in PORP rates, only two of these studies have 
specifically examined the impact of different PDMP features. A 2016 study by Patrick et 
al. utilizing CDC WONDER data from 1999 – 2013 found that PDMPs that monitored four 
or more CS schedules, and updated data at least weekly were associated with 
significantly greater reductions in the rate of opioid-related deaths relative to programs 
without these characteristics.42 In a more recent study also utilizing CDC WONDER data, 
Pardo quantified PDMP ‘strength’ by creating a numeric system that assigned weights to 
different features of operational PDMPs. Pardo did not investigate the impact of 
individual features, but found that every 1-point increase in PDMP ‘strength’ was 
associated with a 1% reduction in the rate of prescription opioid-related mortality.90 
Recently, there has also been interest in associations between PDMP 
implementation and trends heroin use. Ali et al. found that implementation of PDMPs 
was associated with a nonsignificant increase in the number of days of reported heroin 
use in respondents to the National Survey of Drug Use and Health (NSDUH).81 In a non-
peer reviewed report, Justine Mallat found that PDMP implementation had a 
heterogeneous impact on rates of heroin-related crime incidents in a sample of 38 
states.111 Finally, in a 2017 study using TEDS data, Branham found that after PDMPs 
were implemented there was a positive association between number of patients 
reporting prescription opioids and number of patients reporting heroin as their primary 
drug used.80 This finding goes against the theory that increasing heroin use is related to 
decreases in prescription opioid use following PDMP implementation. Taken together, 
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these studies suggest that PDMPs may be associated with increases in heroin use, but 
none offer convincing evidence that PDMPs are driving the recent increases in IORPs.  
 Despite the plethora of research examining the impact of PDMPs on the US 
opioid epidemic, several prominent gaps remain to be addressed. First, only one study 
to date has explored associations between individual PDMP features and trends in 
PORPs. Second, no research has examined differential associations between PDMP 
implementation and trends in rates of PORPs vs. rates of IORPs. The study presented in 
this chapter addresses both of these gaps and is also the first to specifically examine the 
impact of PDMP implementation in a population of privately insured adults. The specific 
aims of this study were to: I. Examine associations between specific features of 
operational PDMPs and trends in PORPs in a nationally representative sample of 
privately insured adults; and II. Assess associations between PDMP features and trends 
in IORPs over time in the same population of privately insured adults. 
Please note that this study consisted two related but distinct analyses. The 
separate components of this study utilized nearly identical methodology to assess the 
two outcomes of interest. For the purposes of brevity and clarity, the methodology and 
discussion of these analyses are presented in tandem however the results are described 
separately.  
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2.2 Methods 
2.2.1 Study Design 
This observational longitudinal study employed a ‘natural experiment’ design to 
assess associations between PDMP features and rates of PORPs and IORPs in a 
nationally representative sample of privately insured adults. Natural experiments are 
empirical studies wherein subjects are exposed to an intervention that is outside the 
control of the investigator.112 Changes in PDMP features—including timing of initial 
legislation enactment and program implementation, or alterations to specific 
functionality—were assessed monthly in all 50 states and the District of Columbia from 
January 2004 to December 2014. PDMP status was assessed on a monthly basis as 
changes in PDMP features occurred frequently and at irregular times during the study 
period. The unit of observation was the state-month, and including 51 states over an 11 
year period, the final dataset included 6,732 state-month observations. As discussed 
above, this study had two distinct outcomes of interest, the first being the number of 
PORPs and the second being the number of IORPs among the beneficiary population in 
each state-month from 2004 – 2014. The relative risk of PORP and IORP was calculated 
for each state-month during this period while controlling for specific PDMP features as 
well as demographic and clinical characteristics of the study population observed in 
each state-month. Given that this study was observational and relied on de-identified 
data collected for research purposes, it was deemed exempt from review by the 
University of Kentucky IRB. 
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2.2.2 Data 
This study utilized data from a variety of sources. Data regarding clinical events 
as well as the demographic and clinical characteristics of the privately insured adult 
population were obtained from the Truven Health Marketscan® Commercial Claims and 
Encounters database.113 Truven offers fully integrated pharmaceutical and medical 
administrative claims data with relevant health plan enrollment and demographic 
information. These data are nationally representative of the non-institutionalized 
privately insured and employed US population, and include all provider, facility and 
pharmaceutical claims for eligible beneficiaries. Truven collects data from a wide variety 
of insurance providers as well as large self-insured employers and includes data on 
approximately 20 – 30 million distinct individuals each year. All individuals who were 
aged 18 or over and were enrolled for at least one full month with pharmacy and 
medical benefits at some point from 2004-2014 were included in the study population. 
Individual patient claims and demographic data were aggregated into rates and 
percentages at the state-month level. 
Data regarding the status of PDMPs in each state-month were gleaned from two 
separate data sources—the National Alliance for Model State Drug Laws (NAMSDL) and 
the Prescription Drug Abuse Policy System (PDAPS). NAMSDL is a non-profit group that 
receives funding from the federal government to assist in the planning and 
enhancement of PDMPs and also publishes resources regarding the past and present 
status of PDMPs.21 PDAPS is a research tool funded by the National Institute on Drug 
Abuse (NIDA) to track state laws related to prescription drug abuse.114 The NAMSDL and 
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PDAPS data were both used to assess the timing of PDMP legislation enactment and 
program operation. Data regarding the status of specific PDMP features, and dates that 
these features were implemented, were obtained from PDAPS. These data sources are 
both commonly used in longitudinal studies examining PDMPs.42,67,81,82,90,115 
2.2.3 Outcome and Covariate Measures 
This study examined two distinct outcomes of interest, the first being the count 
of PORPs observed in each state-month and the second being the count of IORPs 
observed in each state-month. Since these outcomes were assessed in a similar manner, 
they are henceforth referred to collectively as ‘poisonings’ for the remainder of this 
section. Poisonings were identified from inpatient hospital admissions and emergency 
department visit claims where at least one code for either poisoning type was listed. 
Hospital admissions were identified using the inpatient hospital admissions claims file 
from Truven, and emergency department visits were identified as inpatient or 
outpatient claims where the place of service code was marked as ‘23’. The CDC guide to 
ICD-9-CM codes related to poisoning and pain was used to identify ICD-9-CM codes for 
PORPs and IORPs.95 Table 2.1 presents the ICD-9-CM codes used to identify PORPs and 
IORPs. Since patients experiencing a poisoning often have multiple claims where the 
poisoning is listed as a diagnosis, rigorous methods were employed to avoid double 
counting poisoning events. Only one PORP or IORP was counted per patient per day. 
Patients who had both a PORP and IORP diagnosis listed on the same claim were 
counted as having a PORP as well as an IORP on that day. Any poisoning diagnosis 
observed in outpatient claims were required to have the place of service listed as ED as 
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routine follow-up care from an initial poisoning is unlikely to occur in the ED setting. 
Finally, hospital admission claims with a poisoning diagnosis that had the same 
admission date as a preceding poisoning-related hospital admission’s discharge date 
were not counted, as these likely represent transfers from one institution to another.  
Demographic covariates of interest in this study included the percentage of the 
enrolled Truven population in each state-month that were male, the percentage that 
were aged 25 – 35, and the geographic region of each state. For calculating percentages 
at the state-month level, the denominator was the total number of person-months of 
eligibility in each state month. Eligibility was defined as being enrolled for an entire 
month with both pharmacy and medical benefits. For example, the number of male 
person-months was divided by the total number of person-months observed in a given 
state-month to determine the percentage of the population that were male in that 
state-month. These covariates were chosen as they are the only demographic 
characteristics available in the Truven data. The percentage of beneficiaries aged 25-35 
was chosen as a covariate over other age groupings because this group experienced the 
highest rates of drug overdose deaths in 2016.3 Geographic region was defined 
according to US Census Bureau regions.116  
The only clinical covariate included in this study was the rate of diagnosed 
substance use disorder (SUD) observed in each state-month. SUD diagnoses were 
defined according to Clinical Classification Software (CCS) grouping 661 from the 
Healthcare Cost and Utilization Project (HCUP).117 CCS is a diagnosis categorization 
scheme that groups ICD-9-CM codes into clinically meaningful categories, and group 661 
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includes diagnoses related to SUD.117 The rate of SUD in each state-month was 
calculated as the number of person-months in which at least one diagnosis from CCS 
group 661 was observed, per 100,000 total person-months observed in that state-
month. This was chosen as a covariate of interest as diagnosed SUD is a known risk 
factor for PORP.118,119  
Enactment of PDMP legislation may induce changes in prescribing practices 
before the programs are formally operational.42 In order to adjust for this possibility, 
this study was careful to distinguish the date that PDMP legislation was enacted and the 
date that programs became formally operational. For the purposes of this study, PDMPs 
were defined as being operational when they made data available to prescribers or law 
enforcement officials. Dates of PDMP legislation enactment as well as dates of data 
availability are reported by both NAMSDL and PDAPS, however, the dates that these 
groups report are at times inconsistent. To address this shortcoming, the date of PDMP 
legislation enactment was conservatively defined as the earliest date reported by one of 
these groups and the date that PDMPs became operational was conservatively defined 
as the latest date reported by one of these groups. The PDAPS data were used when 
dates were not available from NAMSDL. 
Data regarding the status of specific PDMP features, and dates that these 
features were implemented, were obtained from PDAPS. This study examined five 
distinct features of PDMPs: 1. Whether the PDMP was operational—defined as 
prescribers or law enforcement having access to the data; 2. CS Schedules monitored by 
the PDMP (II only or II-III, II-IV, and II-V); 3. Frequency of data reporting from dispensers 
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to the PDMP central server (monthly or less, weekly, and daily); 4. Requirement for 
unsolicited reporting of patients’ CS prescription history to in-state prescribers or 
licensure boards; and 5. Mandated (as defined by PDAPS) prescriber query of PDMP 
data prior to prescribing in certain circumstances. Other PDMP features of interest, 
including mandatory registration with the PDMP and PDMP utilization rate by 
prescribers, were not included in the study due to data constraints. Nebraska is the only 
state with an operational PDMP that does not require dispensers to report data to the 
PDMP central server.66 Because it is the only PDMP that is entirely voluntary, it was 
excluded from the present analysis.  
Each of the five PDMP variables were coded to reflect when no PDMP legislation 
had been enacted, PDMP legislation was enacted but the program was not yet 
operational, and finally when the PDMP was operational with a given level of the 
covariate. For example, the variable for requirement of unsolicited reporting of patients’ 
CS prescription history was coded as: 0= No PDMP, 1= PDMP enacted but not 
operational, 2= PDMP operational without unsolicited reporting, and 3= PDMP 
operational with some unsolicited reporting. Each PDMP characteristic of interest, and 
its constituent levels are presented in Table 2.2. Changes to specific PDMP features 
were assessed monthly and a set of time varying indicator variables were created to 
describe PDMP features in each state-month. Variables were coded to reflect the first 
full month that a given feature was in place. 
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2.2.4 Statistical Analysis 
Generalized estimating equation (GEE) Poisson regression models were fit to 
estimate the risk of PORP and IORP associated with PDMP features while adjusting for 
demographic and clinical characteristics of the privately insured Truven population. 
While some previous studies have used negative binomial regression methods to model 
counts of drug-related poisonings, over-dispersion was not a significant problem in 
these data (the deviance divided by the degrees of freedom ranged from 1.042 – 1.425 
in the models investigated) and so the simpler Poisson regression model was used 
instead.82,120 The unit of analysis was the state-month and the modeled outcomes of 
interest were the monthly counts of PORP and IORP observed in each state-month. 
Adjusted models were derived separately for the two distinct outcomes of interest for 
each of the five PDMP features. This study was fundamentally interested in examining 
whether certain PDMP features may be more strongly associated with trends in PORP 
rates than other features. With this in mind, separate models were fit for each PDMP 
feature to provide greater granularity in terms of the relative impacts of each feature. 
Thus the primary results of this study are presented in the form of ten separate adjusted 
GEE models—five investigating associations between PORPs and PDMP features, and 
five investigating associations between IORPs and PDMP features.  
All ten adjusted GEE models relied on the same assumptions and were specified 
in a similar manner—the only difference being the particular PDMP feature variable 
included in the model. Each model included one PDMP feature, as well as variables for 
time (coded as the number of months since the study period began, i.e. January 2004 = 
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0 December 2014 = 132 etc.), geographic region, rate of diagnosed SUD, percentage of 
the population that were male, and percentage of the population that were aged 25-35 
years old. State-month Truven beneficiary population counts expressed as natural 
logarithms were used as an offset term in each model to adjust for variation in Truven 
population sizes for any given state-month. Robust standard errors were calculated to 
adjust for repeated measures from each state. The monthly covariance structure in each 
state was selected as a first-order autoregressive process to account for 
autocorrelations in the time series.121 
Each adjusted GEE model also included an interaction between the PDMP 
feature of interest and time, to model the risk difference in PORP or IORP over time in 
states with and without the given PDMP feature. These models are interpreted as fitting 
multiple summary regression lines to the data. The differences in intercepts between 
these lines addresses baseline differences (at month= 0, or January 2004) in mean rates 
of PORP and IORP in states with and without the PDMP feature of interest. Differences 
in slopes—as characterized by the parameter estimate for the interaction term—
represent the different trends in PORP and IORP over time for states at different levels 
of the PDMP feature of interest. As mentioned above, Nebraska was excluded from all 
statistical analyses because it is the only state with a voluntary PDMP.  
The Poisson regression models were fit in SAS Enterprise Guide version 5.1 using 
PROC GENMOD with the REPEATED statement to implement the GEE approach. 
Reference coding scheme was used in regression parameter estimates allowing 
calculation of the adjusted relative risk (aRR) for PORP and IORP associated with each 
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variable by exponentiation of the relevant parameter estimate. Statistical significance 
was assessed as p < 0.05 for all analyses. Figures were generated using SAS Enterprise 
Guide version 5.1, Tableau version 10.3, and JMP version 12. 
2.2.5 Sensitivity Analyses  
Naloxone Access Laws 
 Naloxone is an FDA approved prescription medication that can be used to 
reverse the effects of an acute opioid-related poisoning.122 In recent years, states have 
begun to enact legislation to increase the availability of naloxone for family, friends, and 
other potential bystanders of opioid-related poisonings.123  At present, all states have 
enacted some sort of legislation to remove legal barriers to naloxone access.123 Most 
commonly, states have begun to permit naloxone prescribing to individuals other than 
the person at risk of opioid-related poisoning, or have otherwise removed the need for 
a person to see a prescriber before obtaining the medication.123 Implementation of 
these ‘naloxone access laws’ may be associated with aggregate trends in opioid-related 
poisonings.90,124 With this in mind, this study implemented a sensitivity analyses to 
control for the presence of Naloxone access laws at the state level. Data on the timing 
of naloxone access law implementation were gathered from PDAPS.125 A binary dummy 
variable was created to describe whether states had any type of naloxone access laws in 
place for the majority of each year from 2004 – 2014. The GEE Poisson regression 
models discussed in the statistical analysis section above were re-fit including this 
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variable in order to assess whether naloxone access laws attenuate associations 
between PDMP features and trends in PORPs and IORPs. 
Buprenorphine Prescribing 
Buprenorphine is an FDA approved medication used to treat opioid dependence 
by preventing symptoms of withdrawal from heroin and other opioids.126 Previous 
research has demonstrated that, at the individual level, buprenorphine use is associated 
with a protective effect on risk of opioid-related poisonings.127-129 In the United States, 
physicians interested in prescribing buprenorphine must apply for a waiver from the 
registration requirements of the Controlled Substance Act and also must complete 
required training.130 The number of waivered physicians eligible to prescribe 
buprenorphine has increased rapidly in recent years.130-132 Similarly, the percentage of 
opioid treatment programs offering buprenorphine increased from about 11% in 2003 
to approximately 58% in 2015.133 With this in mind, this study implemented a sensitivity 
analysis to adjust for aggregate rates of buprenorphine prescribing at the state-month 
level. Due to data constraints, rates of buprenorphine use could only be calculated for 
the years 2009 – 2014. Buprenorphine prescribing was identified from outpatient 
pharmacy claims data using GPI codes. Both mono (buprenorphine hydrochloride) and 
combination (buprenorphine hydrochloride and naloxone hydrochloride) buprenorphine 
formulations were included in the analysis. The rate of buprenorphine use was defined 
as the number of individuals receiving at least one buprenorphine prescription in each 
state-month per total 100,000 individuals observed in each state-month. The GEE 
Poisson regression models discussed in the statistical analysis section above were 
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initially re-fit only including observations from 2009 – 2014. Results from these models 
were compared to results of GEE models that included the buprenorphine prescribing 
rate in each state-month as an additional covariate.   
2.3 Results 
2.3.1 Changes to PDMPs 
There was a substantial increase in the number of states with operational PDMPs 
over the study time period. Figure 2.2 presents a visualization of when PDMP legislation 
was enacted and when programs became operational in each state from 2001 – 2014. 
While 13 states had operational PDMPs in December 2014, 47 states and the District of 
Columbia had operational PDMPs at the end of 2014. This time period also saw many 
changes to important characteristics of operational PDMPs. Table 2.3 displays the 
number of states with operational PDMPs with certain features in place for the majority 
of the year in each year from 2004 – 2014. In 2004, only 2 of the 13 (15.4%) operational 
PDMPs required weekly or daily data reporting from dispensers, but by 2014, 38 of the 
47 (80.9%) operational PDMPs had this feature in place. PDMPs also experienced an 
increase in the number of drug schedules monitored. In 2004 nearly one-third of 
operational PDMPs only collected data on Schedule II, or Schedules II + III Controlled 
Substances, however, in 2014 all operational PDMPs monitored either Schedules II – IV 
or all Schedules II – V. PDMPs that sent unsolicited reports to prescribers, law 
enforcement, or licensure boards, as well as PDMPs that required prescribers to query 
the PDMP data in certain situations also became more popular in recent years. In 2014, 
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nearly 40% of operational PDMPs required unsolicited reporting while only 15.4% had 
such a requirement in 2004. Finally, no states required prescribers to query the PDMP 
data in 2004 but in 2014 nearly 20% of operational PDMPs had this requirement in 
place.   
From January 2004 – December 2014 there were 6,600 state-months observed, 
with 3,858 (58.5%) of those state-months having operational PDMPs in place, and 1,111 
(16.8%) having PDMP legislation enacted without operational programs. Table 2.4 
presents descriptive statistics of the state-months included in the study population, 
stratified by PDMP status. Over the 6,600 state-months, there were over 2.6 billion 
person-months observed. The mean percent of the Truven population that were male, 
and the mean percent aged 25 – 35 was generally consistent among state-months with 
and without operational PDMPs. However, substantial variation in the mean rate of 
diagnosed SUD was observed. State-months without PDMPs had a mean rate of 
diagnosed SUD of 66.78 per 100,000 person-months observed, while state-months with 
operational PDMPs had a mean rate of 151.66 per 100,000, and state-months with 
PDMP legislation enacted without operational programs had a mean rate of 102.58 per 
100,000. 
2.3.2 PORP Specific Results 
Over the eleven year study period there were a total 40,766 distinct PORPs 
observed. The overall rate of PORP from 2004 – 2014 was 1.52 per 100,000 person 
months observed. This rate was calculated as the total number of PORP events per 
54 
 
100,000 person-months observed over the entire study period. Figure 2.3 displays the 
overall PORP rate in each year from 2004 – 2014. There was a statistically significant (p < 
0.0001), 108% increase in the mean PORP rate over the study period, from 0.92 per 
100,000 person-months in 2004 to 1.92 per 100,000 person-months in 2014. These 
rates were calculated as the average PORP rate observed in all state-months in 2004 and 
2014. Figure 2.4 presents the trends in overall annual PORP rate stratified by PDMP 
status. This was calculated as the mean PORP rate for all state-months with a given 
PDMP status in each year. This figure shows that state-months with operational PDMPs 
had slightly higher overall PORP rates in 2004 relative to state-months without PDMPs 
(0.946 vs. 0.896 per 100,000 person-months). Again, overall rates were calculated as the 
total number of PORP events observed in state-months with a given PDMP status, per 
100,000 person-months observed in those state-months. Though there was a consistent 
increase in overall PORP rates for all groups from 2004 – 2014, state-months with 
operational PDMPs had a markedly lower overall PORP rate in 2014 than state-months 
without PDMPs (1.792 vs. 2.073 per 100,000 person-months). Referring to Table 2.4, we 
can also see that state-months with operational PDMPs had a higher overall PORP rate 
relative to states without PDMPs over the entire study period (1.621 vs. 1.180 per 
100,000). 
There was substantial variation in the overall PORP rate between states during 
the study period. The heat map in Figure 2.5 displays the overall PORP rate from 2004 – 
2014 in each state. The overall PORP rate ranged from a low of 0.630 per 100,000 
person-months in DC to a high of 2.984 per 100,000 person-months in New Mexico. 
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Figure 2.5 also indicates that states in the Western region of the United States generally 
experienced the greatest overall PORP rates in this population.  
Raw parameter estimates from the GEE Poisson regression model assessing the 
association between PDMP implementation status and PORP rates are presented in 
Table 2.5. In the adjusted model, states with operational PDMPs had significantly higher 
PORP rates compared to states without PDMPs at baseline (p=0.0005). The estimated 
adjusted regression coefficient for time was positive (β= 0.008), suggesting that the 
PORP rate increased significantly over the study period (p < 0.0001). The regression 
coefficient for the interaction between the indicator for ‘PDMP operational’ and time 
was negative (β= -0.005) and statistically significant (<0.0001), suggesting that 
operational PDMPs significantly mitigate the increases in PORP rate over time relative to 
states without PDMPs. Western states were observed to have significantly higher PORP 
rates relative to the rest of the US. Increasing rates of diagnosed SUD and a greater 
proportion of the population being male were associated with significantly increased 
PORP rates. The percentage of the population that were aged 25-35 years old was not 
significantly associated with PORP rates. 
Table 2.6 presents the exponentiated GEE parameter estimates from Table 2.9. 
These may be interpreted as changes in the aRR of PORP associated with a one unit 
change in the covariates of interest. For example, state-months experienced a 
statistically significant increase in the RR of PORP of 1.028 [95% CI: 1.002 – 1.053] times 
for every one percent increase in the percent of the population that was male. The 
exponentiated form of the time effect variables may be used to understand how the 
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aRR of PORP changes over time in states with and without PDMPs. States without 
PDMPs experienced an average increase in aRR of PORP of 1.008 [95% CI: 1.005 – 1.01] 
times from one month to the next over the study period. However, states with 
operational PDMPs only experienced an average increase in aRR of PORP of 1.003 [95% 
CI: 1.001 – 1.004] times from one month to the next. Because this 95% CI does not 
overlap with the CI associated with aRR of PORP over time in states without PDMPs, 
these results imply that states with operational PDMPs had significantly lower increases 
in aRR of PORP over time relative to states without operational programs. 
Adjusted RRs of PORP associated with one month increases in time for states 
with different PDMP features are presented in a forest plot in Figure 2.6. In some 
circumstances, states with operational PDMPs did not have significantly different 
increases in aRR of PORP over time relative to states without PDMPs. Namely, states 
with operational PDMPs that did not require unsolicited reporting, only required 
monthly data reporting from pharmacies, or only monitored Schedule II or Schedule II-III 
Controlled Substances did not have significantly different aRR of PORP over time relative 
to states without PDMPs.  
In all adjusted models, states without PDMPs and those that had passed PDMP 
legislation but did not yet have operational programs, exhibited significant increases in 
the aRR of PORP from one month to the next. In three of the four adjusted models 
examining features of operational PDMPs, states with operational PDMPs that lacked 
specific features had significant increases in aRR of PORP over time (and these increases 
were not significantly different from those in states without PDMPs), but states with 
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operational PDMPs that did have these features did not have significant changes in aRR 
of PORP over time. For example, states with operational PDMPs that did not require 
unsolicited reporting of PDMP data to prescribers or licensure boards experienced an 
average increase in aRR of PORP of 1.003 times (95% CI: 1.001 – 1.005) from one month 
to the next, while states with operational PDMPs that did require unsolicited reporting 
in certain circumstances did not experience a significant change in aRR of PORP over 
time (aRR: 1.001 [95% CI: 0.998 – 1.003]). Further, states with operational PDMPs that 
required dispensers to upload dispensing data on a weekly or daily basis and those with 
PDMPs that required prescribers to query the PDMP data in certain situations, did not 
experience significant changes in aRR of PORP over time, but states with operational 
PDMPs that lacked these features did have significant increases in aRR over time.  
2.3.3 IORP Specific Results 
From 2004 – 2014 there were a total of 10,822 distinct IORPs observed (Table 
2.4). The overall rate of IORP from 2004 – 2014 was 0.403 per 100,000 person-months 
observed. Figure 2.3 displays the overall IORP rate in each year from 2004 – 2014. There 
was a statistically significant (p < 0.0001), 1,219% increase in the mean IORP rate over 
the study period, from 0.076 per 100,000 person-months in 2004 to 1.008 per 100,000 
person-months in 2014. The overall and mean IORP rates were calculated in the same 
manner as for the overall and mean PORP rates. Figure 2.7 presents the trends in overall 
annual IORP rates stratified by PDMP status. The figure shows that state-months with 
operational PDMPs had nearly identical overall IORP rates in 2004 relative to states 
without PDMPs (0.092 vs. 0.087 per 100,000 person-months). There was a consistent 
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increase in overall IORP rates for all groups from 2004 – 2014, and in 2014 state-months 
with operational PDMPs had a slightly higher overall IORP rate relative to states without 
PDMPs (0.973 vs. 0.888 per 100,000 person-months). 
There was substantial variation in the overall IORP rate between states during 
the study period. The heat map in Figure 2.13 displays the overall IORP rate from 2004 – 
2014 in each state. The overall IORP rate ranged from a low of 0 in Hawaii, where we did 
not observe any IORPs over the study period, to a high of 1.030 per 100,000 person-
months in Massachusetts. Figure 2.13 also indicates that states in the Northeast and 
Midwest regions of the United States generally experienced the greatest overall IORP 
rates in this population.  
Raw parameter estimates from the GEE Poisson regression model assessing 
associations between PDMP implementation status and IORP rates are presented in 
Table 2.7. In the fully adjusted model, states with PDMP legislation enacted without 
operational programs, as well as states with operational PDMPs did not have 
significantly different IORP rates relative to states without PDMPs at baseline (p = 0.266 
and p = 0.497 respectively).  The estimated regression coefficient for the time indicator 
was positive and statistically significant (β= 0.0112, p= 0.0013), suggesting that the IORP 
rate increased significantly over the study period. The coefficient for the interaction 
between the indicator variable for ‘PDMP operational’ and time was positive and was 
not statistically significant (β= 0.0025, p= 0.5103). This implies that states with 
operational PDMPs also experienced increases in the IORP rate over the study period, 
but these increases were not significantly different than those observed for states 
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without PDMPs. Midwestern states were seen to have significantly higher IORP rates 
while Southern states had significantly lower IORP rates relative to states in the Western 
region of the US. Increasing rates of diagnosed SUD and a greater percentage of the 
population being male were associated with significantly increased IORP rates. The 
percentage of the population that were aged 25-35 years old was not significantly 
associated with IORP rates.  
Table 2.8 presents the exponentiated GEE parameter estimates from Table 2.14. 
These are interpreted as changes in the aRR of IORP associated with a one unit change 
in the covariates shown. For example, state-months experienced an increase in the aRR 
of IORP of 1.059 [95% CI: 1.002 – 1.120] times for every one percent increase in the 
percent of the population that was male. As in the PORP specific results above, we can 
use the exponentiated form of the time effect variables to understand how the aRR of 
IORP changes over time in states with and without PDMPs. States without PDMPs 
experienced an average increase in the aRR of IORP of 1.011 [95% CI: 1.004 – 1.018] 
times from one month to the next over the study period. States with operational PDMPs 
also experienced statistically significant increases in the aRR of IORP from one month to 
the next (aRR: 1.014 [95% CI: 1.009 – 1.019]). These results indicate that states with 
operational PDMPs experienced slightly greater increases in the aRR of IORP over the 
study time period, however since the confidence intervals overlap substantially, we can 
see that the increases were not significantly different.  
Adjusted RRs of IORP associated with one month increases in time for states with 
different PDMP features are presented in a forest plot in Figure 2.9. In four out of the 
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five models, operational PDMPs—regardless of features present—do not have 
significantly different increases in aRR of IORP over time relative to states without 
PDMPs. The exception is the model investigating unsolicited reporting. States with 
operational PDMPs that require unsolicited reporting experienced average increases in 
aRR of IORP of 1.025 (95% CI: 1.020 – 1.030) times from one month to the next, while 
states without PDMPs experienced average increases of 1.012 (95% CI: 1.004 – 1.018) 
times from one month to the next. Because these CI’s do not overlap, we can see that 
states with operational PDMPs that required unsolicited reporting experienced 
significantly greater increases in aRR of IORP over time relative to states without 
PDMPs. In the model investigating data reporting frequency, states with PDMPs that 
required more frequent data reporting were trending towards having greater increases 
in aRR of IORP over time, however, these increases were not significantly different from 
those for states without PDMPs.  
2.3.4 Sensitivity Analyses 
Naloxone Access Laws 
 The number of states with naloxone access laws in place for the majority of the 
year increased substantially during the study period, from 2 states in 2004 to 25 states 
in 2014. Overall, there were 864 state-months with naloxone access laws in place from 
2004 – 2014. Results of the sensitivity analysis revealed that naloxone access laws were 
associated with reduced PORP rates in each of the GEE models examined, however, 
none of these associations were statistically significant. P-values for the naloxone access 
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law indicator variable ranged from 0.103 – 0.417 in the models investigating PORPs. 
Furthermore, the presence of this variable did not attenuate associations between 
PDMP features and trends in PORP rates over time in any of the models constructed. An 
example of these results are presented in Table 2.9. 
 Results of the sensitivity analysis examining associations between naloxone 
access laws and IORP rates revealed that naloxone access laws were significantly 
associated with greater IORP rates in four of the five models constructed. Raw 
parameter estimates from one of these models are presented in Table 2.10. Even 
though these variables were significantly associated with IORP rates, including them in 
the GEE models did not impact the significance of associations between PDMP features 
and trends in IORP rates. For example, in the main analysis, states with operational 
PDMPs that required proactive reporting were associated with significantly greater 
increases in IORP rates over time relative to states with operational PDMPs that did not 
require proactive reporting. This finding was also observed in the sensitivity analysis, 
despite the parameter estimates for the interaction terms being slightly different than 
those observed in the main analysis. The only model where naloxone access laws were 
not associated with IORP rates was the model examining number of CS schedules 
monitored, and here the naloxone access law indicator variable was trending towards 
significance (p-vale 0.095).  
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Buprenorphine Prescribing 
 The rate of buprenorphine use increased rapidly during the study period, from a 
mean of 64.5 users per 100,000 beneficiaries in 2009 to 137.5 users per 100,000 
beneficiaries in 2014. Greater rates of buprenorphine prescribing were generally 
associated with higher PORP rates at the state month level however these associations 
were not statistically significant. P-values for the buprenorphine prescribing rate 
variable ranged from 0.052 – 0.217 in the GEE models constructed. Parameter estimates 
for the interaction terms between PDMP features and the time indicator variable were 
nearly equivalent in models including and not including the rate of buprenorphine use 
as a covariate. Examples of these results are presented in Tables 2.11 and 2.12. 
 In models examining trends in IORPs, greater rates of buprenorphine use were 
associated with significantly greater rates of IORPs. Despite these variables being 
statistically significant, there were only negligible differences in parameter estimates for 
the interaction terms between PDMP features and the time indicator variables in 
models that did and did not include this covariate. These results may be seen  in Tables 
2.13 and 2.14. For example, in a model that did not include the rate of buprenorphine 
prescribing as a covariate, states with operational PDMPs were associated with an 
increase in IORP rates of 1.0158 times from one month to the next. However, In a model 
that did include the rate of buprenorphine prescribing as a covariate, states with 
operational PDMPs were associated with an increase in IORP rates of 1.0157 times from 
one month to the next. Similar differences were seen in models investigating specific 
PDMP features as well.  
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2.4 Discussion 
Over the last two decades, the number of operational PDMPs in the United 
States has grown rapidly in response to the increasing intensity of the opioid epidemic. 
In the privately insured adult population included in this study, rates of prescription and 
illicit opioid-related poisonings both increased significantly from 2004 – 2014. While the 
rates observed in this study are substantially different from those reported for the 
population at large, the trends observed over this time period generally resemble those 
reported by the CDC (comparing Figure 2.1 and Figure 2.3), which includes data for all 
insurance types and age groups.  
This study found that operational PDMPs, and specifically those with more 
comprehensive or robust features, were associated with higher mean rates of PORP and 
IORP relative to states without PDMPs. However, states that did not have operational 
PDMPs experienced significant increases in the aRR of PORP over time during this study 
period, while states with operational PDMPs with certain robust features did not 
experience significant changes in the aRR of PORP over time. Contrarily, the results of 
this study suggest that operational PDMPs had little effect on changes in the aRR of 
IORP over time.Taken together these results suggest that operational PDMPs have 
helped to mitigate the prescription opioid epidemic but have exerted little effect on 
illicit opioid-related morbidity.   
As seen in the CDC data presented in Figure 2.1, the prescription opioid epidemic 
preceded the recent rise in IORPs. Further, PDMPs have historically been designed to 
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address problems with prescription drug diversion and misuse. With this in mind, it is 
plausible and in fact likely, that state legislatures initially implemented PDMPs and 
further strengthened existing programs in response to relatively high rates of 
prescription opioid-related morbidity and mortality occurring within their states. This 
possibility is reflected in our finding that PDMPs with certain features are associated 
with higher baseline RR of PORP. However, once implemented, operational PDMPs, and 
specifically those with robust features such as sending unsolicited reports and requiring 
more frequent reporting from dispensers, exert a protective effect on at-risk 
populations moving forward. While this framework may not fit each state individually, it 
reflects the population-average results. 
There are several plausible mechanisms by which PDMPs may reduce the supply 
of prescription opioids analgesics and thus reduce the risk of PORP in the privately-
insured adult population. Prescribers may utilize PDMP data at the point of care, 
allowing them to identify patients with multiple provider episodes or potentially 
inappropriate overlapping prescriptions of other CS (i.e. benzodiazepines, muscle 
relaxants etc.). One previous study found that most prescribers surveyed indicated that 
accessing PDMP data altered their CS prescribing.134 PDMPs may also assist professional 
licensure boards and law enforcement officials in identifying and potentially prosecuting 
prescribers with aberrant CS prescribing. The current study does not fully elucidate the 
mechanism by which PDMPs may reduce opioid-related morbidity. However, we did find 
that states with operational PDMPs that send unsolicited reports to professional 
licensure boards or prescribers, as well as those that require prescribers to query the 
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PDMP data in certain situations avoided significant increases in the aRR of PORP over 
time.  
Some researchers and pundits have pointed to PDMPs—along with other system 
level interventions attempting to reduce overall supply of prescription opioids—as a 
potential catalyst for the increases in IORPs observed in recent years.102-106 
Theoretically, by making it more difficult to obtain prescription opioids, individuals 
suffering from drug addiction are forced to substitute prescription drugs for illicit 
opioids such as heroin. If PDMPs were driving this substitution, our results would have 
indicated that operational PDMPs were associated with significantly greater increases in 
aRR of IORP over time relative to states without PDMPs. In actuality, we observed little 
differences in changes in aRR of IORP over time between states with and without 
operational PDMPs.  
Although this substitution theory did not clearly play out in our data, there are 
several reasons why it may still be true despite our failure to observe it in this 
population.  First, it may be that this type of substitution is more prominent in the 
Medicaid or uninsured populations relative to the privately insured. Descriptive results 
from this study show that the privately insured are substantially less prone to IORPs 
relative to PORPs (Table 2.4). Second, it may be that the substitution is engendered by 
other opioid-related policies not investigated in this study, such as crackdowns on pill 
mills in certain states, or the release of abuse deterrent oxycodone. Finally, it may be 
that the time frame included in this study is not recent enough to adequately capture 
the phenomenon. Theoretically, this type of substitution would be a downstream effect 
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of robust PDMP policies that were just beginning to increase in popularity towards the 
end of the study period.  
Presently, every state except for Missouri has an operational PDMP, however, 
the results of this study may be used as evidence to support the adoption of several key 
features. As in previous studies, these results indicate that PDMPs should strive to 
monitor all CS Schedules and should require dispensers to report prescription data on a 
daily or at least weekly basis. Results of this study also show that operational PDMPs 
that lack specific features, specifically mandatory querying or unsolicited reporting, are 
associated with significant increases in the aRR of PORP over time. In contrast, 
significant changes in aRR of PORP over time were not observed in states with 
operational programs that have implemented these features. These findings should be 
used by state policymakers to support the adoption of progressive PDMP features, and 
should also quell concerns that robust PDMPs are pushing individuals to use illicit 
opioids.  
The main results of this study still held upon completion of two robust sensitivity 
analyses. In the first, GEE models were re-fit including an indicator variable for naloxone 
access laws. Results of this sensitivity analysis indicated that naloxone access laws were 
not significantly associated with PORP rates at the state level, nor did they impact 
observed associations between PDMP features and trends in PORP rates over time. On 
the other hand, these laws were observed to be significantly associated with greater 
IORP rates. However, again it was seen that including this variable in the adjusted GEE 
models did not lead to substantial changes in the observed associations between PDMP 
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features and trends in IORP rates. It is not immediately clear why naloxone access laws 
were observed to be  significantly associated with higher IORP rates but were not 
significantly associated with PORP rates. It may be that states with the highest IORP 
rates reactively implement naloxone access laws, or use of naloxone may allow more 
individuals to survive initial IORPs and eventually be seen in the ED. 
The second sensitivity analysis sought to examine whether trends in 
buprenorphine prescribing  impacted observed associations between PDMP features 
and trends in rates of PORPs and IORPs. Results indicated that state-month rates of 
buprenorphine prescribing were not significantly associated with PORP rates, and 
associations between PDMP features and trends in PORP rates were nearly equivalent in 
models that did and did not include buprenorphine prescribing as a covariate. In models 
examining rates of IORPs, it was observed that greater rates of buprenorphine 
prescribing were generally associated with significantly higher IORP rates. Despite this 
statistical significance though, associations between PDMP features and trends IORP 
rates over time were not substantially different in models that did and did not include 
buprenorphine prescribing as a covariate. 
This study addressed several important gaps in the PDMP literature. First, even 
though it is well known that PDMPs exhibit variability among states, most studies 
investigating the impact of PDMPs on prescription opioid-related morbidity and 
mortality do not address program heterogeneity. Two recent studies investigating 
specific PDMP features found that PDMPs that monitor more schedules, require more 
frequent data reporting from dispensers, and have a greater number of robust features, 
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are associated with significantly lower rates of opioid-related mortality.42,90 The current 
study used rigorous feature attribution and statistical methods to both confirm and 
expand on the results of these studies. In addition to the two aforementioned features, 
our study also highlights the importance of PDMPs sending unsolicited reports and 
requiring mandatory data querying prior to controlled substance prescribing. 
Additionally, our study developed separate statistical models for each PDMP feature of 
interest to provide greater granularity in terms of the effects of individual program 
elements and, thus, offers further evidence to guide PDMP best-practices. 
This study is also the first to our knowledge to specifically assess differential 
effects of PDMPs on prescription vs. illicit opioid-related poisonings. The findings of this 
study suggest that PDMPs offer a useful tool in addressing increasing rates of PORP but 
that they have had little impact on burgeoning rates of IORP in recent years. This implies 
that in order to address recent increases in IORPs, additional system level interventions 
are needed, or PDMPs need to implement some novel functionality that goes beyond 
their historical function of solely monitoring CS prescribing. The existing PDMP 
infrastructure could serve as a useful starting point for innovations to help providers 
identify persons with SUD and assist them in obtaining treatment. PDMP data could be 
integrated with other data sources such as medical records or arrest records to identify 
persons at high risk of IORP or PORP and allow providers to intervene at an early stage.  
Finally, this study was the first to examine associations between PDMP 
implementation and rates of PORP and IORP specifically in a population of privately 
insured adults. Given that this is a generally healthy and employed population, the 
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overall rates of PORP and IORP observed in this study were substantially lower than 
annual rates reported by the CDC. Despite the relatively low rates in this population, it is 
still of interest for several reasons. Research suggests that the current opioid epidemic 
disproportionately impacts middle-class individuals relative to previous crises which 
have predominantly impacted the Medicaid population and minority groups.98,135,136 A 
recent study of opioid-related hospital admissions from 1993 - 2012 found a greater 
rate of increase in the privately-insured population than in the Medicaid or uninsured 
populations 137. Finally, as health care based programs, it is plausible that PDMPs may 
have a differential impact on the privately insured population than on the American 
public at large. If so, this might explain why previous studies, relying on data from all 
payer groups, have failed to find significant associations between PDMP implementation 
and trends in opioid-related mortality.  
2.5 Limitations 
Despite the strengths of this study, it was subject to several notable limitations. 
Most importantly, the administrative claims data used in this study are generated for 
reimbursement—not research—purposes and are prone to diagnosis misclassification. 
In particular, ICD-9-CM codes related to drug poisonings suffer from poor sensitivity due 
to limited utilization of drug screenings in healthcare settings. 138,139 A recent study by 
Rowe et al. found that the ICD-9-CM codes used in this study identified opioid-related 
poisoning ED visits with a sensitivity of 25% and a specificity of 99.9%.139 Importantly, 
this study did not differentiate the sensitivity and specificity for codes related to 
prescription vs. illicit opioid-related poisonings. Given this poor sensitivity and high 
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specificity, the aRR estimates found in this study are likely substantially below their true 
values.140 Although this impacts the magnitude of the aRR estimates found in this study, 
the results of this study are still valuable in terms of understanding the relative 
contribution of PDMP features. Take for example the model investigating associations 
between data reporting frequency and changes in the aRR of PORP over time. Even 
though each of these aRRs is likely underestimated, it still holds that weekly and daily 
data reporting are associated with protective effects on the aRR of PORP over time 
relative to monthly data reporting—regardless of what the actual magnitudes of those 
effects are.  
In addition to the poor sensitivity of opioid-related poisoning codes in general, it 
may also be difficult to differentiate PORPs from IORPs in the absence of drug screening 
data. Previous studies have found that drug screenings take place in only about 40% of 
ED visits for drug related poisonings.141,142 This is particularly problematic considering 
the recent rise of illicitly manufactured fentanyl. Although fentanyl is technically a 
prescription opioid, many of the fentanyl poisoning cases encountered today are due to 
fentanyl manufactured in China and shipped to the United States to be sold as heroin.96 
Presumably, in the absence of drug screenings, ED physicians will ask patients what 
substances may have led to their suffering an acute poisoning. Even if patients are 
forthcoming with this information, it is unlikely that they will know whether their 
‘heroin’ was in fact fentanyl mixed with other substances. Ideally, fentanyl poisonings 
would be examined separately from other ‘licit’ opioid-related poisonings, but the ICD-
9-CM codes used in this study are not able to distinguish fentanyl poisonings from other 
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types of PORPs. Fortunately for this study though, rates of fentanyl-related poisonings 
did not begin increasing rapidly until about 2014 (as seen in Figure 2.1), which was the 
last year of the study period. Further complicating this issue is the fact that heroin is 
metabolized into morphine.141 Thus even when drug screenings are used, they may 
misidentify heroin related poisonings if they are applied long after the poisoning event. 
This study also suffered from several other data limitations in addition to the 
weaknesses related to the opioid-related poisoning codes. The administrative claims 
data used in this study are also lacking several demographic measures of interest, 
including the racial/ethnic makeup and socioeconomic status of the study population. 
The two datasets used to characterize the timing of PDMP legislation enactment and 
operation were inconsistent at times. However, by using two datasets we were able to 
conservatively define dates of program enactment and operation and thus mitigate the 
chances of misclassification which may have impacted the results of previous studies of 
PDMPs 92. 
Finally, the ‘natural experiment’ design utilized in this study is only capable of 
demonstrating associations and cannot be used to make inferences about causality 112. 
This is a particularly salient point considering that additional interventions such as 
expanded access to naloxone, the release of abuse deterrent opioid formulations, and 
other state specific policy changes may have impacted trends in opioid-related 
morbidity during the study time period. Using a natural experiment approach, it is 
difficult to disentangle the effects of these interventions from that associated with 
implementation of PDMPs. Although these additional interventions may bias the 
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parameter estimates observed in this study, the results are still valid in terms of 
demonstrating the relative impacts of different PDMP features on trends in opioid-
related morbidity. Put differently, even if these results overestimate the impact of 
PDMPs in general, they still offer valuable evidence to suggest that PDMPs with certain 
features are better able to mitigate trends in PORPs relative to PDMPs without these 
features.  
2.6 Conclusion 
Results of this study showed that privately-insured adults residing in states with 
operational PDMPs were, on one hand, exposed to higher baseline risk of PORP, but, on 
the other, more protected from increases in PORP risk during a period of intensification 
of the opioid epidemic. Conversely, adults residing in states with PDMPs were not seen 
to have significantly different trends in IORP risk relative to adults in states without 
PDMPs. Specific PDMP features, including requiring unsolicited reporting to prescribers, 
law enforcement, or professional licensure boards, more frequent data reporting by 
dispensers, and monitoring more CS Schedules, were associated with stronger 
protective effects on PORP risk over time compared to states with operational programs 
that lack these features. However, these features did not appear to impact trends in 
IORP risk. These results may be used to improve the efficacy of current and future 
PDMPs which are proliferating worldwide. Future research is necessary to assess 
whether these features are also associated with opioid prescribing, and other measures 
of prescription opioid misuse. Finally, in order to have the greatest impact on the opioid 
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epidemic in the United States, PDMPs may need to innovate to help health care 
providers rapidly identify individuals who may be in need of SUD treatment. 
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Figure 2.1: Overdose deaths involving opioids, by type of opioid, United States 2000 – 
2016 143 
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Table 2.1: Prescription and illicit opioid-related poisonings ICD-9-CM Codes 
Type of diagnosis ICD-9-CM Codes 
Prescription opioid-related poisoning 965.00, 965.02, 965.09, E850.1, E850.2 
Illicit opioid-related poisoning 965.01, E850.0 
 
Table 2.2: Coding scheme for PDMP features of interest 
Variable Levels 
Status of the PDMP 0= No PDMP 
1= PDMP legislation enacted only 
2= PDMP operational 
Is the PDMP required to send proactive 
reports to any entities?  
0= No PDMP 
1= PDMP legislation enacted only 
2= No 
3= Yes 
How often are pharmacies required to 
upload data to the PDMP?  
0= No PDMP 
1= PDMP legislation enacted only 
2= Monthly or less often 
3= Weekly 
4= Daily 
What Schedules is the PDMP required to 
monitor?  
0= No PDMP 
1= PDMP legislation enacted only 
2= II Only, or II – III  
3= II – IV  
4= II – V  
Are prescribers required to query the 
PDMP data in certain situations?  
0= No PDMP 
1= PDMP legislation enacted only 
2= No 
3= Yes 
Acronyms: PDMP- Prescription Drug Monitoring Program 
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Figure 2.2: Visualization of PDMP operational dates and implementation of unsolicited 
reporting requirements 
 
Acronyms: PDMP- Prescription Drug Monitoring Program 
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Table 2.3: Number of states with different PDMP features in place at the end of each 
year 
 2004 2005 2006 2007 2008 2009 2010 2011 2012 2013 2014 
No PDMP 29 27 22 16 13 12 8 3 3 2 1 
PDMP 
Legislation 
Passed 
8 9 12 12 11 6 9 13 7 4 2 
PDMP 
operational 
13 14 16 22 26 32 33 34 40 44 47 
 
Data reporting frequency 
Monthly 11 12 14 20 21 24 21 18 14 12 9 
Weekly 2 2 2 2 5 8 11 15 24 28 28 
Daily 0 0 0 0 0 0 1 1 2 4 10 
 
The PDMP is required to send unsolicited reports to certain entities 
No 11 10 11 17 19 22 22 21 25 27 29 
Yes 2 4 5 5 7 10 11 13 15 17 18 
 
Drug schedules required to be reported to the PDMP 
II only or  
II-III 
4 4 4 4 4 4 2 1 0 0 0 
II – IV 1 2 2 2 2 4 5 5 5 5 5 
II – V 8 8 10 16 20 24 26 28 35 39 42 
 
Prescribers are Required to query the PDMP in certain situations 
No 13 14 16 22 26 32 33 34 39 41 41 
Yes 0 0 0 0 0 0 0 0 1 3 6 
Acronyms: PDMP- Prescription Drug Monitoring Program 
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Table 2.4: Characteristics of state-months with and without operational PDMPs 
 No PDMP PDMP 
Enacted 
PDMP 
operational 
Overall 
State-months 1,631 1,111 3,858 6,600 
Person-months 380,773,381 507,559,090 1,798,838,473 2,687,170,944 
Number of PORPs 4,493 7,112 29,161 40,766 
Overall PORP rate 1.180 1.401 1.621 1.517 
Mean PORP rate 1.128 1.306 1.650 1.463 
Number of IORPs 632 1,934 8,256 10,822 
Overall IORP rate 0.166 0.381 0.459 0.403 
Mean IORP rate 0.145 0.294 0.414 0.328 
Average SUD rate 66.78 102.58 151.66 122.42 
Mean percent 
male 
47.3% 48.0% 48.1% 47.9% 
Mean percent 
aged 25-35 
21.7% 19.9% 20.6% 20.8% 
Acronyms: PDMP- Prescription Drug Monitoring Program; PORP- prescription opioid-
related poisoning; IORP- Illicit opioid-related poisoning; SUD- Substance use disorder 
*Rates expressed per 100,000 person-months 
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Figure 2.3: Overall PORP and IORP rates per 100,000 person-months observed in each 
year 2004 – 2014  
 
Acronyms: PORP- prescription opioid-related poisoning; IORP- illicit opioid-related 
poisoning 
 
Figure 2.4: Overall PORP rates per 100,000 person-months observed in each year 
stratified by PDMP status 
 
Acronyms: PDMP- Prescription Drug Monitoring Program; PORP- prescription opioid-
related poisoning 
  
0
0.2
0.4
0.6
0.8
1
1.2
1.4
1.6
1.8
2
2004 2005 2006 2007 2008 2009 2010 2011 2012 2013 2014
Overall Rates of PORP and IORP
PORP Rate IORP Rate
0
0.5
1
1.5
2
2.5
2004 2005 2006 2007 2008 2009 2010 2011 2012 2013 2014
Overall PORP Rates by PDMP Status
No PDMP PDMP Enacted PDMP Operational
80 
 
Figure 2.5: Overall rate of PORP per 100,000 person-months in each state form 2004 – 
2014  
 
Acronyms: PORP- prescription opioid-related poisoning 
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Table 2.5: GEE parameter estimates for model examining associations between PDMP 
status and PORP rates 
Variable GEE 
Parameter 
Estimate 
Standard 
Error 
95% CI 
Lower 
95% CI 
Upper 
P 
Value 
 
PDMP Status 
No PDMP Ref. 
PDMP Enacted -0.046 0.087 -0.216 0.124 0.5951 
PDMP Operational 0.288 0.083 0.126 0.451 0.0005 
 
Time Effect 
Month 0.008 0.001 0.005 0.01 <.0001 
PDMP Enacted*Month -0.001 0.001 -0.003 0.002 0.6847 
PDMP Operational*Month -0.005 0.001 -0.008 -0.003 <.0001 
 
Region 
West Ref. 
Midwest -0.237 0.109 -0.450 -0.024 0.0290 
Northeast -0.316 0.098 -0.509 -0.124 0.0013 
South -0.167 0.077 -0.318 -0.016 0.0304 
 
Continuous Variables 
% male population 0.027 0.013 0.002 0.052 0.0337 
% of population aged 25-35 -0.006 0.010 -0.026 0.014 0.5464 
CCS SUD Rate 0.002 0.0004 0.001 0.002 0.0004 
Acronyms: PDMP- Prescription Drug Monitoring Program; PORP- prescription opioid-
related poisoning; GEE- generalized estimating equation; CI- confidence interval; Ref- 
Reference; CCS- clinical classification software; SUD- substance use disorder 
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Table 2.6: Adjusted relative risk of PORP in model investigating PDMP status 
Variable Adjusted Relative 
Risk 
95% CI 
Lower 
95% CI 
Upper 
P 
Value 
 
PDMP Status 
No PDMP Ref. 
PDMP Enacted 0.9551 0.8061 1.1315 0.5951 
PDMP Operational 1.3342 1.1345 1.5691 0.0005 
 
Time Effect 
Month 1.0076 1.0054 1.0099 <.0001 
PDMP Enacted*Month 1.0071 1.0053 1.0089 <.0001 
PDMP Operational*Month 1.0026 1.0010 1.0042 0.0011 
 
Region 
West Ref. 
Midwest 0.7888 0.6375 0.9761 0.0290 
Northeast 0.7290 0.6012 0.8838 0.0013 
South 0.8461 0.7273 0.9843 0.0304 
 
Continuous Variables 
% male population 1.0275 1.0021 1.0536 0.0337 
% of population aged 25-35 0.9939 0.9742 1.0139 0.5464 
CCS SUD Rate 1.0015 1.0007 1.0024 0.0004 
Acronyms: PDMP- Prescription Drug Monitoring Program; PORP- prescription opioid-
related poisoning; GEE- generalized estimating equation; CI- confidence interval; Ref- 
Reference; CCS- clinical classification software; SUD- substance use disorder 
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Figure 2.6: Forest plot displaying changes in aRR of PORP from one month to the next 
associated with each PDMP feature of interest 
Acronyms: PDMP- Prescription Drug Monitoring Program; PORP- prescription opioid-
related poisoning; aRR- adjusted relative risk; LCL- lower confidence limit; UCL- upper 
confidence limit 
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Figure 2.7: Overall IORP rate per 100,000 person-months in each year by PDMP status 
2004 – 2014  
 
Acronyms: PDMP- Prescription Drug Monitoring Program; IORP- illicit opioid-related 
poisoning; 
Figure 2.8: Overall rate of IORP per 100,000 person-months in each state from 2004 – 
2014  
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Acronyms: PDMP- Prescription Drug Monitoring Program; IORP- illicit opioid-related 
poisoning; 
Table 2.7: GEE parameter estimates for model examining associations between PDMP 
status and IORP rates 
Variable GEE 
Parameter 
Estimate 
Standard 
Error 
95% CI 
Lower 
95% CI 
Upper 
P 
Value 
 
PDMP Status 
No PDMP Ref. 
PDMP Enacted -0.5903 0.5314 -1.6318 0.4511 0.2666 
PDMP Operational -0.2569 0.3781 -0.9979 0.4842 0.4969 
 
Time Effect 
Month 0.0112 0.0035 0.0044 0.0181 0.0013 
PDMP Enacted*month 0.0080 0.0052 -0.0021 0.0182 0.1219 
PDMP Operational*month 0.0025 0.0037 -0.0049 0.0098 0.5103 
 
Region 
West Ref. 
Midwest 0.6788 0.1763 0.3332 1.0244 0.0001 
Northeast 0.3364 0.1903 -0.0365 0.7093 0.0770 
South -0.3483 0.1602 -0.6623 -0.0344 0.0297 
 
Continuous Variables 
% male population 0.0576 0.0286 0.0016 0.1137 0.0438 
% of population aged 25-35 -0.0221 0.0259 -0.0729 0.0288 0.3950 
CCS SUD Rate 0.0051 0.0007 0.0037 0.0065 <.0001 
Acronyms: PDMP- Prescription Drug Monitoring Program; IORP- illicit opioid-related 
poisoning; GEE- generalized estimating equation; CI- confidence interval; Ref- 
Reference; CCS- clinical classification software; SUD- substance use disorder 
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Table 2.8: Adjusted relative risk of IORP in model investigating PDMP status 
Variable Adjusted Relative 
Risk 
95% CI 
Lower 
95% CI 
Upper 
P 
Value 
 
PDMP Status 
No PDMP Ref. 
PDMP Enacted 0.5541 0.1956 1.5701 0.2666 
PDMP Operational 0.7735 0.3687 1.6228 0.4969 
 
Time Effect 
Month 1.0113 1.0044 1.0183 0.0013 
PDMP Enacted*Month 1.0195 1.0113 1.0276 <.0001 
PDMP Operational*Month 1.0138 1.0091 1.0185 <.0001 
 
Region 
West Ref. 
Midwest 1.9716 1.3954 2.7855 0.0001 
Northeast 1.3999 0.9642 2.0326 0.0770 
South 0.7059 0.5157 0.9662 0.0297 
 
Continuous Variables 
% male population 1.0593 1.0016 1.1204 0.0438 
% of population aged 25-35 0.9782 0.9297 1.0292 0.3950 
CCS SUD Rate 1.0051 1.0037 1.0065 <.0001 
Acronyms: PDMP- Prescription Drug Monitoring Program; IORP- illicit opioid-related 
poisoning; GEE- generalized estimating equation; CI- confidence interval; Ref- 
Reference; CCS- clinical classification software; SUD- substance use disorder 
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Figure 2.9: Forest plot displaying changes in aRR of IORP from one month to the next 
associated with each PDMP feature of interest 
Acronyms: PDMP- prescription drug monitoring program; IORP- Illicit opioid-related 
poisoning; aRR- adjusted relative risk; LCL- lower confidence limit; UCL- upper 
confidence limit 
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Table 2.9: GEE parameter estimates for model examining associations between PDMP 
status and PORP rates, controlling for Naloxone access laws 
Variable GEE 
Parameter 
Estimate 
Standard 
Error 
95% CI 
Lower 
95% CI 
Upper 
P 
Value 
 
PDMP Status 
No PDMP Ref. 
PDMP Enacted -0.0433 0.0872 -0.2142 0.1276 0.6195 
PDMP Operational 0.2715 0.0869 0.1012 0.4418 0.0018 
 
Time Effect 
Month 0.0075 0.0011 0.0053 0.0097 <.0001 
PDMP Enacted*Month -0.0007 0.0014 -0.0034 0.0020 0.6060 
PDMP Operational*Month -0.0046 0.0013 -0.0072 -0.0020 0.0006 
 
Region 
West Ref. 
Midwest -0.2356 0.1083 -0.4478 -0.0234 0.0295 
Northeast -0.2868 0.1128 -0.5079 -0.0658 0.0110 
South -0.1766 0.0800 -0.3334 -0.0199 0.0272 
 
Naloxone Access Law in Place? 
No Ref. 
Yes -0.0929 0.0825 -0.2546 0.0688 0.2602 
 
Continuous Variables 
% male population 0.0259 0.0131 0.0003 0.0516 0.0477 
% of population aged 25-35 -0.0053 0.0103 -0.0256 0.0150 0.6090 
CCS SUD Rate 0.0016 0.0004 0.0008 0.0024 0.0001 
Acronyms: PDMP- Prescription Drug Monitoring Program; PORP- prescription opioid-
related poisoning; GEE- generalized estimating equation; CI- confidence interval; Ref- 
Reference; CCS- clinical classification software; SUD- substance use disorder 
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Table 2.10: GEE parameter estimates for model examining associations between 
PDMP status and IORP rates, controlling for Naloxone access laws 
Variable GEE 
Parameter 
Estimate 
Standard 
Error 
95% CI 
Lower 
95% CI 
Upper 
P 
Value 
 
PDMP Status 
No PDMP Ref. 
PDMP Enacted -0.6250 0.5519 -1.7067 0.4567 0.2574 
PDMP Operational -0.2069 0.3724 -0.9367 0.5230 0.5786 
 
Time Effect 
Month 0.0116 0.0035 0.0048 0.0185 0.0009 
PDMP Enacted*Month 0.0088 0.0054 -0.0017 0.0194 0.1011 
PDMP Operational*Month 0.0013 0.0037 -0.0060 0.0085 0.7342 
 
Region 
West Ref. 
Midwest 0.6739 0.1519 0.3762 0.9716 <.0001 
Northeast 0.2615 0.2032 -0.1367 0.6597 0.1981 
South -0.3197 0.1423 -0.5986 -0.0409 0.0246 
 
Naloxone Access Law in Place? 
No Ref. 
Yes 0.2106 0.0995 0.0156 0.4057 0.0343 
 
Continuous Variables 
% male population 0.0619 0.0286 0.0059 0.1180 0.0304 
% of population aged 25-35 -0.0281 0.0269 -0.0808 0.0247 0.2971 
CCS SUD Rate 0.0049 0.0007 0.0036 0.0062 <.0001 
Acronyms: PDMP- Prescription Drug Monitoring Program; IORP- illicit opioid-related 
poisoning; GEE- generalized estimating equation; CI- confidence interval; Ref- 
Reference; CCS- clinical classification software; SUD- substance use disorder 
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Table 2.11: GEE parameter estimates for model examining associations between 
PDMP status and PORP rates from 2009 – 2014 
Variable GEE 
Parameter 
Estimate 
Standard 
Error 
95% CI 
Lower 
95% CI 
Upper 
P 
Value 
 
PDMP Status 
No PDMP Ref. 
PDMP Enacted -0.1489 0.2972 -0.7313 0.4336 0.6164 
PDMP Operational 0.1425 0.2493 -0.3462 0.6312 0.5678 
 
Time Effect 
Month -0.0004 0.0027 -0.0058 0.0050 0.8921 
PDMP Enacted*Month 0.0011 0.0032 -0.0051 0.0073 0.7177 
PDMP Operational*Month -0.0025 0.0028 -0.0080 0.0030 0.3697 
 
Region 
West Ref. 
Midwest -0.1863 0.1236 -0.4286 0.0559 0.1317 
Northeast -0.2425 0.1031 -0.4446 -0.0404 0.0187 
South -0.1255 0.0807 -0.2836 0.0327 0.1200 
 
Continuous Variables 
% male population 0.0326 0.0139 0.0053 0.0598 0.0192 
% of population aged 25-35 -0.0033 0.0127 -0.0283 0.0217 0.7956 
CCS SUD Rate 0.0016 0.0005 0.0006 0.0027 0.0021 
Acronyms: PDMP- Prescription Drug Monitoring Program; PORP- prescription opioid-
related poisoning; GEE- generalized estimating equation; CI- confidence interval; Ref- 
Reference; CCS- clinical classification software; SUD- substance use disorder 
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Table 2.12: GEE parameter estimates for model examining associations between 
PDMP status and PORP rates from 2009 – 2014, controlling for rates of buprenorphine 
prescribing 
Variable GEE 
Parameter 
Estimate 
Standard 
Error 
95% CI 
Lower 
95% CI 
Upper 
P 
Value 
 
PDMP Status 
No PDMP Ref. 
PDMP Enacted -0.1890 0.2938 -0.7648 0.3868 0.5200 
PDMP Operational 0.1230 0.2444 -0.3561 0.6021 0.6147 
 
Time Effect 
Month -0.0006 0.0027 -0.0059 0.0046 0.8132 
PDMP Enacted*Month 0.0015 0.0031 -0.0047 0.0076 0.6360 
PDMP Operational*Month -0.0023 0.0027 -0.0077 0.0030 0.3961 
 
Region 
West Ref. 
Midwest -0.2245 0.1114 -0.4429 -0.0061 0.0439 
Northeast -0.2769 0.0996 -0.4721 -0.0817 0.0054 
South -0.2079 0.0794 -0.3635 -0.0524 0.0088 
 
Continuous Variables 
% male population 0.0246 0.0146 -0.0040 0.0531 0.0914 
% of population aged 25-35 0.0001 0.0120 -0.0235 0.0237 0.9930 
CCS SUD Rate 0.0008 0.0007 -0.0005 0.0021 0.2141 
Buprenorphine Rx rate 0.0012 0.0006 -0.0000 0.0023 0.0518 
Acronyms: PDMP- Prescription Drug Monitoring Program; PORP- prescription opioid-
related poisoning; GEE- generalized estimating equation; CI- confidence interval; Ref- 
Reference; CCS- clinical classification software; SUD- substance use disorder; Rx- 
prescription 
 
  
92 
 
Table 2.13: GEE parameter estimates for model examining associations between 
PDMP status and IORP rates from 2009 – 2014 
Variable GEE 
Parameter 
Estimate 
Standard 
Error 
95% CI 
Lower 
95% CI 
Upper 
P 
Value 
 
PDMP Status 
No PDMP Ref. 
PDMP Enacted -0.4354 0.6983 -1.8041 0.9333 0.5330 
PDMP Operational -0.4970 0.5860 -1.6455 0.6515 0.3963 
 
Time Effect 
Month 0.0113 0.0052 0.0012 0.0214 0.0282 
PDMP Enacted*Month 0.0067 0.0064 -0.0059 0.0192 0.2959 
PDMP Operational*Month 0.0043 0.0051 -0.0057 0.0143 0.3999 
 
Region 
West Ref. 
Midwest 0.7498 0.1666 0.4233 1.0763 <.0001 
Northeast 0.3077 0.1703 -0.0261 0.6416 0.0708 
South -0.3310 0.1434 -0.6120 -0.0499 0.0210 
 
Continuous Variables 
% male population 0.0567 0.0337 -0.0095 0.1228 0.0930 
% of population aged 25-35 -0.0157 0.0260 -0.0667 0.0354 0.5475 
CCS SUD Rate 0.0051 0.0006 0.0040 0.0063 <.0001 
Acronyms: PDMP- Prescription Drug Monitoring Program; IORP- illicit opioid-related 
poisoning; GEE- generalized estimating equation; CI- confidence interval; Ref- 
Reference; CCS- clinical classification software; SUD- substance use disorder 
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Table 2.14: GEE parameter estimates for model examining associations between 
PDMP status and IORP rates from 2009 – 2014, controlling for rates of buprenorphine 
prescribing 
Variable GEE 
Parameter 
Estimate 
Standard 
Error 
95% CI 
Lower 
95% CI 
Upper 
P 
Value 
 
PDMP Status 
No PDMP Ref. 
PDMP Enacted -0.5197 0.6702 -1.8333 0.7939 0.4381 
PDMP Operational -0.5975 0.5613 -1.6976 0.5026 0.2871 
 
Time Effect 
Month 0.0102 0.0049 0.0006 0.0198 0.0374 
PDMP Enacted*Month 0.0074 0.0061 -0.0046 0.0194 0.2265 
PDMP Operational*Month 0.0054 0.0048 -0.0041 0.0148 0.2654 
 
Region 
West Ref. 
Midwest 0.6766 0.1540 0.3749 0.9784 <.0001 
Northeast 0.2470 0.1483 -0.0437 0.5377 0.0959 
South -0.5504 0.1466 -0.8377 -0.2630 0.0002 
 
Continuous Variables 
% male population 0.0261 0.0363 -0.0452 0.0973 0.4733 
% of population aged 25-35 0.0011 0.0246 -0.0472 0.0493 0.9645 
CCS SUD Rate 0.0035 0.0008 0.0020 0.0050 <.0001 
Buprenorphine Rx rate 0.0028 0.0009 0.0010 0.0046 0.0018 
Acronyms: PDMP- Prescription Drug Monitoring Program; IORP- illicit opioid-related 
poisoning; GEE- generalized estimating equation; CI- confidence interval; Ref- 
Reference; CCS- clinical classification software; SUD- substance use disorder; Rx- 
prescription 
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Chapter 3: Examining Differential Associations Between PDMP Features and Trends In 
Prescription Opioid-Related Poisonings In Populations With Different Types of 
Insurance Coverage 
3.1 Introduction 
In order to efficiently and effectively address the US opioid epidemic, it is critical 
that policy makers and researchers understand where the epidemic is exerting the 
greatest effects. With the passage of the 21st Century Cures Act, the federal government 
is making available substantial funding to promote both prevention and treatment 
related to opioid addiction.144 In order for these resources to be deployed effectively, 
we must understand what groups are most in need. For patients with public or private 
insurance, many interventions related to both prevention and treatment of opioid 
addiction require engagement with the existing health insurance infrastructure. 
Alternatively, uninsured or underinsured individuals will need access to federally 
subsidized or charitable treatment services. To adequately address the needs of these 
diverse populations, it is imperative that we understand where resources should be 
directed to have the most impact. 
Unfortunately, very little reliable data exists regarding the burden of opioid 
addiction and substance use disorder (SUD) among populations with different types of 
insurance coverage. The CDC regularly prepares reports on trends in both prescription 
and illicit opioid-related mortality.145 These data are aggregated from cause of death 
reports and contain basic demographic information related to age, gender, race etc. The 
CDC often reports trends in mortality stratified by these demographic characteristics, 
however, they lack information related to insurance status of the deceased. Without 
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this type of aggregate data, it is impossible to ascertain how opioid-related mortality 
varies among individuals with different types of insurance.  
There have been several previous studies assessing potential opioid misuse and 
multiple provider episodes by individuals with different types of insurance. Sullivan et al. 
developed a numeric score to define the potential for opioid misuse in a population of 
commercially insured individuals and Medicaid recipients.146 In a population of patients 
receiving chronic opioid therapy, they found that 24% of the privately insured and 20% 
of the Medicaid patients met their criteria for possible opioid misuse, and 6% of the 
privately insured and 3% of the Medicaid patients met their criteria for probable opioid 
misuse.146 A 2017 report from the Office of the Inspector General found that about 
22,000 Medicare beneficiaries nationwide appeared to be doctor shopping for opioids in 
2015.147 In contrast, a 2009 report from the Government Accountability Office found 
that more than 65,000 Medicaid beneficiaries in a five state sample engaged in doctor 
shopping during fiscal years 2006 and 2007.148  Although The GAO report is outdated 
and doesn’t differentiate between opioids and other CS, these results still seem to imply 
that doctor shopping for opioids is likely to be substantially more common in the 
Medicaid population as a whole. 
Several studies examining demographic characteristics associated with 
prescription opioid-related morbidity offer some evidence of variation by insurance 
status. A 2015 study using data from the National Emergency Department Sample 
(NEDS) found that the Medicare population had significantly more unintentional PORPs 
from 2006 – 2011 relative to all other insurance types.149 This same study found that the 
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privately insured population had significantly more intentional PORPs relative to all 
other insurance types over the same time period.149 An earlier study from Hasegawa et 
al. examined two years of emergency department data from Florida and California and 
found that privately insured, Medicare, and uninsured patients each accounted for 
equal proportions of all opioid-related ED visits.150 This study may have found different 
results than the NEDS study because it failed to differentiate prescription and illicit 
opioid-related ED visits. A prominent limitation to both of these studies, however, is 
that they only examine counts and not rates of opioid-related poisonings. By only 
presenting counts of poisonings attributable to each insurance type, it is difficult to 
assess whether one group is experiencing disproportionally more or less opioid-related 
morbidity than the others. 
Prescription drug monitoring programs (PDMPs) have been widely implemented 
as a tool to reduce prescription opioid-related morbidity and mortality. Presently, 49 
states and the District of Columbia have operational PDMPs.151 Although there is a 
tremendous amount of research examining the impact of PDMPs on both opioid 
prescribing as well as opioid-related morbidity and mortality, no studies, to date, have 
examined whether these programs exert differential effects on individuals with different 
types of health insurance. As healthcare based programs that operate at the point-of-
care, it is plausible that PDMPs may have different effects on patients with and without 
insurance, or with different types of insurance. In this sense, type of insurance coverage 
may impart differential associations between PDMP implementation and trends in 
opioid-related morbidity. Also, it remains to be seen whether specific features of 
97 
 
operational PDMPs are more or less successful at reducing opioid-related morbidity in 
patients with certain types of insurance coverage.  
To date, all studies examining associations between PDMP implementation and 
trends in prescription opioid-related mortality have done so using the CDC WONDER 
data or state specific mortality data which do not include data on insurance status of the 
deceased.42,67,88,90,91 Two previous studies assessing associations between PDMP 
implementation and trends in nonfatal PORPs were conducted using DAWN and 
RADARS data which also do not include data on patients’ insurance status.82,83 In 2016, 
Meara et al. conducted a study using Medicare claims data to explore associations 
between PDMPs and PORP-related ED visits in a population of disabled Medicare 
beneficiaries—this was the first and only study to date to examine the effects of PDMPs 
in a population where the patients’ insurance status was known to the researchers.85 
Meara et al. found that individuals residing in PDMP states did not have significantly 
different odds of experiencing a PORP relative to patients in non-PDMP states.85 The 
study presented in Chapter 2 of this dissertation found that states with operational 
PDMPs were associated with significantly lower increases in PORP rates over time 
relative to states without PDMPs. Taken together, these two studies indicate that 
insurance status may impart differential associations between PDMPs and nonfatal 
PORPs in populations with different types of coverage. 
This study will address several important gaps in the existing literature 
examining the opioid epidemic and PDMPs. This study will be the largest study to date 
to assess trends In PORP rates among populations with different types of insurance, and 
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will also be the first to examine differential associations between PDMP implementation 
and trends in PORPs in populations with different types of insurance coverage. The 
specific aims of this study are to: I. Describe trends in PORP-related hospital discharges 
in the privately insured, Medicaid, Medicare, and uninsured populations; II. Examine 
differential associations between PDMP implementation and trends in PORPs in 
populations with different types of insurance coverage; and III. Assess whether there 
are also differential associations between specific PDMP features and trends in PORPs in 
populations with different types of insurance coverage  
3.2 Methods 
3.2.1 Study Design 
This analysis employed an observational longitudinal, ‘natural experiment’ 
design to assess associations between PDMP features and rates of PORPs in populations 
with different insurance status. Natural experiments are empirical studies wherein 
subjects are exposed to an intervention that is outside the control of the investigator.112 
This study included a sample of 16 states and included observations for every county in 
each of those states. Changes to PDMP features—including timing of initial legislation 
enactment and program implementation, or alterations to specific functionality—were 
assessed annually in the 16 state study sample from 2001 – 2014. The unit of 
observation was the county-year-plan type (i.e. there was one observation per county, 
per year, per insurance plan type of interest). This assessed four distinct insurance plan 
types—private insurance, Medicaid, Medicare, and uninsured status. The outcome of 
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interest in this study was the number of PORPs observed in hospital discharge data in 
each county-year-plan type set from 2001 – 2014. The relative risk of PORP was 
calculated for each county-year-plan type set during this period while controlling for 
specific PDMP features as well as demographic and clinical characteristics of the study 
population observed at the county-year-plan type, or county-year level (in cases where 
plan type specific data was unavailable). Given that this study was observational and 
relied on de-identified data collected for research purposes, it was deemed exempt 
from review by the University of Kentucky IRB.  
3.2.2 Data 
This study utilized data from multiple sources. Data regarding clinical events as 
well as clinical and some demographic characteristics of the privately insured, Medicaid, 
Medicare, and uninsured population were obtained from the Healthcare Cost and 
Utilization Project (HCUP) State Inpatient Databases (SID). The HCUP SID data include 
inpatient discharge records from community hospitals in 48 participating states. This 
study utilized a sample of 16 states from 2001 – 2014. Table 3.1 details the specific 
states included in this analysis and the time period during which each states’ data were 
available. Most states were observed for the entire study time period from 2001 – 2014, 
however, 4 of the 16 states had limited years of data available. These 16 states were 
chosen in conjunction with this time period as it allowed most states to be observed 
both before and after their PDMPs became operational.  
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HCUP SID data are translated into a uniform format to allow multi-state 
comparisons and analyses. The SID data encompass approximately 97% of all US 
community hospital discharges in participating states.152 Data elements collected at 
discharge include diagnoses observed during the hospital stay, demographic 
characteristics including age, gender, and race, and primary expected payer for the 
hospital admission. These data are unique in that they encompass hospital stays from all 
payer types, including individuals covered by Medicare, Medicaid, private insurance, and 
individuals who are uninsured. All hospital discharges observed in the 16 state sample 
during the years of data available for each state were included in the analysis. Individual 
discharges were aggregated into rates and percentages at the county-year-plan type 
level.  
Several demographic characteristics of interest including the mean 
unemployment rate and poverty rate in each county were assessed using external data 
sources. The Bureau of Labor Statistics’ Local Area Unemployment data were used to 
assess the annual unemployment rate in each county in the 16 states of interest from 
2001 – 2014.153 The US Census Bureau’s Small Area Income and Poverty Estimates data 
were used to assess the annual poverty rate in each county in the 16 state sample from 
2001 – 2014.154 These data could not be examined by insurance status, and so were 
assessed only at the county-year level rather than the county-year-plan type level.  
Data regarding the status of PDMPs in each state-month were gleaned from two 
separate data sources—the National Alliance for Model State Drug Laws (NAMSDL) and 
the Prescription Drug Abuse Policy System (PDAPS). NAMSDL is a non-profit group that 
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receives funding from the federal government to assist in the planning and 
enhancement of PDMPs and also publishes resources regarding the past and present 
status of PDMPs.21 PDAPS is a research tool funded by the National Institute on Drug 
Abuse (NIDA) to track state laws related to prescription drug abuse.114 The NAMSDL and 
PDAPS data were both used to assess the timing of PDMP legislation enactment and 
program operation. Data regarding the status of specific PDMP features, and dates that 
these features were implemented, were obtained from PDAPS. These data sources are 
both commonly used in longitudinal studies examining PDMPs.42,67,81,82,90,115 
3.2.3 Outcome and Covariate Measures 
The outcome of interest in this study was the number of hospital discharges with 
a PORP diagnosis observed in each county-year-plan type set. This study chose to focus 
on PORPs as we hypothesize that PDMPs have a proximal impact on this injury outcome. 
PORP related discharges included discharges where a PORP diagnosis was observed in 
any one of the diagnosis code fields. The CDC guide to ICD-9-CM codes related to 
poisoning and pain was used to identify ICD-9-CM codes related to PORPs. The same 
codes were used to define the outcome in this study as the PORP codes used in the 
second chapter of this dissertation—see Table 2.1 for a list of the codes. Discharges 
were not double counted if patients had more than one PORP code on a given 
discharge.  
 Insurance status of patients observed in the HCUP discharge data was classified 
according to the ‘expected primary payer’ variable associated with each discharge 
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record. Each HCUP partner state collects this information in varying level of detail. To 
ensure uniformity of coding across states, the expected primary payer variable in the 
HCUP SID data aggregates the detailed categories reported by states into more general 
groups—i.e. states may report primary expected payer as Medicaid fee-for-service or 
Medicaid managed care, and HCUP will combine both of these to reflect the more 
general Medicaid as the primary expected payer. The four insurance types of interest in 
this study were Medicaid, Medicare, private insurance, and uninsured. In defining the 
uninsured population, this study combined discharges where the primary expected 
payer was listed as ‘self-pay’, ‘no charge’, or ‘other’, as these codes are commonly used 
in HCUP data to identify the uninsured population.155 
Demographic covariates of interest in this study included the percentage of 
discharges in each county-year-plan type set corresponding to males, median age in 
each county-year-plan type set, geographic region of each state, and the poverty rate 
and unemployment rate in each county-year. For calculating the percentage of male 
discharges in each county-year-plan type set, the total number of discharges 
corresponding to male patients was divided by the total number of discharges where 
gender was not missing. Gender was missing in less than 0.1% of discharges. Median age 
was chosen as a covariate rather than a particular age grouping (as in the previous 
study) because patients’ ages vary greatly by insurance type. Region was defined 
according to US Census Bureau regions and was selected as a covariate to control for 
geographic trends in PORP rates.116 Unemployment rate and poverty rate were coded as 
the percentage of the population that were unemployed and the percentage of all ages 
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in poverty respectively, in each county-year. These covariates were chosen as they are 
generally indicative of a county’s socioeconomic status. County year unemployment rate 
and poverty rate were modestly but not significantly correlated.  
Clinical covariates assessed in this study included the rates of chronic and acute 
pain diagnoses observed in county-year-plan type sets, and the overall discharge rate 
observed in each county-year. Chronic pain was defined according to the CDC guide to 
ICD-9-CM codes for poisoning and pain, and includes codes related to back pain, neck 
pain, arthritis/join pain, headache/migraine, and neuropathy.95 Acute pain was defined 
according to the CDC guide to ICD-9-CM codes for poisoning and pain, and includes 
codes related to acute injuries. Discharges were considered to be chronic or acute pain-
related if a diagnosis corresponding to either of these categories was observed in any 
diagnostic field on the discharge record. Rates were calculated as the number of 
discharges that were pain-related per 1,000 total discharges in each county-year-plan 
type set. These covariates were chosen as they are known to be associated with opioid 
prescribing. State-year-plan type rates of chronic and acute pain were also modestly but 
not significantly correlated. The overall discharge rate in each county-year was 
calculated as the total number of discharges observed in each county-year per 1,000 
total residents in each county-year (as defined by the US Census Bureau). This covariate 
was included to adjust for overall trends in ‘healthcare utilization’ within each county.  
Enactment of PDMP legislation may induce changes in prescribing practices 
before the programs are formally operational.42 In order to adjust for this possibility, 
this study was careful to distinguish the date that PDMP legislation was enacted and the 
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date that programs became formally operational. For the purposes of this study, PDMPs 
were defined as being operational when they made data available to prescribers or law 
enforcement officials. Dates of PDMP legislation enactment as well as dates of data 
availability are reported by both NAMSDL and PDAPS, however the dates that these 
groups report are at times inconsistent. To address this shortcoming, the date of PDMP 
legislation enactment was conservatively defined as the earliest date reported by one of 
these groups and the date that PDMPs became operational was conservatively defined 
as the latest date reported by one of these groups. The PDAPS data were used when 
dates were not available from NAMSDL. 
Data regarding the status of specific PDMP features, and dates that these 
features were implemented, were obtained from PDAPS. This study examined five 
distinct features of PDMPs: 1. Whether the PDMP was operational—defined as 
prescribers or law enforcement having access to the data; 2. CS Schedules monitored by 
the PDMP (II-IV or II-V); 3. Frequency of data reporting from dispensers to the PDMP 
central server (monthly or less, or weekly); 4. Requirement for unsolicited reporting of 
patients’ CS prescription history to in-state prescribers or licensure boards; and 5. 
Mandated (as defined by PDAPS) prescriber query of PDMP data prior to prescribing in 
certain circumstances. Other PDMP features of interest, including mandatory 
registration with the PDMP and PDMP utilization rate by prescribers, were not included 
in the study due to data constraints 
Each of the five PDMP variables were coded to reflect when no PDMP legislation 
had been enacted, PDMP legislation was enacted but the program was not yet 
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operational, and finally when the PDMP was operational with a given level of the 
covariate. Each PDMP characteristic of interest, and its constituent levels are presented 
in Table 3.2. Due to data constraints, not all PDMP variables in this study were coded 
identically to those in the study discussed in Chapter 2. For example, the variable for 
number of Schedules monitored was coded as having five levels in the Chapter 2 study 
but was only coded as having four levels in the present study because there were no 
state-years in the current study sample that had operational PDMPs that only 
monitored Schedule II or Schedule II+III Controlled Substances. Changes to specific 
PDMP features were assessed monthly and a set of time varying indicator variables 
were created to describe PDMP features in each state-year. Variables were coded to 
reflect the first full year that a given feature was in place for at least six months out of 
that year.  
3.2.4 Statistical Analysis 
Generalized estimating equation (GEE) Poisson regression models were fit to 
estimate the risk of PORP associated with PDMP features while adjusting for 
demographic and clinical characteristics of the HCUP sample. As in the study in Chapter 
2, over-dispersion was not a significant problem in these data for any of the insurance 
groups investigated (the values of the deviance divided by degrees of freedom ranged 
from 1.416 – 1.697 in the models investigated), so Poisson regression models were 
chosen instead of negative binomial regression models. The unit of observation was the 
county-year-plan type and the modeled outcome of interest was the monthly count of 
PORP related discharges observed in each county-year-plan type set. Adjusted models 
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were derived separately for each insurance plan type and for each PDMP feature of 
interest. As in the previous study, separate models were fit for each PDMP feature to 
provide greater granularity in terms of the differential impacts of each feature. 
Additionally, separate models were constructed for each insurance plan type to 
investigate whether there are differential associations between PDMP features and 
PORP rates by type of coverage. Thus the primary results of this study are presented in 
the form of twenty separate adjusted GEE models—five models for each of the four 
insurance types investigated. Interaction terms could have been used rather than 
stratifying the models by insurance type. However, as the primary interest in this study 
is the association between PDMPs and changes in PORP rates over time, this would have 
required a three-way interaction term, which can complicate model interpretation.  
All twenty adjusted GEE models relied on the same assumptions and were 
specified in a similar manner—the only differences being the particular PDMP feature 
variable included in the model and the insurance group being investigated. Each model 
included one PDMP feature variable as well as variables for time (coded as the number 
of years since the study period began (i.e. 2001 = 0, 2014 = 13 etc.), geographic region, 
percent of discharges for males, median age, chronic pain rate, acute pain rate, 
unemployment rate, poverty rate, and discharge rate. The total count of discharges 
observed in each County-year-plan type set, expressed as natural logarithms were used 
as offset terms in each model to adjust for variation in the hospital utilization for any 
given county-year-plan type set. Robust standard errors were calculated to adjust for 
repeated measures from each state. The monthly covariance structure in each state was 
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selected as a first-order autoregressive process to account for autocorrelations in the 
time series for each county.  
As in the previous study, all twenty adjusted GEE models also included 
interaction terms between the PDMP feature of interest and time, to model the risk 
difference in PORP over time in counties with and without the given PDMP feature. 
These models may be interpreted as fitting multiple summary regression lines to the 
data. The difference in intercepts between these lines addresses baseline differences (at 
year= 0, or 2004) in mean rates of PORP in states with and without the PDMP feature of 
interest. Differences in slopes—as characterized by the parameter estimate for the 
interaction term—represent the different trends in PORP over time for states at 
different levels of the PDMP features of interest.  
The Poisson regression models were fit in SAS Enterprise Guide version 5.1 using 
PROC GENMOD with the REPEATED statement to implement the GEE approach. A BY 
statement was used to stratify the analysis by insurance plan type. Reference coding 
scheme was used in regression parameter estimates allowing calculation of the adjusted 
relative risk (aRR) for PORP associated with each variable by exponentiation of the 
relevant parameter. Statistical significance was assessed as p < 0.05 for all analyses. 
Figures were generated using SAS Enterprise Guide version 5.1, Tableau version 10.3 
and JMP version 12.0. 
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3.2.5 Sensitivity Analyses 
Naloxone Access Laws  
Naloxone is an FDA approved prescription medication that can be used to 
reverse the effects of an acute opioid-related poisoning.122 In recent years, states have 
begun to enact legislation to increase the availability of naloxone for family, friends, and 
other potential bystanders of opioid-related poisonings.123  At present, all states have 
enacted some sort of legislation to remove legal barriers to naloxone access.123 Most 
commonly, states have begun to permit naloxone prescribing to individuals other than 
the person at risk of opioid-related poisoning, or have otherwise removed the need for 
a person to see a prescriber before obtaining the medication.123 Implementation of 
these ‘naloxone access laws’ may be associated with aggregate trends in opioid-related 
poisonings.90,124 As with the study in Chapter 2, this study implemented a sensitivity 
analyses to control for the presence of naloxone access laws at the state level. Data on 
the timing of naloxone access law implementation were gathered from PDAPS.125 A 
binary dummy variable was created to describe whether states had any type of 
naloxone access laws in place for the majority of each year from 2001 – 2014. The GEE 
Poisson regression models discussed in the statistical analysis section above were re-fit 
including this variable in order to assess whether naloxone access laws attenuate 
associations between PDMP features and trends in PORPs.  
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Restricted Sample of States 
Four of the states included in the main analysis of this study (NM, SD, WI and 
WV) are missing data for at least one year during the study period. Missing data can bias 
the results of longitudinal studies.121 With this in mind, a sensitivity analysis was 
conducted removing all observations from states with limited years of data. This 
method, known as listwise deletion, or complete case selection, is commonly used in 
longitudinal studies with missing data.121 However, the validity of this method is 
contingent on the data being ‘missing completely at random’. Data missing completely 
at random implies that the data are missing because of a completely random process 
that cannot be explained by any variable within or outside of the data available.121 The 
four states listed above are missing data due to limited availability of the HCUP SID 
county level data in certain years.156 This limited availability is purely administrative and 
not related to any variables included or not included in the present analysis. Thus this 
missing data arguably meets the aforementioned definition of being missing completely 
at random. Results of GEE models excluding all observations from states with data 
missing completely at random were compared to results from the main analysis to 
qualitatively examine whether missing data from these states substantially impacted 
results of the study.  
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3.3 Results  
3.3.1 Changes to PDMPs 
The counties in the 16 state sample included in this study experienced 
substantial changes in both the prevalence of PDMPs and PDMP features present from 
2001 – 2014. The number of counties with operational PDMPs and the number with 
specific PDMP features are displayed in Table 3.3. While 58.7% of the counties observed 
in 2001 did not have PDMPs, all counties observed in 2014 had operational PDMPs in 
place. Most PDMPs also began implementing robust features over this same period. In 
2001, greater than three quarters of counties with operational PDMPs required 
dispensers to report data monthly or less frequently, but in 2014, nearly all counties 
with operational PDMPs required data reporting daily or more often. In 2001, no 
counties with operational PDMPs had mandates requiring unsolicited reporting or 
mandatory data querying, however in 2014, 35.1% and 25.7% respectively, of counties 
with operational PDMPs had these features in place. Most counties with operational 
PDMPs required all Schedules of CS to be reported throughout the study period.  
3.3.2 PORP Trends 
From 2001 – 2014 there were nearly 164 million discharges observed in the 16 
state sample, with over 245 thousand of those discharges associated with PORPs. Over 
the study period there was a statistically significant 144.4% (p < 0.0001) increase in the 
mean overall PORP rate, from 88.8 to 217.0 per 100,000 total discharges. Figure 3.1 
displays trends in the annual overall PORP rate from 2001 – 2004, as well as PORP rates 
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stratified by insurance type. The mean PORP rate increased significantly for all insurance 
types from 2001 – 2014. The Medicare population experienced an increase of 262%, the 
Medicaid population had an increase of 168% and the privately insured and uninsured 
populations both saw an increase of 109% in the mean PORP rate in 2014 relative to 
2001. With the exception of the Medicare population, all other insurance groups had 
their highest PORP rates in 2011 before experiencing a decline in subsequent years.  
There was substantial variation in the overall PORP rate observed at the state 
level from 2001 – 2014. The overall PORP rates observed in each state during the study 
period are displayed in Table 3.1. Several states that were only observed for limited 
years from 2001 – 2014 had overall PORP rates that are markedly different from those 
of other states, however, this is not unusual given the relatively limited samples from 
these states (i.e. only three years observed in WI and only one year observed in WV). 
Among states that were observed for the entire study period, the overall PORP rates 
ranged from a high of 235.71 per 100,000 discharges in Oregon to a low of 102.4 per 
100,000 discharges in Nebraska.  
The overall PORP rate also varied substantially by insurance type. Table 3.4 
presents the overall PORP rate and other demographic and clinical characteristics 
stratified by insurance type. The uninsured population observed in this study had an 
overall PORP rate over three times greater than that observed in the privately insured 
HCUP population. The Medicaid population had the second highest PORP rate with 
108.7 per 100,000 total discharges. Demographic and clinical characteristics of the HCUP 
population also varied markedly by insurance status. The mean percent of discharges for 
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male patients varied from 34.5% in the Medicaid population to nearly 54% in the 
uninsured population. The mean of the median age observed in each county year also 
varied as would be expected, with the Medicaid population having a mean median age 
of about 24.5 and the Medicare population having a mean median age of nearly 73. 
While the Medicare population had the highest rate of discharges related to chronic 
pain, the uninsured population had the highest rate related to acute pain / injuries.  
3.3.3 Generalized Estimating Equation Results 
* Please note that PDMPs are state-level and not county-level programs, 
however for the sake of brevity, ‘counties with operational PDMPs’ will be used to 
describe the results throughout this section rather than the more accurate ‘counties in 
states with operational PDMPs’. * 
Raw parameter estimates from the GEE Poisson regression models assessing 
associations between PDMP implementation status and PORP rates, stratified by 
insurance plan type, are presented in Tables 3.5 A-D. Across all insurance plan types, 
counties with operational PDMPs had significantly higher PORP rates relative to counties 
without PDMPs at baseline. The estimated adjusted regression coefficients for time 
were also positive and statistically significant for all insurance plan types. This finding is 
reflected in Figure 3.6—showing that all insurance groups experienced significant 
increases in PORP rates over the study period. The adjusted regression coefficient for 
the interaction between the indicator for ‘PDMP operational’ and time was negative and 
statistically significant for all insurance groups, suggesting that operational PDMPs 
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mitigate the increases in PORP rates overt time relative to increases in counties without 
PDMPs. Although all parameter estimates for the interaction between PDMP and time 
were negative, the magnitude of these estimates varied markedly by PDMP status, 
implying that operational PDMPs exert differential effects by insurance type. The only 
other covariates that were significantly associated with PORP rates in all insurance 
groups were those for geographic region, as well as rates of unemployment, chronic 
pain, and acute injuries. The parameter estimates associated with these variables 
generally trended in the same direction for all insurance types.  
The exponentiated GEE parameter estimates from Tables 3.5 A-D are presented 
in Tables 3.6 A-D. These are interpreted as changes in the adjusted relative risk (aRR) of 
PORP associated with a one unit change in a given covariate while holding other 
covariates constant. The main interest in these tables are the results of the time effect 
variables, which indicate how the aRR of PORP changes from one year to the next in 
counties with and without PDMPs. These results are also plotted in a forest plot in 
Figure 3.2. In the Medicaid population (Table 3.6 A), counties without PDMPs 
experienced significant increases in aRR of PORP from one year to the next (aRR: 1.023 
[95% CI: 1.004 – 1.045]), while counties with operational PDMPs did not experience 
significant changes in aRR of PORP over time (aRR: 0.989 [95% CI: 0.976 – 1.003]). The 
uninsured population (Table 3.6 D) demonstrated similar results, with counties without 
PDMPs experiencing significant increases in aRR of PORP from one year to the next 
(aRR: 1.059 [95% CI: 1.037 – 1.080]), and counties with operational PDMPs not 
experiencing any significant changes over time (aRR: 0.996 [95% CI: 0.981 – 1.012]. In 
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the privately insured population (Table 3.6 C), counties without PDMPs as well as 
counties with operational PDMPs both experienced significant increases in aRR of PORP 
over time (aRR: 1.059 [95% CI: 1.043 – 1.075] and aRR: 1.019 [95% CI: 1.006 – 1.033], 
respectively). Because the 95% CI’s for these two estimates do not overlap, these results 
imply that in the privately insured population counties with operational PDMPs were 
associated with significantly lower increases in aRR of PORP from one year to the next 
relative to counties without PDMPs. Finally, in the Medicare population (Table 3.6 B), 
counties without PDMPs as well as those with PDMPs experienced significant increases 
in the aRR of PORP from one year to the next (aRR: 1.097 [95% CI: 1.078 – 1.117] and 
aRR: 1.067 [95% CI: 1.056 – 1.079], respectively). However, since the 95% CI’s for these 
estimates slightly overlap, these results suggest that in the Medicare population there 
was not a significant difference in increases in aRR of PORP over time between counties 
with and without PDMPs.  
Results of the time effect variables in models investigating unsolicited reporting 
status are presented in a forest plot in Figure 3.3. In the Medicaid population, counties 
with operational PDMPs that did not require unsolicited reporting did not experience 
any significant change in aRR of PORP over time (aRR: 0.992 [95% CI: 0.978 – 1.005]), 
while counties with PDMPs that required unsolicited reporting experienced a protective 
effect on changes in the aRR of PORP over time (aRR: 0.967 [95% CI: 0.948 – 0.985]). 
Similar results were observed in the uninsured population, however the magnitude of 
the protective effect in counties with proactive reporting was slightly less than that 
observed in the Medicaid population (aRR: 0.981 [95% CI: 0.962 – 0.9996]). Meanwhile 
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in the privately insured population, counties with operational PDMPs that did not have 
unsolicited reporting requirements experienced significant increases in aRR of PORP 
over time and counties with PDMPs that did require unsolicited reporting experienced 
significant decreases in aRR from one year to the next. Finally, in the Medicare 
population, counties with operational PDMPs with and without unsolicited reporting 
requirements both experienced significant increases in aRR over time, but those that 
required unsolicited reporting experienced increases that were significantly less than 
increases in counties without unsolicited reporting.  
The forest plot in figure 3.4 presents the results of the time effect variables in 
models investigating the number of Controlled Substance Schedules monitored. In the 
Medicaid population counties with PDMPs that monitored Schedules II-IV were 
associated with a protective effect on changes in aRR of PORP over time while those 
monitoring all Schedules were not associated with any significant change over time. 
Similarly, in the privately insured population counties that monitored Schedules II-IV 
were not associated with any changes in aRR of PORP over time while those monitoring 
all Schedules were associated with significant increases in aRR over time. Conversely, in 
the uninsured population, counties that monitored all Schedules were associated with 
no change in aRR over time while those only monitoring Schedules II-IV were associated 
significant increases over time. In the Medicare population there was very little 
difference in changes in aRR of PORP over time in counties that monitored all Schedules 
vs. Schedules II-IV.  
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Results of the time effect variables from GEE models investigating data reporting 
frequency are presented in a forest plot in Figure 3.5 and generally indicate that PDMPs 
requiring pharmacies to report data weekly or more frequently are associated with 
protective effects on increases in aRR of PORP over time relative to PDMPs requiring 
less frequent data reporting. In the Medicaid and uninsured population, counties with 
weekly data reporting experienced decreases in aRR of PORP over time while counties 
with operational PDMPs requiring less frequent reporting experienced no significant 
change over time or significant increases over time respectively. In the privately insured 
population counties with operational PDMPs that required weekly data reporting did 
not experience any significant change in aRR of PORP over time while states with 
operational PDMPs requiring less frequent reporting experienced significant increases. 
Finally, in the Medicare population, counties with PDMPs that required weekly data 
reporting were associated with significant increases in aRR of PORP over time, but these 
increases were significantly less than the increases in aRR in counties without PDMPs 
and those with operational PDMPs that required less frequent reporting.  
The forest plot in figure 3.6 presents results of the time effect variables from 
models assessing whether PDMPs require prescribers to query the PDMP data in certain 
situations. In the Medicare and privately insured populations counties with operational 
PDMPs that required some mandatory querying did not experience any significant 
changes in aRR of PORP over time while counties with operational PDMPs that did not 
require mandatory querying experienced significant increases in aRR of PORP over time. 
In the Medicaid population, counties with operational PDMPs that did and did not 
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require mandatory querying were not associated with significant changes in aRR of 
PORP over time. In the uninsured population, counties with PDMPs that required 
mandatory querying were associated with significant decreases in aRR of PORP over 
time while counties with operational PDMPs that lacked this provision were not 
associated with significant changes in aRR over time.  
3.3.4 Sensitivity Analyses 
Naloxone Access Laws 
 The number of states in the study sample with naloxone access laws in place 
increased substantially during the study period, from 1 state in 2001 to 25 states in 
2014. Overall, there were 112 state-years with naloxone access laws in place from 2001-
2014 included in the study population. Sample Results of GEE models that were re-fit 
including the naloxone access law indicator variable are presented in Tables 3.7A – 3.7D. 
In the Medicaid and privately insured populations (Tables 3.7A and 3.7C, respectively), 
naloxone access laws were associated with greater PORP rates, however these 
associations were not statistically significant in any of the models investigated. P-values 
associated with the naloxone access law variable ranged from 0.103 – 0.283 in the 
Medicaid GEE models, and ranged from 0.286 – 0.747 in the privately insured GEE 
models.  
 In the Medicare population, naloxone access laws were associated with 
significantly lower PORP rates at the state-year level in all models investigated. 
Parameter estimates from one of these models are presented in Table 3.7B. Although 
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the naloxone access variable was statistically significant, it generally did not impact 
observed associations between PDMP features and trends PORP rates. For example, in 
the model presented in Table 3.7B, states both with and without operational PDMPs 
experienced significant increases in PORP rates from one year to the next, and the 
confidence intervals for these estimates overlap substantially. These results are nearly 
identical to the results presented in the main analysis, where naloxone access laws were 
not included.  
Finally, in the uninsured population, naloxone access laws were associated with 
lower PORP rates, but these associations generally were not statistically significant. An 
example of these results is presented in Table 3.7D. Naloxone access laws were only 
significantly associated with PORP rates in the uninsured population in the GEE model 
investigating data reporting frequency to PDMP servers. However, once again, it was 
observed that including this variable in the model only resulted in negligible changes to 
the parameter estimate for the interaction between the PDMP feature variable and the 
time indicator variable. 
Restricted Sample of States 
Results of GEE models excluding observations from states with missing data are 
presented in Figures 3.7 – 3.11. Generally speaking, removing these four states from the 
analysis had few consequential impacts on the primary results of interest. Figure 3.7 
presents a forest plot displaying changes in aRR of PORP from one year to the next in 
states with operational PDMPs. Comparing Figure 3.7 with Figure 3.2, it can be seen that 
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the magnitude of the time effects in the sensitivity analysis are slightly different from 
those in the main analysis, but the statistical significance of these time effects remains 
the same in all insurance types investigated. For example, in both the main analysis and 
the sensitivity analysis, it was seen that in the uninsured population, states with 
operational PDMPs did not experience significant changes in the PORP rate from one 
year to the next, while states without PMPDs experienced significant increases in PORP 
rates over time. Similarly, in both analyses, it was seen that in the privately insured 
population, states with operational PDMPs were associated with significantly lower 
increases in PORP rates over time relative to states without PDMPs in place. These same 
types of similarities between the sensitivity analysis and main analysis were also 
observed in all models investigating unsolicited reporting requirements, as well as 
models examining the number of CS Schedules monitored by the PDMP.  
Although most of the results of the sensitivity analysis were very similar to those 
observed in the main analysis, several notable differences were observed. For example, 
in models investigating mandatory querying requirements in the main analysis, the 
Medicaid population in states with these requirements in place did not experience any 
significant changes in PORP rates over time, and the uninsured population in states with 
these requirements experienced significant decreases in PORP rates over time (Figure 
3.5). However, in the sensitivity analyses examining this feature, the Medicaid 
population experienced significant increases in PORP rates over time while the 
uninsured population did not experience any significant changes over time (Figure 3.10).  
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A notable difference between the main analysis and sensitivity analysis was also 
observed in models investigating how often dispensers are required to report data to 
the PDMP server. In the main analysis, the privately insured population in states with 
weekly data reporting did not experience any statistically significant change in PORP 
rates over time. However, in the sensitivity analysis, this population experienced a 
significant decrease in PORP rates from one year to the next (Figure 3.11). For all other 
populations, the statistical significance of the time effects remained the same in the 
sensitivity analysis. 
3.4 Discussion 
From 2001 – 2014, the PORP rate observed in hospital discharge data in this 16 
state sample increased significantly across all insurance types. Though the uninsured 
population had the highest mean PORP rate throughout the study period, the greatest 
relative increase from 2001 – 2014 occurred in the Medicare population. The overall 
trend observed in this study is consistent with the trend reported in a previous analysis 
of HCUP data.97 
This study found that across all insurance types, counties with operational 
PDMPs were associated with significantly higher mean rates of PORP at baseline relative 
to counties without PDMPs. Once implemented though, PDMPs generally exerted a 
protective effect on increases in the aRR of PORP over time relative to counties that did 
not have programs in place. Furthermore, counties with operational PDMPs that had 
more robust features such as requiring more frequent data reporting from pharmacies 
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or requiring unsolicited reporting to prescribers or boards of licensure experienced 
stronger protective effects on increasing rates of PORP over time relative to counties 
with operational programs that lacked these features. In general these results parallel 
those observed in the previous study utilizing Truven data. However, the most 
significant finding of the present analysis is that differential associations between PDMP 
features and trends in PORP rates do exist depending on type of insurance coverage.  
Results of this study indicate that PDMPs exert particularly strong effects on the 
Medicaid and uninsured populations. These were the only two groups where counties 
with operational PDMPs did not experience significant changes in aRR of PORP over 
time, while counties without PDMPs experienced significant increases over time. The 
Medicaid and uninsured populations were also particularly impacted by more frequent 
data reporting. Again, these were the only two groups where counties with operational 
PDMPs that required dispensers to report PDMP data weekly or more frequently 
actually experienced decreases in the aRR of PORP over time. In contrast, counties with 
operational PDMPs that required less frequent data reporting experienced either no 
change or significant increases in aRR of PORP over time in the Medicaid and uninsured 
populations. Finally, the uninsured population was the only group to experience 
decreasing RR of PORP over time in counties with operational PDMPs that required 
prescribers to query the PDMP data in certain situations. 
 The results of models investigating the privately insured population in this study 
closely resembled the results observed in the study utilizing Truven data. Once again we 
see that counties with operational PDMPs experienced significant increases in the aRR 
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of PORP over time, however these increases were significantly lower than the increases 
observed in counties without PDMPs. Similarly, we again see that counties with 
operational PDMPs that require weekly data reporting, as well as those that require 
prescribers to query the PDMP data did not experience significant changes in aRR of 
PORP over time while counties with PDMPs that lacked these features experienced 
significant increases over time. The only marginally different result observed in the 
HCUP population was that counties with unsolicited reporting requirements 
experienced significant decreases in aRR over time, while in the Truven population this 
feature was not associated with any significant change over time.  
While PDMPs appeared to exert significant effects on the Medicaid, uninsured, 
and privately insured HCUP population, the results of this study suggest that they had 
less association with PORP trends in the Medicare population. The Medicare population 
was the only group where counties with operational PDMPs did not experience 
significantly different changes in aRR of PORP over time relative to counties without 
PDMPs. However, in counties with operational PDMPs that required unsolicited 
reporting, or weekly data reporting, the increases in aRR of PORP over time were 
significantly lower than the increases observed in counties without PDMPs.  
There are several potential reasons why PDMP implementation in general was 
not seen to be associated with reductions in PORP rates in the Medicare population. For 
one, prescribing in this population is potentially more likely to be related to the 
treatment of chronic pain and end of life care than in other populations. This is 
supported by the finding in this study that the Medicare population had a mean rate of 
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chronic pain related discharges that was nearly twice as high as any other group. In this 
sense, ‘overprescribing’ in patients experiencing long-term chronic pain or end of life 
care may warrant less intervention from actors utilizing the PDMP, and, as such, PDMP 
implementation is less associated with trends in PORP rates in this population. Second, a 
primary goal of PDMPs is to reduce the diversion of CS by making doctor shopping 
easier to detect. It is plausible that PDMP implementation has less of an impact on PORP 
rates Medicare population relative to other groups because this population is engaged 
in less diversion and doctor shopping.  
Doctor shopping and diversion may also explain the stronger impact of PDMPs 
on the Medicaid and uninsured population relative to the Medicare and privately 
insured populations. Presumably, if PDMPs are effective at reducing doctor shopping, 
then they will have a greater impact on the populations that engage in doctor shopping 
at a higher rate. While it is difficult to precisely estimate the number of individuals 
engaging in doctor shopping, some reports suggest that the Medicaid population 
engages in doctor shopping a much higher rate than the Medicare population. A 2017 
report from the Office of the Inspector General found that about 22,000 Medicare 
beneficiaries nationwide appeared to be doctor shopping for opioids in 2015.147 In 
contrast, a 2009 report from the Government Accountability Office found that more 
than 65,000 Medicaid beneficiaries in a five state sample engaged in doctor shopping 
during fiscal years 2006 and 2007.148  Though the GAO report is outdated and doesn’t 
differentiate between opioids and other CS, these results still imply that doctor 
shopping for opioids is likely to be substantially more common in the Medicaid 
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population as a whole. It is even more difficult to estimate the prevalence of doctor 
shopping in the uninsured population as few standardized data sources exist to monitor 
their healthcare utilization. However, in his book Dreamland, journalist Sam Quinones 
anecdotally reports that doctor shopping is a common practice among uninsured 
individuals seeking prescription opioids.8  
The main findings of this study still held upon completion of two robust 
sensitivity analyses. In the first sensitivity analysis, GEE models were re-fit including an 
indicator variable for the presence of naloxone access laws at the state level. Naloxone 
access laws were observed to be significantly associated with PORP rates in both the 
Medicare and uninsured populations. However, including this variable in the adjusted 
GEE models did not result in consequential changes to the interaction terms capturing 
associations between PDMP features and trends in PORP rates over time—which were 
of primary interest in this study. As in the previous study, naloxone access laws were not 
seen to be significantly associated  with PORP rates in the privately insured population. 
In the second sensitivity analysis, GEE models were re-fit excluding observations 
from states with missing data. There were several notable differences observed in the 
results of this sensitivity analysis relative to the results observed in the main analysis of 
this study. Despite these differences though, the primary implications of the study 
findings were generally consistent in both the sensitivity analysis and the main analysis. 
Finally, this second sensitivity analysis was arguably unnecessary as the missing data in 
the main analysis was ostensibly missing completely at random.  
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Although every state except for Missouri currently has an operational PDMP, the 
results of this study are still valuable to policy makers in several ways. These results 
indicate that PDMPs have been more successful at mitigating trends in the opioid 
epidemic in the Medicaid, uninsured, and privately insured populations than in the 
Medicare population. On one hand this is good news, as the uninsured and Medicaid 
populations had the highest overall rates of PORP related hospital discharges from 2001 
– 2014. But on the other hand, these results also imply that more needs to be done to 
address increasing PORP rates in the Medicare population—which saw the greatest 
relative increase in PORP rates from 2001 – 2014. Importantly, the results of this study 
imply that certain robust PDMP features may help mitigate increases in the risk of PORP 
over time in the Medicare population.  
This study addressed several important gaps in the PDMP literature. Most 
notably, this study is the first to our knowledge to investigate differential associations 
between PDMP implementation and trends in PORP risk over time in populations with 
different types of insurance coverage. Prior research examining PDMPs has found mixed 
results in assessing their impact on trends in opioid-related morbidity and mortality. 
This study found that PDMPs exert differential effects on populations with different 
types of insurance coverage. Much of the previous research examining PDMPs relies on 
nationwide mortality data that does not capture insurance status. As such, this research 
has not been able to account for differential associations between PDMP 
implementation and trends in PORPs in populations with different types of insurance 
coverage—potentially explaining the lack of conclusive findings. For example, if the 
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Medicare population suffers from opioid-related mortality at a substantially higher rate 
than the uninsured or Medicaid population, it could mask the effect of PDMPs in the 
latter groups and indicate that PDMPs are not significantly associated with trends in 
opioid-related mortality. At the very least, this research would show a diminished 
impact of PDMPs on the overall population. The current study stratified results by 
insurance status to provide greater granularity in terms of differential impacts of 
insurance type on associations between PDMP implementation and trends in PORP.  
Additionally, this study reinforced the findings in the previous chapter that 
specific robust features of PDMPs impart protective effects on increasing rates of PORP 
over time. Previous studies that have found that PDMPs are not effective in addressing 
the opioid epidemic have often failed to take the heterogeneity of PDMP features into 
account. As in the study presented in chapter two of this dissertation, the results of this 
study highlight the importance of PDMPs sending unsolicited reports to prescribers or 
licensure boards and requiring pharmacies to report PDMP data on a weekly basis. 
These features were seen to be associated with protective effects on trends in PORP 
rates over time among populations with different insurance types while adjusting for 
demographic and clinical characteristics of the populations.  
3.5 Limitations 
This study suffered from several limitations relating both to the data sources and 
study design utilized. Perhaps most notably, this study relied on the same ICD-9-CM 
codes to identify PORPs as were used in Chapter 2, and thus is subject to the same 
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limitations associated with the weak sensitivity of these codes.139 As in Chapter 2 
though, the poor sensitivity and high specificity of these codes imply that the 
magnitudes of the aRR estimates found in this study are likely underestimated relative 
to their true values.140  Once again though, even though the magnitudes of these 
estimates are biased, the estimates are still valuable to compare the relative impacts of 
different PDMP features. Most importantly, this study’s finding that differential 
associations between PDMP features and trends in PORP rates exist based on insurance 
type would still hold even if the actual magnitudes of the parameter estimates are 
systematically underestimated. This will hold true unless there is differential outcome 
misclassification by insurance status, which is possible but unlikely.  
HCUP SID data used in this study also suffers from several limitations specific to 
this dataset. For example, while data on the racial makeup of HCUP hospital discharges 
is available, it is often not coded, so was not used in this study. Further, there are known 
weaknesses associated with using the expected primary payer variable to define 
insurance status. As the variable name suggests, hospital administrators code this 
variable based on who they ‘expect’ to reimburse the hospital for the patient’s stay, and 
does not always reflect the patient’s true insurance status.155 The codes used to identify 
uninsured patients also vary from state to state and may include patients whose care is 
paid for by state specific charity groups. Whether or not these patients should be 
classified as truly ‘uninsured’ is up for debate. The primary expected payer variable also 
does not differentiate patients who are dually eligible for Medicare and Medicaid 
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benefits, and this population may be markedly different from the general Medicare and 
Medicaid populations.  
The HCUP data used in this study also only includes a limited sample of 16 states. 
These 16 states were selected based on availability of data pre and post implementation 
of the PDMPs in each of these states. The limited state sample is also in part due to 
funding constraints from the grant paying for the data. Several of the PDMP features of 
interest were parameterized differently in this study than they were in the study in 
Chapter 2 due to the limited sample size. For example, the variable coding the number 
of Controlled Substance Schedules monitored was coded differently in the present study 
because the limited study sample did not include any state-years with operational 
PDMPs that only monitored Schedule II or II-III drugs. The limited number of state-years 
in the current study also hampered models investigating the impact of mandatory 
querying. The parameter estimates associated with this variable, and this variables 
interaction with time, had unusually large standard errors because there were very few 
county-years in the present study where this feature was in place.  
Finally, as in the previous study, the ‘natural experiment’ design utilized in this 
study is only capable of demonstrating associations and cannot be used to make 
inferences about causality. Once again this is a particularly important point considering 
that additional federal and state-level interventions intended to mitigate the opioid 
epidemic were implemented at various points throughout the study time period. The 
present study design is not able to disentangle the effects of these interventions form 
the impact of PDMPs. However, even if the magnitude of the parameter estimates 
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observed in this study are biased due to additional interventions that weren’t adjusted 
for, they are still valuable in terms of assessing differential associations between PDMP 
features and PORP rates in populations with different types of insurance coverage. 
Implementation of state specific interventions may confound the impact of PDMPs in 
those states, but presumably these interventions would impact people similarly 
regardless of insurance status. If this assumption holds then the results of this study are 
still valid in terms of the finding that PDMP implementation exerts differential effects 
based on insurance type.  
3.6 Conclusion 
The 16 states included in this study sample experienced major changes to their 
PDMPs from 2001 – 2014. This study was the first to examine trends in prescription 
opioid-related morbidity in populations with different types of insurance. Over the 
fourteen year study period the privately insured, Medicare, Medicaid, and uninsured 
populations observed in the study sample all experienced significant increases in PORP 
rates. The uninsured and Medicaid population had the highest overall PORP rates, but 
the Medicare population experienced the greatest relative increase in PORP rates over 
the study time period. This study was also the first to investigate differential 
associations between PDMP features and trends in PORPs in populations with different 
types of insurance coverage. Results of this study indicate that PDMPs have had a 
greater impact on the Medicaid and uninsured populations relative to the Medicare 
population. These results suggest that more needs to be done to address increasing 
PORP rates in the Medicare population. Findings from the privately insured population 
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in this study generally validate the findings in the previous chapter. Future research is 
necessary to examine whether differential associations also exist between PDMP 
features and trends in illicit opioid-related poisonings in populations with different types 
of insurance. 
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Table 3.1: Characteristics of states included in the HCUP SID sample 
State Time 
Period 
Total 
Counties 
County 
Years 
Total 
Discharges 
PORP 
Discharges 
Total 
PORP 
Rate 
Mean 
PORP 
Rate 
AZ 2001 - 
2014 
15 210 10,856,641 20,921 192.70 145.35 
CO 2001 - 
2014 
64 896 7,093,062 13,906 196.05 217.45 
FL 2001 - 
2014 
67 938 38,419,719 75,482 196.47 273.53 
IA 2001 - 
2014 
99 1386 4,820,907 5,657 117.34 143.15 
KY 2001 - 
2014 
120 1680 9,110,030 17,373 190.70 246.59 
MI 2001 - 
2014 
83 1162 18,519,932 32,549 175.75 296.91 
NC 2001 - 
2014 
100 1400 16,213,054 27,677 170.71 196.55 
NJ 2001 - 
2014 
21 294 16,753,795 17,672 105.48 117.13 
NM 2008 - 
2014 
33 231 1,578,189 4,823 305.60 273.64 
NY 2001 - 
2014 
62 868 36,656,825 37,541 102.41 157.46 
OR 2001 - 
2014 
36 504 5,319,184 12,538 235.71 260.29 
SD 2007 - 
2014 
66 528 768,899 1,092 142.02 138.65 
VT 2001 - 
2014 
14 196 689,341 1,109 160.88 237.47 
WA 2001 - 
2014 
39 546 8,948,500 18,337 204.92 245.71 
WI 2012 - 
2014 
72 216 1,871,023 4,411 235.75 219.01 
WV 2001 - 
2001 
55 55 261,342 241 92.22 95.37 
Acronyms: HCUP- Healthcare cost and utilization project; SID- State inpatient databases; 
PORP- prescription opioid-related poisonings; States use standard postal abbreviations 
**Rates expressed per 100,000 discharges** 
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Table 3.2: Coding scheme for PDMP variables of interest 
Variable Levels 
Status of the PDMP 0= No PDMP 
1= PDMP legislation enacted only 
2= PDMP operational 
Is the PDMP required to send proactive 
reports to any entities?  
0= No PDMP 
1= PDMP legislation enacted only 
2= No 
3= Yes 
How often are pharmacies required to 
upload data to the PDMP?  
0= No PDMP 
1= PDMP legislation enacted only 
2= Monthly or less often 
3= Weekly or more often 
What Schedules is the PDMP required to 
monitor?  
0= No PDMP 
1= PDMP legislation enacted only 
2= II – IV  
3= II – V  
Are prescribers required to query the 
PDMP data in certain situations?  
0= No PDMP 
1= PDMP legislation enacted only 
2= No 
3= Yes 
Acronyms: PDMP- prescription drug monitoring program 
 
133
 
 
134 
 
Figure 3.1: Annual PORP rate per 100,000 Discharges by insurance type 2001 – 2014  
 
Acronyms: PORP- prescription opioid-related poisoning 
Table 3.4: Characteristics of the HCUP sample stratified by insurance type 
 Medicaid Medicare Private Uninsured 
Total 
Observations 
11,101 11,110 11,110 11,104 
Discharges 32,447,345 62,743,302 54,569,968 13,999,539 
PORP Count 58,631 81,543 59,338 45,793 
Overall PORP 
rate 
180.70 129.96 108.74 327.10 
Mean PORP 
rate 
192.43 125.63 113.85 362.56 
Mean percent 
male 
34.54 44.74 41.01 53.99 
Mean of 
median age 
24.47 72.89 42.22 41.06 
Mean CP rate 117.18 365.46 189.59 193.41 
Mean AP rate 76.87 147.25 114.19 187.57 
Acronyms: HCUP: Healthcare Cost and Utilization Project; PORP- prescription opioid-
related poisoning; CP- chronic pain; AP- Acute pain 
**Rates expressed per 100,000 discharges** 
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Table 3.5A: GEE parameter estimates from model investigating PORPs in the Medicaid 
population 
Variable GEE Parameter 
Estimate 
Standard 
Error 
95% CI 
Lower 
95% CI 
Upper 
P 
Value 
 
PDMP Status 
No PDMP Ref. 
PDMP Enacted 0.0722 0.0824 -0.0893 0.2337 0.3812 
PDMP Operational 0.2303 0.0791 0.0752 0.3854 0.0036 
 
Time Effect 
Year 0.0239 0.0104 0.0036 0.0443 0.0211 
PDMP Enacted*year -0.0088 0.0104 -0.0292 0.0116 0.3979 
PDMP Operational*year -0.0346 0.0087 -0.0517 -0.0175 <.0001 
 
Region 
West Ref. 
Midwest -0.1377 0.0510 -0.2377 -0.0377 0.0070 
Northeast -0.3361 0.0741 -0.4813 -0.1908 <.0001 
South -0.2601 0.0765 -0.4101 -0.1101 0.0007 
 
Continuous Variables 
% male population 0.0048 0.0072 -0.0093 0.0188 0.5041 
Median Age -0.0051 0.0039 -0.0127 0.0025 0.1901 
Chronic Pain Rate 0.0074 0.0008 0.0059 0.0089 <.0001 
Acute Pain Rate 0.0015 0.0006 0.0003 0.0027 0.0182 
Unemployment Rate 0.0266 0.0057 0.0154 0.0378 <.0001 
Poverty Rate -0.0203 0.0056 -0.0313 -0.0093 0.0003 
Discharge Rate 0.0001 0.0006 -0.0011 0.0013 0.8537 
Acronyms: PORP- prescription opioid-related poisoning; GEE- generalized estimating 
equation; CI- confidence interval; PDMP- prescription drug monitoring program;  
**Rates expressed per 100,000 discharges** 
  
136 
 
Table 3.5B: GEE parameter estimates from model investigating PORPs in the Medicare 
population 
Variable GEE Parameter 
Estimate 
Standard 
Error 
95% CI 
Lower 
95% CI 
Upper 
P 
Value 
 
PDMP Status 
No PDMP Ref. 
PDMP Enacted 0.1240 0.0597 0.0071 0.2409 0.0377 
PDMP Operational 0.1571 0.0552 0.0490 0.2652 0.0044 
 
Time Effect 
Year 0.0928 0.0089 0.0752 0.1103 <.0001 
PDMP Enacted*year -0.0185 0.0072 -0.0326 -0.0044 0.0100 
PDMP Operational*year -0.0277 0.0069 -0.0412 -0.0142 <.0001 
 
Region 
West Ref. 
Midwest -0.4723 0.0467 -0.5638 -0.3808 <.0001 
Northeast -0.6984 0.0517 -0.7998 -0.5970 <.0001 
South -0.3120 0.0591 -0.4278 -0.1961 <.0001 
 
Continuous Variables 
% male population -0.0152 0.0053 -0.0256 -0.0049 0.0039 
Median Age -0.0210 0.0057 -0.0322 -0.0097 0.0002 
Chronic Pain Rate 0.0015 0.0004 0.0008 0.0022 <.0001 
Acute Pain Rate 0.0014 0.0004 0.0006 0.0023 0.0010 
Unemployment Rate 0.0176 0.0049 0.0080 0.0272 0.0003 
Poverty Rate -0.0021 0.0042 -0.0103 0.0062 0.6251 
Discharge Rate -0.0001 0.0004 -0.0009 0.0007 0.7410 
Acronyms: PORP- prescription opioid-related poisoning; GEE- generalized estimating 
equation; CI- confidence interval; PDMP- prescription drug monitoring program;  
**Rates expressed per 100,000 discharges** 
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Table 3.5C: GEE parameter estimates from model investigating PORPs in the privately 
insured population 
Variable GEE Parameter 
Estimate 
Standard 
Error 
95% CI 
Lower 
95% CI 
Upper 
P 
Value 
 
PDMP Status 
No PDMP Ref. 
PDMP Enacted 0.0606 0.0578 -0.0527 0.1738 0.2945 
PDMP Operational 0.1225 0.0567 0.0114 0.2336 0.0306 
 
Time Effect 
Year 0.0569 0.0077 0.0418 0.0719 <.0001 
PDMP Enacted*year -0.0228 0.0070 -0.0365 -0.0090 0.0012 
PDMP Operational*year -0.0377 0.0062 -0.0499 -0.0255 <.0001 
 
Region 
West Ref. 
Midwest -0.2097 0.0422 -0.2924 -0.1270 <.0001 
Northeast -0.3777 0.0584 -0.4923 -0.2632 <.0001 
South -0.1608 0.0449 -0.2488 -0.0727 0.0003 
 
Continuous Variables 
% male population 0.0023 0.0057 -0.0088 0.0134 0.6803 
Median Age 0.0038 0.0023 -0.0007 0.0083 0.0965 
Chronic Pain Rate 0.0036 0.0007 0.0023 0.0050 <.0001 
Acute Pain Rate 0.0020 0.0004 0.0012 0.0028 <.0001 
Unemployment Rate 0.0188 0.0040 0.0109 0.0267 <.0001 
Poverty Rate -0.0149 0.0045 -0.0237 -0.0061 0.0010 
Discharge Rate 0.0004 0.0006 -0.0007 0.0016 0.4408 
Acronyms: PORP- prescription opioid-related poisoning; GEE- generalized estimating 
equation; CI- confidence interval; PDMP- prescription drug monitoring program;  
**Rates expressed per 100,000 discharges** 
  
138 
 
 
Table 3.5D: GEE parameter estimates from model investigating PORPs in the 
uninsured population 
Variable GEE Parameter 
Estimate 
Standard 
Error 
95% CI 
Lower 
95% CI 
Upper 
P 
Value 
 
PDMP Status 
No PDMP Ref. 
PDMP Enacted 0.0687 0.0777 -0.0836 0.2209 0.3766 
PDMP Operational 0.2645 0.0747 0.1181 0.4109 0.0004 
 
Time Effect 
Year 0.0564 0.0104 0.0361 0.0768 <.0001 
PDMP Enacted*year -0.0221 0.0090 -0.0398 -0.0045 0.0139 
PDMP Operational*year -0.0600 0.0084 -0.0765 -0.0435 <.0001 
 
Region 
West Ref. 
Midwest 0.1039 0.0543 -0.0025 0.2103 0.0557 
Northeast -0.2632 0.0740 -0.4083 -0.1182 0.0004 
South 0.4199 0.0671 0.2885 0.5513 <.0001 
 
Continuous Variables 
% male population 0.0145 0.0027 0.0093 0.0198 <.0001 
Median Age -0.0018 0.0038 -0.0091 0.0056 0.6394 
Chronic Pain Rate 0.0039 0.0007 0.0025 0.0054 <.0001 
Acute Pain Rate 0.0025 0.0004 0.0018 0.0032 <.0001 
Unemployment Rate 0.0364 0.0054 0.0259 0.0469 <.0001 
Poverty Rate -0.0257 0.0061 -0.0377 -0.0137 <.0001 
Discharge Rate -0.0020 0.0014 -0.0047 0.0006 0.1344 
Acronyms: PORP- prescription opioid-related poisoning; GEE- generalized estimating 
equation; CI- confidence interval; PDMP- prescription drug monitoring program;  
**Rates expressed per 100,000 discharges** 
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Table 3.6A: Adjusted relative risk of PORP in the Medicaid population 
Variable Adjusted Relative 
Risk 
95% CI 
Lower 
95% CI 
Upper 
P 
Value 
 
PDMP Status 
No PDMP Ref. 
PDMP Enacted 1.0748 0.9145 1.2632 0.3812 
PDMP Operational 1.2590 1.0782 1.4702 0.0036 
 
Time Effect 
Year 1.0242 1.0036 1.0452 0.0211 
PDMP Enacted*year 1.0153 0.9935 1.0374 0.1698 
PDMP Operational*year 0.9894 0.9756 1.0033 0.1346 
 
Region 
West Ref. 
Midwest 0.8714 0.7884 0.9630 0.0070 
Northeast 0.7146 0.6180 0.8263 <.0001 
South 0.7710 0.6636 0.8958 0.0007 
 
Continuous Variables 
% male population 1.0048 0.9908 1.0190 0.5041 
Median Age 0.9949 0.9874 1.0025 0.1901 
Chronic Pain Rate 1.0075 1.0060 1.0090 <.0001 
Acute Pain Rate 1.0015 1.0003 1.0027 0.0182 
Unemployment Rate 1.0270 1.0155 1.0385 <.0001 
Poverty Rate 0.9799 0.9692 0.9907 0.0003 
Discharge Rate 1.0001 0.9989 1.0013 0.8537 
Acronyms: PORP- prescription opioid-related poisoning; CI- confidence interval; PDMP- 
prescription drug monitoring program;  
**Rates expressed per 100,000 discharges** 
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Table 3.6B: Adjusted relative risk of PORP in the Medicare population  
Variable Adjusted Relative 
Risk 
95% CI 
Lower 
95% CI 
Upper 
P 
Value 
 
PDMP Status 
No PDMP Ref. 
PDMP Enacted 1.1320 1.0071 1.2724 0.0377 
PDMP Operational 1.1701 1.0503 1.3037 0.0044 
 
Time Effect 
Year 1.0972 1.0781 1.1166 <.0001 
PDMP Enacted*year 1.0771 1.0593 1.0951 <.0001 
PDMP Operational*year 1.0672 1.0561 1.0785 <.0001 
 
Region 
West Ref. 
Midwest 0.6236 0.5690 0.6833 <.0001 
Northeast 0.4974 0.4494 0.5505 <.0001 
South 0.7320 0.6519 0.8219 <.0001 
 
Continuous Variables 
% male population 0.9849 0.9748 0.9951 0.0039 
Median Age 0.9792 0.9683 0.9903 0.0002 
Chronic Pain Rate 1.0015 1.0008 1.0022 <.0001 
Acute Pain Rate 1.0014 1.0006 1.0023 0.0010 
Unemployment Rate 1.0178 1.0080 1.0276 0.0003 
Poverty Rate 0.9980 0.9898 1.0062 0.6251 
Discharge Rate 0.9999 0.9991 1.0007 0.7410 
Acronyms: PORP- prescription opioid-related poisoning; CI- confidence interval; PDMP- 
prescription drug monitoring program;  
**Rates expressed per 100,000 discharges** 
 
  
141 
 
Table 3.6C: Adjusted relative risk of PORP in the privately insured population  
Variable Adjusted Relative 
Risk 
95% CI 
Lower 
95% CI 
Upper 
P 
Value 
 
PDMP Status 
No PDMP Ref. 
PDMP Enacted 1.0624 0.9487 1.1898 0.2945 
PDMP Operational 1.1303 1.0115 1.2631 0.0306 
 
Time Effect 
Year 1.0585 1.0427 1.0746 <.0001 
PDMP Enacted*year 1.0347 1.0165 1.0531 0.0002 
PDMP Operational*year 1.0193 1.0057 1.0331 0.0052 
 
Region 
West Ref. 
Midwest 0.8108 0.7464 0.8807 <.0001 
Northeast 0.6854 0.6112 0.7686 <.0001 
South 0.8515 0.7797 0.9299 0.0003 
 
Continuous Variables 
% male population 1.0023 0.9913 1.0135 0.6803 
Median Age 1.0038 0.9993 1.0083 0.0965 
Chronic Pain Rate 1.0037 1.0023 1.0050 <.0001 
Acute Pain Rate 1.0020 1.0012 1.0028 <.0001 
Unemployment Rate 1.0189 1.0109 1.0270 <.0001 
Poverty Rate 0.9852 0.9766 0.9940 0.0010 
Discharge Rate 1.0004 0.9993 1.0016 0.4408 
Acronyms: PORP- prescription opioid-related poisoning; CI- confidence interval; PDMP- 
prescription drug monitoring program;  
**Rates expressed per 100,000 discharges** 
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Table 3.6D: Adjusted relative risk of PORP in the uninsured population  
Variable Adjusted Relative 
Risk 
95% CI 
Lower 
95% CI 
Upper 
P 
Value 
 
PDMP Status 
No PDMP Ref. 
PDMP Enacted 1.0711 0.9198 1.2472 0.3766 
PDMP Operational 1.3028 1.1253 1.5082 0.0004 
 
Time Effect 
Year 1.0581 1.0367 1.0799 <.0001 
PDMP Enacted*year 1.0349 1.0124 1.0579 0.0022 
PDMP Operational*year 0.9964 0.9814 1.0117 0.6450 
 
Region 
West Ref. 
Midwest 1.1095 0.9975 1.2340 0.0557 
Northeast 0.7686 0.6648 0.8886 0.0004 
South 1.5218 1.3344 1.7355 <.0001 
 
Continuous Variables 
% male population 1.0146 1.0093 1.0200 <.0001 
Median Age 0.9982 0.9909 1.0056 0.6394 
Chronic Pain Rate 1.0040 1.0025 1.0054 <.0001 
Acute Pain Rate 1.0025 1.0018 1.0032 <.0001 
Unemployment Rate 1.0371 1.0262 1.0481 <.0001 
Poverty Rate 0.9746 0.9630 0.9864 <.0001 
Discharge Rate 0.9980 0.9953 1.0006 0.1344 
Acronyms: PORP- prescription opioid-related poisoning; CI- confidence interval; PDMP- 
prescription drug monitoring program;  
**Rates expressed per 100,000 discharges** 
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Figure 3.2: Forest plot displaying change in aRR of PORP from one year to the next in 
states with operational PDMPs, stratified by insurance type 
 
Acronyms: aRR- adjusted relative risk; PORP- prescription opioid-related poisoning; 
PDMP- prescription drug monitoring program; LCL- lower confidence limit; UCL- upper 
confidence limit; CI- Confidence interval  
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Figure 3.3: Forest plot displaying change in aRR of PORP from one year to the next in 
states with operational PDMPs with unsolicited reporting requirements, stratified by 
insurance type 
Acronyms: aRR- adjusted relative risk; PORP- prescription opioid-related poisoning; 
PDMP- prescription drug monitoring program; LCL- lower confidence limit; UCL- upper 
confidence limit; CI- Confidence interval 
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Figure 3.4: Forest plot displaying change in aRR of PORP from one year to the next in 
states with operational PDMPs that monitor all CS Schedules, stratified by insurance 
type 
 
Acronyms: aRR- adjusted relative risk; PORP- prescription opioid-related poisoning; 
PDMP- prescription drug monitoring program; LCL- lower confidence limit; UCL- upper 
confidence limit; CI- Confidence interval  
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Figure 3.5: Forest plot displaying change in aRR of PORP from one year to the next in 
states with operational PDMPs with mandatory querying requirements, stratified by 
insurance type 
 
Acronyms: aRR- adjusted relative risk; PORP- prescription opioid-related poisoning; 
PDMP- prescription drug monitoring program; LCL- lower confidence limit; UCL- upper 
confidence limit; CI- Confidence interval  
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Figure 3.6: Forest plot displaying change in aRR of PORP from one year to the next in 
states with operational PDMPs that require weekly data reporting, stratified by 
insurance type 
Acronyms: aRR- adjusted relative risk; PORP- prescription opioid-related poisoning; 
PDMP- prescription drug monitoring program; LCL- lower confidence limit; UCL- upper 
confidence limit; CI- Confidence interval 
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Table 3.7A: GEE parameter estimates from model investigating PORP rates in the 
Medicaid population, controlling for naloxone access laws 
Variable GEE Parameter 
Estimate 
Standard 
Error 
95% CI 
Lower 
95% CI 
Upper 
P 
Value 
PDMP Status 
No PDMP Ref. 
PDMP Enacted 0.0776 0.0838 -0.0866 0.2418 0.3543 
PDMP Operational 0.2418 0.0816 0.0819 0.4018 0.0030 
Time Effect 
Year 0.0234 0.0104 0.0030 0.0439 0.0249 
PDMP Enacted*year -0.0097 0.0105 -0.0303 0.0109 0.3561 
PDMP Operational*year -0.0364 0.0088 -0.0535 -0.0192 <.0001 
Region 
West Ref. 
Midwest -0.1276 0.0508 -0.2271 -0.0281 0.0120 
Northeast -0.3507 0.0694 -0.4867 -0.2147 <.0001 
South -0.2537 0.0752 -0.4011 -0.1062 0.0007 
Naloxone Access Law in Place? 
No Ref. 
Yes 0.0399 0.0304 -0.0196 0.0995 0.1890 
Continuous Variables 
% male population 0.0044 0.0072 -0.0098 0.0186 0.5426 
Median Age -0.0049 0.0038 -0.0124 0.0026 0.2003 
Chronic Pain Rate 0.0074 0.0008 0.0059 0.0089 <.0001 
Acute Pain Rate 0.0015 0.0006 0.0003 0.0027 0.0150 
Unemployment Rate 0.0272 0.0058 0.0158 0.0387 <.0001 
Poverty Rate -0.0203 0.0056 -0.0313 -0.0093 0.0003 
Discharge Rate 0.0001 0.0006 -0.0011 0.0013 0.8814 
Acronyms: PORP- prescription opioid-related poisoning; GEE- generalized estimating 
equation; CI- confidence interval; PDMP- prescription drug monitoring program; Ref- 
reference 
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Table 3.7B: GEE parameter estimates from model investigating PORP rates in the 
Medicare population, controlling for naloxone access laws 
Variable GEE Parameter 
Estimate 
Standard 
Error 
95% CI 
Lower 
95% CI 
Upper 
P 
Value 
PDMP Status 
No PDMP Ref. 
PDMP Enacted 0.1169 0.0595 0.0002 0.2336 0.0495 
PDMP Operational 0.1451 0.0571 0.0332 0.2571 0.0111 
Time Effect 
Year 0.0936 0.0089 0.0762 0.1110 <.0001 
PDMP Enacted*year -0.0175 0.0072 -0.0316 -0.0034 0.0149 
PDMP Operational*year -0.0259 0.0070 -0.0397 -0.0121 0.0002 
Region 
West Ref. 
Midwest -0.1276 0.0508 -0.2271 -0.0281 0.0120 
Northeast -0.3507 0.0694 -0.4867 -0.2147 <.0001 
South -0.2537 0.0752 -0.4011 -0.1062 0.0007 
Naloxone Access Law in Place? 
No Ref. 
Yes -0.0560 0.0232 -0.1015 -0.0106 0.0156 
Continuous Variables 
% male population -0.0155 0.0053 -0.0258 -0.0052 0.0033 
Median Age -0.0214 0.0057 -0.0326 -0.0102 0.0002 
Chronic Pain Rate 0.0016 0.0004 0.0009 0.0023 <.0001 
Acute Pain Rate 0.0014 0.0005 0.0005 0.0023 0.0029 
Unemployment Rate 0.0167 0.0049 0.0071 0.0264 0.0007 
Poverty Rate -0.0017 0.0042 -0.0100 0.0065 0.6813 
Discharge Rate -0.0002 0.0004 -0.0010 0.0006 0.6531 
Acronyms: PORP- prescription opioid-related poisoning; GEE- generalized estimating 
equation; CI- confidence interval; PDMP- prescription drug monitoring program; Ref- 
reference 
  
150 
 
Table 3.7C: GEE parameter estimates from model investigating PORP rates in the 
privately insured population, controlling for naloxone access laws 
Variable GEE Parameter 
Estimate 
Standard 
Error 
95% CI 
Lower 
95% CI 
Upper 
P 
Value 
PDMP Status 
No PDMP Ref. 
PDMP Enacted 0.0608 0.0576 -0.0520 0.1736 0.2909 
PDMP Operational 0.1248 0.0576 0.0120 0.2377 0.0301 
Time Effect 
Year 0.0568 0.0077 0.0417 0.0718 <.0001 
PDMP Enacted*year -0.0230 0.0070 -0.0367 -0.0093 0.0010 
PDMP Operational*year -0.0384 0.0064 -0.0509 -0.0258 <.0001 
Region 
West Ref. 
Midwest -0.2060 0.0435 -0.2913 -0.1207 <.0001 
Northeast -0.3824 0.0586 -0.4973 -0.2675 <.0001 
South -0.1585 0.0454 -0.2475 -0.0695 0.0005 
Naloxone Access Law in Place? 
No Ref. 
Yes 0.0161 0.0307 -0.0441 0.0764 0.5994 
Continuous Variables 
% male population 0.0023 0.0057 -0.0088 0.0134 0.6838 
Median Age 0.0038 0.0023 -0.0007 0.0083 0.0978 
Chronic Pain Rate 0.0036 0.0007 0.0023 0.0049 <.0001 
Acute Pain Rate 0.0020 0.0004 0.0012 0.0028 <.0001 
Unemployment Rate 0.0191 0.0041 0.0111 0.0271 <.0001 
Poverty Rate -0.0149 0.0045 -0.0238 -0.0061 0.0009 
Discharge Rate 0.0004 0.0006 -0.0007 0.0016 0.4329 
Acronyms: PORP- prescription opioid-related poisoning; GEE- generalized estimating 
equation; CI- confidence interval; PDMP- prescription drug monitoring program; Ref- 
reference 
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Table 3.7D: GEE parameter estimates from model investigating PORP rates in the 
uninsured population, controlling for naloxone access laws 
Variable GEE Parameter 
Estimate 
Standard 
Error 
95% CI 
Lower 
95% CI 
Upper 
P 
Value 
PDMP Status 
No PDMP Ref. 
PDMP Enacted 0.0609 0.0782 -0.0923 0.2141 0.4361 
PDMP Operational 0.2534 0.0772 0.1020 0.4048 0.0010 
Time Effect 
Year 0.0575 0.0105 0.0369 0.0780 <.0001 
PDMP Enacted*year -0.0211 0.0091 -0.0389 -0.0034 0.0198 
PDMP Operational*year -0.0581 0.0087 -0.0753 -0.0410 <.0001 
Region 
West Ref. 
Midwest 0.0872 0.0556 -0.0217 0.1962 0.1167 
Northeast -0.2459 0.0771 -0.3971 -0.0947 0.0014 
South 0.4068 0.0684 0.2727 0.5410 <.0001 
Naloxone Access Law in Place? 
No Ref. 
Yes -0.0740 0.0410 -0.1544 0.0064 0.0712 
Continuous Variables 
% male population 0.0146 0.0027 0.0093 0.0198 <.0001 
Median Age -0.0020 0.0038 -0.0093 0.0054 0.6000 
Chronic Pain Rate 0.0040 0.0008 0.0025 0.0055 <.0001 
Acute Pain Rate 0.0025 0.0004 0.0017 0.0032 <.0001 
Unemployment Rate 0.0352 0.0055 0.0244 0.0461 <.0001 
Poverty Rate -0.0252 0.0062 -0.0373 -0.0131 <.0001 
Discharge Rate -0.0021 0.0014 -0.0048 0.0006 0.1215 
Acronyms: PORP- prescription opioid-related poisoning; GEE- generalized estimating 
equation; CI- confidence interval; PDMP- prescription drug monitoring program; Ref- 
reference 
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Figure 3.7: Forest plot displaying change in aRR of PORP from one year to the next in 
states with operational PDMPs, stratified by insurance type, excluding states with 
missing data 
 
Acronyms: aRR- adjusted relative risk; PORP- prescription opioid-related poisoning; 
PDMP- prescription drug monitoring program; LCL- lower confidence limit; UCL- upper 
confidence limit; CI- Confidence interval 
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Figure 3.8: Forest plot displaying change in aRR of PORP from one year to the next in 
states with operational PDMPs with unsolicited reporting requirements, stratified by 
insurance type, excluding states with missing data 
 
Acronyms: aRR- adjusted relative risk; PORP- prescription opioid-related poisoning; 
PDMP- prescription drug monitoring program; LCL- lower confidence limit; UCL- upper 
confidence limit; CI- Confidence interval 
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Figure 3.9: Forest plot displaying change in aRR of PORP from one year to the next in 
states with operational PDMPs that monitor all CS Schedules, stratified by insurance 
type, excluding states with missing data 
 
 
Acronyms: aRR- adjusted relative risk; PORP- prescription opioid-related poisoning; 
PDMP- prescription drug monitoring program; LCL- lower confidence limit; UCL- upper 
confidence limit; CI- Confidence interval 
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Figure 3.10: Forest plot displaying change in aRR of PORP from one year to the next in 
states with operational PDMPs with mandatory querying requirements, stratified by 
insurance type, excluding states with missing data 
 
Acronyms: aRR- adjusted relative risk; PORP- prescription opioid-related poisoning; 
PDMP- prescription drug monitoring program; LCL- lower confidence limit; UCL- upper 
confidence limit; CI- Confidence interval 
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Figure 3.11: Forest plot displaying change in aRR of PORP from one year to the next in 
states with operational PDMPs that require weekly data reporting, stratified by 
insurance type, excluding states with missing data 
 
Acronyms: aRR- adjusted relative risk; PORP- prescription opioid-related poisoning; 
PDMP- prescription drug monitoring program; LCL- lower confidence limit; UCL- upper 
confidence limit; CI- Confidence interval 
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Chapter 4: Reflections and Recommendations  
4.1 Filling in the gaps 
Clarifying the role of operational PDMPs 
The literature review in Chapter 1 notes that many of the previous studies 
examining the impact of PDMPs on opioid-related morbidity and mortality failed to 
adequately describe what they considered to be operational PDMPs. Green et al. 
articulated this criticism in response to an earlier study by Paulozzi et al. Green and 
colleagues argued that it was inappropriate for Paulozzi to consider PDMPs as ‘active’ or 
operational when the programs had not yet made data available to authorized users. 
Understandably, as data based interventions, it is difficult to conceive how these 
programs could serve any of their intended goals if users were not able to access, and 
subsequently act on, the data collected. The studies in this dissertation make clear that 
PDMPs are only considered operational when they have made data available to 
authorized users. Furthermore, several previous studies that did specify that PDMPs 
were only considered operational when they had made data available to users, only 
used one data source to identify dates of user access.42,90 This is problematic because 
NAMSDL and PDAPS both report dates of user access, but the dates they report are at 
times inconsistent. The studies in this dissertation used dates reported by both NAMSDL 
and PDAPS to conservatively define PDMPs as operational only after the latest date 
reported by one of these groups. 
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The studies presented in this dissertation found that states with operational 
PDMPs are generally associated with higher baseline PORP rates, but once implemented 
these programs are associated with significantly lower increases in PORP rates over time 
relative to states without PDMPs. This finding held for all groups examined except for 
the Medicare population, which did not experience significant differences in trends in 
PORP rates regardless of whether they lived in PDMP states. It is plausible that states 
that have the worst problems with PORPs are the states that choose to implement these 
programs sooner. This hypothesis is consistent with the finding that states with 
operational PDMPs had higher PORP rates at the beginning of the study periods relative 
to states without operational PDMPs. 
Associations between PDMP features and PORPs 
Despite the well-known heterogeneity of PDMPs between states, many studies 
investigating the effects of PDMPs simply classify the programs as being ‘on’ or ‘off’ and 
fail to account for the subtle differences in specific features of operational PDMPs. To 
date, only two previous studies have investigated associations between specific features 
of operational PDMPs and trends in PORP rates.42,90 Further, one of these studies only 
shows that states with more PDMP features are associated with reductions in PORP 
rates, and does not present results that can be used to interpret the effects of individual 
PDMP features.90 The studies presented in this dissertation utilized rigorous feature 
attribution methods to characterize features of PDMPs in every state in every year from 
2001 – 2014. The study presented in Chapter 2 also builds on previous studies by 
examining features of PDMPs in every month rather than on a yearly basis. PDMPs 
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frequently integrate new features in the middle of calendar years so examining changes 
monthly may better capture the immediate impact of these features. Finally, the studies 
in this dissertation also developed separate statistical models for each PDMP feature of 
interest, so these results provide greater granularity than those of previous studies in 
terms of the relative effects of each PDMP feature on trends in PORPs and IORPs.  
The studies in this dissertation found that several features of operational PDMPs 
are associated with significantly lower increases in PORP risk over time relative to states 
with operational PDMPs that lack these features. For example, in the privately insured 
population, states with operational PDMPs that required pharmacies to submit data on 
a weekly basis, and those that required prescribers to query the PDMP data in certain 
situations were not associated with significant changes in PORP rates over time, while 
those states with operational PDMPs that lacked these features, were associated with 
significant increases in PORP rates over time. This study also found that states with 
operational PDMPs with these features were associated with protective effects on 
increases in PORP rates over time in the Medicaid and uninsured populations. Overall, 
this study found that three of the four specific PDMP features investigated imparted 
beneficial effects on all populations studied. Namely, operational PDMPs that required 
unsolicited reporting, mandated prescribers query the PDMP data in certain situations, 
and those that required pharmacies to submit data more frequently were associated 
with either protective effects on the trends in PORP rates over time, or at worst, were 
associated with lower increases in PORP rates over time relative to states with 
operational PDMPs that lacked these features. These findings both confirm and expand 
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upon the findings of previous studies investing associations between PDMP features and 
trends in PORP rates. 
Differential associations in populations with different types of insurance 
None of the previous studies investigating associations between PDMPs and 
trends in PORPs have taken into account the possibility of differential associations in 
populations with different types of insurance coverage. As healthcare based programs 
that operate at the point-of-care, it is plausible that operational PDMPs and PDMPs with 
certain features will exert differential impacts on trends in opioid-related morbidity and 
mortality in different insurance beneficiary populations. However, nearly all of the 
previous research examining the impact of PDMPs on fatal and nonfatal PORPs has been 
conducted using data sources where the researchers cannot observe the insurance 
status of individuals included in the study. The study in Chapter 3 used hospital 
discharge records that included data on the expected primary payer for each hospital 
stay. Thus this study was able to construct separate models for each payer type to 
investigate associations between PDMP implementation and trends in PORPs. This study 
also investigated whether type of insurance coverage exerts differential effects on 
associations between specific PDMP features and trends in PORPs. Results of this study 
both elucidated the importance of insurance status on the effects of PDMPs and 
validated the results observed in the study in Chapter 2. 
Importantly, the results of models investigating the privately insured population 
in Chapter 3 validate the results observed in Chapter 2. Inspecting Figures 2.3 and 3.1, 
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we can see that the privately insured Truven population and the privately insured HCUP 
population generally experienced similar trends in PORP rates from 2004 – 2014. In both 
populations the PORP rate approximately doubled from 2004 – 2011 and has since 
levelled off. Models investigating associations between PDMP features and changes in 
PORP rates over time also revealed similar results for these two populations. Figure 4.1 
presents a side-by-side comparison of these results. Although the magnitudes of the 
observed parameter estimates differ, these results are generally trending in the same 
direction. For example, in both populations, states with operational PDMPs are 
associated with significantly lower increases in PORP rates over time relative to states 
without PDMPs. These results also held when investigating specific features of 
operational PDMPs. For example, in both populations, states with operational PDMPs 
that required weekly data reporting were not associated with significant changes in 
PORP rates over time, while states with operational PDMPs that required monthly or 
less frequent data reporting were associated with significant increases in PORP rates 
over time. Given these similarities, we can see that these results are not merely a 
‘function of the data’, and are likely indicative of the true associations between PMDP 
implementation and trends in PORPs in the privately insured population.  
Associations between PDMPs and IORPs 
Few studies to date have attempted to investigate associations between PDMP 
implementation and trends in illicit opioid-related morbidity. Mortality data from the 
CDC suggests that increases in fatal PORPs have begun to level off in recent years while 
rates of fata IORPs have increased dramatically.143 Similar trends in PORP and IORP rates 
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were observed in Chapter 2 of this dissertation. Some individuals have argued that the 
widespread implementation of PDMPs may in part be contributing to increases in IORPS, 
however few researchers have sought to empirically test this hypothesis. The study 
presented in Chapter 2 was the first study to examine differential associations between 
PDMP implementation and trends in PORPs vs. IORPs. Results of the study are bolstered 
by the fact that these distinct analyses were conducted using nearly identical 
methodologies on the exact same population of privately insured adults. Thus the 
different results from the separate analyses cannot be attributed to variations in study 
design or the population observed. This study also examined whether specific features 
of operational PDMPs had differential associations with trends in IORP rates. 
Results of the study presented in Chapter 2 indicate that PDMPs likely are not 
driving the recent increase in IORPs. In this study, states with operational PDMPs 
experienced significant increases in the risk of IORP over time, but these increases were 
not significantly different than those observed in states without PDMPs. In most cases, 
States with specific PDMP features also did not experience significant differences in 
increases in IORP risk over time relative to states without PDMPs. The exception were 
states with operational PDMPs that required unsolicited reporting. States with 
operational PDMPs that required unsolicited reporting experienced significantly greater 
increases in IORP risk over time relative to states with operational PDMPs that did not 
require unsolicited reporting, and relative to states without PDMPs. In models 
examining associations between PDMP features and trends in PORPs, PDMPs that 
required unsolicited reporting were associated with protective effects changes in PORP 
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rates over time. Taken together these results lend some credence to the theory that 
PDMPs may reduce PORPs while increasing IORPs. However, it is not immediately clear 
why data reporting frequency—which was also associated with significant protective 
effects on risk of PORP over time—is not also associated with increased risk of IORP over 
time.  
4.2 Directions for future research 
The studies included in this dissertation investigated a number of widely 
implemented PDMP features. However, there are several additional characteristics of 
PDMPs that may also be associated with trends in PORP and IORP rates that were not 
included in this study due to data constraints. Some PDMPs have begun requiring 
prescribers and pharmacists to register with the PDMP system. Previous research in 
Kentucky found that implementation of this feature was associated with reductions in 
doctor shopping, but prior studies have not examined associations between mandatory 
registration and trends in PORPs or IORPs.53 Unfortunately, at the time that the studies 
in this dissertation were conducted, data on mandatory registration were not available 
from PDAPS or other sources. In addition to mandatory registration, the rate at which 
prescribers query the PDMP data may also be associated with trends in opioid-related 
morbidity. Likewise though, aggregate data on prescriber querying rates are not readily 
available. Finally, interstate data sharing between PDMPs in neighboring states has 
become increasingly popular in recent years however the effect of this feature on PORPs 
and IORPs has yet to be examined. Future research is necessary to understand whether 
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these characteristics of PDMPs are associated with trends in prescription and illicit 
opioid-related morbidity and mortality. 
One of the primary limitations of the studies in this dissertation is that they fail 
to account for additional state and federal interventions that may have impacted trends 
in PORPs and IORPs during the study periods. State-level policy changes that may have 
impacted trends in opioid-related morbidity include things like crackdowns on pill mills 
in certain states, medical marijuana legislation, and Good Samaritan laws. National-level 
changes may include things like the release of abuse deterrent formulations of 
oxycodone, implementation of the Patient Protection and Affordable Care Act, and the 
revising of opioid prescribing guidelines. Some previous research has examined how 
these state and national-level interventions have effected trends in PORPs and IORPs. 
However, additional research is necessary to examine the impact of these trends in the 
context of changes to PDMP features over the last 20 years.  
Future research is also needed to elucidate the particular mechanisms by which 
PDMP features are associated with aggregate trends in rates of PORPs and IORPs, and 
whether these mechanisms operate differently in populations with different types of 
insurance. The studies presented here found that certain PDMP features are associated 
with significant protective effects on trends in PORP rates in multiple diverse 
populations, represented by different data sources. However, these results do not 
immediately make clear the mechanisms underlying these associations. It may be that 
PDMPs lead to reductions in PORP rates as they equip physicians with timely data on 
patients’ CS use history, which will allow physicians to make more informed prescribing 
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decisions. Alternatively, PDMPs may primarily act to reduce aggregate PORP rates by 
allowing law enforcement, or boards of licensure, to identify patients and prescribers 
that may be contributing to medication diversion. Once identified, law enforcement, or 
boards of licensure, may remove these ‘bad actors’ and ultimately reduce the aggregate 
risk of PORP at the state level. These different mechanisms may contribute to the 
finding that PMDPs have weaker associations with PORP trends in the Medicare 
population relative to populations with different types of insurance coverage. Future 
research, attempting to elucidate these mechanisms, may allow for the implementation 
of additional policy measures to further strengthen existing PDMPs, and to improve the 
effectiveness of PDMPs at reducing PORP rates in the Medicare population. 
Finally, future research is needed to explore associations between PDMP 
features and trends in additional outcomes such as opioid prescribing and doctor 
shopping. There has been a great deal of research examining the impact of PDMP 
implementation on opioid prescribing. Many of these studies have found that PDMPs 
are associated with decreases in Schedule II opioid prescribing and increases in Schedule 
III opioid prescribing.157-160 However, much of this research suffers from the same 
limitation as previous research examining associations between PDMPs and opioid-
related morbidity, in that many of these studies fail to account for the heterogeneity of 
PDMP features between states. Future research on this topic should control for the 
PDMP features observed in this dissertation to exert protective effects on trends in 
PORP rates. There is also a general dearth of research examining associations between 
PDMPs and doctor shopping. One study in Kentucky found that requiring prescribers to 
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register with the PDMP was associated with a reduction in doctor shopping in the 
Medicaid population.53 Additional research is necessary to identify whether this was an 
isolated finding, and also whether additional features of PDMPs may be associated with 
trends in doctor shopping in populations with other types of insurance coverage.  
4.3 Policy Recommendations 
Implement robust PDMP features 
This findings presented in this dissertation should be used as empirical evidence 
to support the adoption of several robust PDMP features. At present, 49 states and the 
District of Columbia have operational statewide PDMPs in place.66 The last holdout, 
Missouri, has enacted PDMP legislation and the program is operational in certain 
counties. Even though almost all states now have operational PDMPs, many of these 
programs lack features that this dissertation found to exert protective effects on trends 
in PORP risk. As of July 1st, 2016, 45 of the 50 operational PDMPs require dispensers to 
upload data to the PDMP server at least weekly. However, only 15 of those PDMPs 
require dispensers to upload data daily or more frequently.66 The study in Chapter 2 
found that states with daily or more frequent reporting were associated with significant 
decreases in PORP risk over time. This finding suggests that more states should 
implement this feature moving forward. Similarly, 11 states with operational PDMPs still 
do not have unsolicited reporting requirements in place, which this study also found to 
be associated with protective effects on changes in PORP rates over time in certain 
populations.49 Finally, the studies in this dissertation found that states with operational 
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PDMPs that require prescribers to query the PDMP data in certain situations were not 
associated with significant changes in PORP risk over time, while states with operational 
PDMPs that lacked this feature were associated with significant increases over time.66 
Unfortunately, estimates for this variable were generally imprecise due to the limited 
sample of state-years where this feature was in place during the study periods. As of 
2016, only 18 PDMPs had this feature in place.66  
Implementation of robust PDMP features may not immediately lead to 
reductions in PORP rates, but the findings presented in this dissertation suggest that at 
worst they will exert protective effects on increases in PORP rates over time. These 
studies also suggest that PDMPs are not necessarily contributing to recent increases in 
rates of IORPs, as has been suggested anecdotally. Regardless of their impact on the 
current opioid epidemic however, robust PDMPs will inevitably serve an important 
utility to the US healthcare infrastructure moving forwards. Having a widely accessible, 
real time data collection tool in place to monitor CS prescribing and dispensing, will 
almost certainly help mitigate future increases in rates of prescription CS poisonings, 
before these issues reach the scope of the current opioid epidemic. For example, 
gabapentin has recently emerged as a medication commonly found in post-mortem 
toxicology reports.161 While PDMPs largely served as reactive interventions to the opioid 
epidemic, they can now serve as proactive tools to prevent a potential gabapentin 
epidemic long before it begins. However, in order for PDMPs to serve the greatest utility 
in preventing future prescription drug epidemics, it is vitally important that they 
implement the robust features identified in this study.  
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Treating demand as well as supply 
Addiction is a neurobiological disease that fundamentally alters the brain’s 
pleasure-reward pathways.162 PDMPs are supply-side interventions that inherently act 
to reduce the amount of opioids available to a population. These programs may make it 
more difficult for individuals to become addicted in the first place—i.e. by encouraging 
appropriate prescribing practices or reducing the supply of medication that can be 
diverted to patients who are not yet addicted—but they do little to assist patients who 
are already compulsively seeking and taking drugs. Individuals addicted to prescription 
opioids who are suddenly facing reduced accessibility have a cheap and readily available 
substitute in the form of heroin, or illicitly manufactured fentanyl. Previous research has 
found that supply side interventions intended to reduce opioid related-morbidity and 
mortality may be ineffective in the presence of substitutes.163 With this framework in 
mind, it is important that PMDPs attempt to innovate in order to also address the 
‘demand’ side of the prescription opioid marketplace.  
Presently, PDMPs offer few tools to assist patients in need of addiction 
treatment. Prescribers who fastidiously check the PDMP data may find that patients are 
actively engaged in doctor shopping and may thus choose not to prescribe these 
patients opioids. Indeed, prior research has found that some doctors alter their 
prescribing decision-making upon reviewing patients CS history via a PDMP.134,164 
Unfortunately, this decision will likely serve little benefit to a patient who is already 
addicted to prescription opioids. Instead, it would be more helpful if doctors in this 
situation were to offer counseling or refer patients to an SUD treatment provider. 
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PDMPs could be equipped to help facilitate this process by providing doctors in this 
situation with sample language on how to discuss patients’ CS history, or by providing 
the doctor information on SUD treatment services available in the area. Furthermore, 
PDMPs could be integrated with additional data sources to help doctors identify 
patients who may be suffering from SUD. West Virginia’s PDMP has begun to take this 
approach as recent legislation requires all first responders and ER physicians to report 
acute opioid-related poisonings to the states PDMP.165  
The PDMP innovations proposed above may be both costly and years away from 
implementation. In the meantime, states should work in concert with the federal 
government to improve access to SUD treatment services. Kentucky and West Virginia, 
two of the states hardest hit by the opioid epidemic, are already taking strides in this 
direction through the implementation of Medicaid 1115 waivers that will open up new 
treatment services to Medicaid recipients.166 When these waivers are implemented 
managed care organizations in these states will be required to reimburse providers for 
certain types of SUD treatment services related to both behavioral therapy as well as 
medication assisted treatment that were previously not available to the Medicaid 
populations in these states. Presumably, alleviating the financial burden of treatment 
will encourage more SUD patients to seek care, and ideally will eventually lead to better 
outcomes. In order for this to work though, it is important for individuals to retain 
access to Medicaid coverage. Results in this dissertation showed that the uninsured 
population had substantially higher PORP rates from 2001 – 2014 than any group with 
public or private insurance. With this in mind, states and the federal government will 
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need to provide services for these individuals as well. However the quality and financial 
source of this care is up for debate. It will also be important for states and the federal 
government to work to improve access to Naloxone in order to reduce opioid-related 
mortality. 
4.4 Conclusion 
Over the last 20 years, PDMPs have been a key element in the fight against the 
opioid epidemic. These programs offer an unrivaled utility to track and prevent CS 
misuse and diversion, and by way of these efforts, to ultimately reduce the burden of 
prescription opioid-related morbidity and mortality on the US public health 
infrastructure. The results presented here demonstrate that states with operational 
PDMPs experienced significantly lower increases in PORP rates from 2004 – 2014 
relative to states without operational PDMPs. However, these results differed by the 
insurance status of the population being studied. The studies in this dissertation also 
found that specific features of operational PDMPs are associated with stronger 
protective effects on changes in PORP risk over time relative to states with operational 
PDMPs that lack these features. These findings have addressed several prominent 
shortcomings of the existing PDMP literature. Moving forward, PDMPs should continue 
to implement requirements for more frequent data reporting from pharmacies, 
mandatory querying of the PDMP data, and unsolicited reporting to providers and 
boards of licensure. Furthermore, additional ‘demand’ side interventions related to SUD 
treatment are necessary to have the greatest impact on the US opioid epidemic. 
Ultimately, PDMPs have served a demonstrated benefit in addressing the current opioid 
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epidemic, and now that the ground work is in place, they will ideally help prevent future 
prescription drug epidemics as well. 
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